{
  "id": "d72b777f-3158-419a-8d55-fff892809575",
  "userId": "Dig2_Batch_Tester",
  "fileName": "EMR200095-004 ProtAmend-2017-05-19-VER-V4.0-000008.pdf",
  "documentFilePath": "\\\\quintiles.net\\enterprise\\Services\\protdigtest\\pilot_iqvxml\\d72b777f-3158-419a-8d55-fff892809575",
  "iqvdataToc": "\"{\\\"index\\\": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 868, 869, 870, 871, 872, 873, 874, 875, 876, 877, 878, 879, 880, 881, 882, 883, 884, 885, 886, 887, 888, 889, 890, 891, 892, 893, 894, 895, 896, 897, 898, 899, 900, 901, 902, 903, 904, 905, 906, 907, 908, 909, 910, 911, 912, 913, 914, 915, 916, 917, 918, 919, 920, 921, 922, 923, 924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 940, 941, 942, 943, 944, 945, 946, 947, 948, 949, 950, 951, 952, 953, 954, 955, 956, 957, 958, 959, 960, 961, 962, 963, 964, 965, 966, 967, 968, 969, 970, 971, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999, 1000, 1001, 1002, 1003, 1004, 1005, 1006, 1007, 1008, 1009, 1010, 1011, 1012, 1013, 1014, 1015, 1016, 1017, 1018, 1019, 1020, 1021, 1022, 1023, 1024, 1025, 1026, 1027, 1028, 1029, 1030, 1031, 1032, 1033, 1034, 1035, 1036, 1037, 1038, 1039, 1040, 1041, 1042, 1043, 1044, 1045, 1046, 1047, 1048, 1049, 1050, 1051, 1052, 1053, 1054, 1055, 1056, 1057, 1058, 1059, 1060, 1061, 1062, 1063, 1064, 1065, 1066, 1067, 1068, 1069, 1070, 1071, 1072, 1073, 1074, 1075, 1076, 1077, 1078, 1079, 1080, 1081, 1082, 1083, 1084, 1085, 1086, 1087, 1088, 1089, 1090, 1091, 1092, 1093, 1094, 1095, 1096, 1097, 1098, 1099, 1100, 1101, 1102, 1103, 1104, 1105, 1106, 1107, 1108, 1109, 1110, 1111, 1112, 1113, 1114, 1115, 1116, 1117, 1118, 1119, 1120, 1121, 1122, 1123, 1124, 1125, 1126, 1127, 1128, 1129, 1130, 1131, 1132, 1133, 1134, 1135, 1136, 1137, 1138, 1139, 1140, 1141, 1142, 1143, 1144, 1145, 1146, 1147, 1148, 1149, 1150, 1151, 1152, 1153], \\\"columns\\\": [\\\"section_level\\\", \\\"CPT_section\\\", \\\"type\\\", \\\"content\\\", \\\"font_info\\\", \\\"level_1_CPT_section\\\", \\\"file_section\\\", \\\"file_section_num\\\", \\\"file_section_level\\\", \\\"seq_num\\\"], \\\"data\\\": [[\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Clinical Trial Protocol Amendment\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 36, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 36, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE\\\", \\\"\\\", 1, 1], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Protocol Amendment No.</td>\\\\n      <td>4.0</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Scope</td>\\\\n      <td>Global</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Date of Protocol Amendment</td>\\\\n      <td>19 May 2017</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Classification of Amendment</td>\\\\n      <td>Substantial</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Clinical Trial Protocol No.</td>\\\\n      <td>EMR200095-004</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>Title</td>\\\\n      <td>A Multicenter, Randomized, Phase Ib/II Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of MSC2156119J as Monotherapy Versus Sorafenib in Asian Subjects with MET+ Advanced Hepatocellular Carcinoma and Child-Pugh Class A Liver Function</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>Phase</td>\\\\n      <td>Ib/II</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td>Coordinating Investigator</td>\\\\n      <td>Dr Shukui Qin Medical Oncology Department Nanjing Bayi Hospital Nanjing, China</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>8</th>\\\\n      <td>Sponsor</td>\\\\n      <td>Merck KGaA Frankfurter Strasse 250 64293 Darmstadt, Germany Medical Responsible: Charles Zhao, MD, MBA EMD Serono, Inc. 45A Middlesex Turnpike Billerica MA 01821 United States of America Tel. +1 978 294 1133 Fax: +1 978 294 1200</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>9</th>\\\\n      <td>Previous Trial Protocol Version</td>\\\\n      <td>24 June 2016/Version 3.0</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>10</th>\\\\n      <td>Current Trial Protocol Version 19 May 2017/Version 4.0</td>\\\\n      <td>Current Trial Protocol Version 19 May 2017/Version 4.0</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"0\\\", \\\"TableIndex\\\": \\\"1\\\", \\\"TableName\\\": \\\"Clinical Trial Protocol Amendment\\\", \\\"Header\\\": [0, 1, 2, 3]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE\\\", \\\"\\\", 1, 2], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"- Confidential -\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE\\\", \\\"\\\", 1, 3], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This document is the property of Merck KGaA, Darmstadt, Germany, or one of its subsidiaries.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE\\\", \\\"\\\", 1, 4], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"It is intended for restricted use only and may not - in full or part - be passed on, reproduced, published or used without express permission of Merck KGaA, Darmstadt, Germany, or its subsidiary.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE\\\", \\\"\\\", 1, 5], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Copyright \\\\u00a9 2017 by Merck KGaA, Darmstadt, Germany, or its subsidiary.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE\\\", \\\"\\\", 1, 6], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"All rights reserved.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE\\\", \\\"\\\", 1, 7], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE\\\", \\\"\\\", 1, 8], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Previous Protocol Amendments\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE\\\", \\\"\\\", 1, 9], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Previous Protocol Amendments:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE\\\", \\\"\\\", 1, 10], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Amendment no. 1.1 (Substantial); 29 November 2013 (Local)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE\\\", \\\"\\\", 1, 11], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"o\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Courier New\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE\\\", \\\"\\\", 1, 12], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Implemented in: South Korea\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE\\\", \\\"\\\", 1, 13], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Amendment no. 1.2 (Substantial); 20 December 2013 (Local)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE\\\", \\\"\\\", 1, 14], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"o\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Courier New\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE\\\", \\\"\\\", 1, 15], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Implemented in: South Korea\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE\\\", \\\"\\\", 1, 16], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Amendment no. 2.0 (Substantial); 02 December 2014 (Global)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE\\\", \\\"\\\", 1, 17], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Amendment no. 2.1 (Substantial); 26 March 2015 (Local)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE\\\", \\\"\\\", 1, 18], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"o\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Courier New\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE\\\", \\\"\\\", 1, 19], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Implemented in: South Korea\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE\\\", \\\"\\\", 1, 20], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Amendment no. 3.0 (Substantial); 24 June 2016 (Global)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE\\\", \\\"\\\", 1, 21], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Amendment no. 3.1 (Substantial); 11 August 2016 (Local)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE\\\", \\\"\\\", 1, 22], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"o\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Courier New\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE\\\", \\\"\\\", 1, 23], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Implemented in: South Korea\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE\\\", \\\"\\\", 1, 24], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE\\\", \\\"\\\", 1, 25], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE\\\", \\\"\\\", 1, 26], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE\\\", \\\"\\\", 1, 27], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE\\\", \\\"\\\", 1, 28], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Further Sponsor Responsible Persons\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE\\\", \\\"\\\", 1, 29], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Biostatistician\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE\\\", \\\"\\\", 1, 30], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Name, academic degree</td>\\\\n      <td>Dongli Zhou, PhD</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Function</td>\\\\n      <td>Senior Principal Biostatistician</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Institution</td>\\\\n      <td>Merck Serono (Beijing), Pharmaceutical R&D Co. Ltd.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Telephone number</td>\\\\n      <td>+86 10 59077400</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Fax number</td>\\\\n      <td>+86 10 59072433</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>E-mail address Clinical Trial Leader</td>\\\\n      <td>dongli.zhou@merckgroup.com</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>Name, academic degree</td>\\\\n      <td>Nicole Hu, MSc</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td>Function</td>\\\\n      <td>Global Clinical Operations</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>8</th>\\\\n      <td>Telephone number</td>\\\\n      <td>+86 21 22265585</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>9</th>\\\\n      <td>Fax number</td>\\\\n      <td>+86 21 22265599</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>10</th>\\\\n      <td>E-mail address</td>\\\\n      <td>nicole.hu@merckgroup.com</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"0\\\", \\\"TableIndex\\\": \\\"2\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": []}, {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE\\\", \\\"\\\", 1, 31], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Trial Title</td>\\\\n      <td>A Multicenter, Randomized, Phase Ib/II Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of MSC2156119J as Monotherapy Versus Sorafenib in Asian Subjects with MET+ Advanced Hepatocellular Carcinoma and Child-Pugh Class A Liver Function</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Protocol Amendment No./Date Corresponding Clinical Trial</td>\\\\n      <td>Protocol Amendment 4.0/19 May 2017.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Protocol Version</td>\\\\n      <td>Version 4.0/19 May 2017</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"0\\\", \\\"TableIndex\\\": \\\"3\\\", \\\"TableName\\\": \\\"Principal Investigator Signature\\\", \\\"Header\\\": [0, 1, 2]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"TITLE\\\", \\\"\\\", 1, 32], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\" Table of Contents\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading1\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Table of Contents\\\", \\\"\\\", \\\"1\\\", 33], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Signature Page\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Table of Contents\\\", \\\"\\\", \\\"1\\\", 34], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Table of Contents\\\", \\\"\\\", \\\"1\\\", 35], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"..............................................................................................................4\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Table of Contents\\\", \\\"\\\", \\\"1\\\", 36], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Table of Contents 8\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Table of Contents\\\", \\\"\\\", \\\"1\\\", 37], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"1 Introduction 9\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Table of Contents\\\", \\\"\\\", \\\"1\\\", 38], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2 Rationale for Changes 9\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Table of Contents\\\", \\\"\\\", \\\"1\\\", 39], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2.1 Rationale for Changes Relating to the Early Discontinuation of\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Table of Contents\\\", \\\"\\\", \\\"1\\\", 40], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Prescreening 9\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Table of Contents\\\", \\\"\\\", \\\"1\\\", 41], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2.2 Rationale for the Changes Relating to Re-scoring MET Status 10\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Table of Contents\\\", \\\"\\\", \\\"1\\\", 42], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2.3 Rationale for Clarifying the Role of the Independent Review\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Table of Contents\\\", \\\"\\\", \\\"1\\\", 43], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Committee 10\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Table of Contents\\\", \\\"\\\", \\\"1\\\", 44], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2.4 Rationale for Corrections 10\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Table of Contents\\\", \\\"\\\", \\\"1\\\", 45], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2.5 Ratio nale for Other Protocol Clarifications 11\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Table of Contents\\\", \\\"\\\", \\\"1\\\", 46], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"3 List of Changes 12\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Table of Contents\\\", \\\"\\\", \\\"1\\\", 47], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"4 Appendices 53\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Table of Contents\\\", \\\"\\\", \\\"1\\\", 48], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"4.1 Updated Treatment Duration Figure (Figure 3) 53\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Table of Contents\\\", \\\"\\\", \\\"1\\\", 49], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"4.2 Updated Phase Ib Schedule of Dosing and Assessments (Appendix H) 54\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Table of Contents\\\", \\\"\\\", \\\"1\\\", 50], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"4.3 Updated Phase II Schedule of Dosing and Assessments (Appendix I) 57\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Table of Contents\\\", \\\"\\\", \\\"1\\\", 51], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"4.4 Updated Blood Sampling Schedule and Blood Volumes for PK,\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Table of Contents\\\", \\\"\\\", \\\"1\\\", 52], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Pd/Biomarkers, and PGx (Appendix J) 61\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Table of Contents\\\", \\\"\\\", \\\"1\\\", 53], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Table of Contents\\\", \\\"\\\", \\\"1\\\", 54], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\" Introduction\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading1\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Introduction\\\", \\\"1\\\", \\\"1\\\", 55], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The purpose of this protocol amendment and the changes to be made are:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Introduction\\\", \\\"1\\\", \\\"1\\\", 56], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The formal interim futility analysis will be replaced by a formal primary analysis.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Introduction\\\", \\\"1\\\", \\\"1\\\", 57], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The data cut-off for the primary analysis will be changed from 50% of time to progression (TTP) events to 40 TTP events (confirmed by the Independent Review Committee [IRC]) or 15 August 2017, whichever occurs first.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Introduction\\\", \\\"1\\\", \\\"1\\\", 58], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The primary analysis will include all subjects enrolled into the trial prior to the enrollment stop date (15 August 2017).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Introduction\\\", \\\"1\\\", \\\"1\\\", 59], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The final analysis will be conducted approximately 6 months after the last subject is first dosed.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Introduction\\\", \\\"1\\\", \\\"1\\\", 60], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A final database lock will be performed after the last subject's last visit.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Introduction\\\", \\\"1\\\", \\\"1\\\", 61], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects who sign the Informed Consent Form prior to 15 August 2017 and undergo prescreening/screening after the enrollment stop date may still be randomized in the trial.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Introduction\\\", \\\"1\\\", \\\"1\\\", 62], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects currently receiving study treatment at the time of stopping enrollment may continue treatment after discussion with their Investigator.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Introduction\\\", \\\"1\\\", \\\"1\\\", 63], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If a subject decides to continue treatment, they will continue on their originally randomized treatment, at their most current dose as according to the protocol.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Introduction\\\", \\\"1\\\", \\\"1\\\", 64], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Safety monitoring and data collection will continue without modification through to the end of the trial.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Introduction\\\", \\\"1\\\", \\\"1\\\", 65], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"To clarify that the primary analysis will exclude subjects with a change in c-MET immunohistochemistry (IHC) score from 2+ or 3+ to either 1+ or \\\\u2018not assessable', based on a re-assessment of c-MET IHC score planned for quality assurance purposes.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Introduction\\\", \\\"1\\\", \\\"1\\\", 66], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"To clarify the role of the IRC in this trial.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Introduction\\\", \\\"1\\\", \\\"1\\\", 67], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"To make minor corrections and clarifications to the clinical trial protocol.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Introduction\\\", \\\"1\\\", \\\"1\\\", 68], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The changes to be made to the clinical trial protocol and the rationale for the changes are described below.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Introduction\\\", \\\"1\\\", \\\"1\\\", 69], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\" Rationale for Changes\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading1\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Changes\\\", \\\"2\\\", \\\"1\\\", 70], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\" 2.1Rationale for Changes Relating to the Early Discontinuation\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Changes Relating to the Early Discontinuation\\\", \\\"2.1\\\", \\\"2\\\", 71], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\" of Prescreening\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Changes Relating to the Early Discontinuation\\\", \\\"2.1\\\", \\\"2\\\", 72], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Due to business-related considerations not related to any safety issue, the sponsor decided to stop prescreening/enrollment after 40 TTP events are observed (assessed by an IRC) or on 15 August 2017, whichever occurs first.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Changes Relating to the Early Discontinuation\\\", \\\"2.1\\\", \\\"2\\\", 73], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Forty TTP events are expected to provide a power of approximately 48% for analysis of the Phase II primary objective.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Changes Relating to the Early Discontinuation\\\", \\\"2.1\\\", \\\"2\\\", 74], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The primary analysis will include all subjects enrolled prior to the enrollment stop date, regardless of the subject's status at the time of the primary analysis (subjects with IHC c-Met status of 1+ or \\\\u2018not assessable' on re-scoring will be excluded from the primary analysis).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Changes Relating to the Early Discontinuation\\\", \\\"2.1\\\", \\\"2\\\", 75], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The final analysis will be conducted approximately 6 months after the last subject is first dosed.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Changes Relating to the Early Discontinuation\\\", \\\"2.1\\\", \\\"2\\\", 76], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\" 2.2Rationale for the Changes Relating to Re-scoring MET Status\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for the Changes Relating to Re-scoring MET Status\\\", \\\"2.2\\\", \\\"2\\\", 77], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In Phase II, MET+ status, as determined by the central laboratory, is an inclusion criterion.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for the Changes Relating to Re-scoring MET Status\\\", \\\"2.2\\\", \\\"2\\\", 78], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Determination of MET status is performed at Molecular Prescreening (Phase Ib retrospectively, Phase II for subject selection) and a MET status re-scoring procedure has been implemented as a quality control measure.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for the Changes Relating to Re-scoring MET Status\\\", \\\"2.2\\\", \\\"2\\\", 79], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Subjects with a change in c-Met immunohistochemistryscore from MET+ (2+ or 3+) to 1+ or \\\\u2018not assessable' on re-scoring will be excluded from the analysis of baseline characteristics and efficacy.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for the Changes Relating to Re-scoring MET Status\\\", \\\"2.2\\\", \\\"2\\\", 80], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The mITT population is defined as subjects who have MET+ (2+ or 3+) hepatocellular carcinoma (HCC) and are randomized to study treatment.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for the Changes Relating to Re-scoring MET Status\\\", \\\"2.2\\\", \\\"2\\\", 81], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The mITT population excludes subjects who were randomized but for whom, retrospectively, a c-Met status of 1+ or \\\\u2018not assessable' was detected.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for the Changes Relating to Re-scoring MET Status\\\", \\\"2.2\\\", \\\"2\\\", 82], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\" 2.3Rationale for Clarifying the Role of the Independent Review\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Clarifying the Role of the Independent Review\\\", \\\"2.3\\\", \\\"2\\\", 83], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\" Committee\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Clarifying the Role of the Independent Review\\\", \\\"2.3\\\", \\\"2\\\", 84], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In this trial, the IRC will assess tumor imaging data using both Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and modified RECIST (mRECIST).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Clarifying the Role of the Independent Review\\\", \\\"2.3\\\", \\\"2\\\", 85], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The Phase II primary endpoint is time to progression\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Clarifying the Role of the Independent Review\\\", \\\"2.3\\\", \\\"2\\\", 86], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"based on tumor assessment\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Clarifying the Role of the Independent Review\\\", \\\"2.3\\\", \\\"2\\\", 87], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"by the IRC using RECIST v1.1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Clarifying the Role of the Independent Review\\\", \\\"2.3\\\", \\\"2\\\", 88], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Progression-free survival\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Clarifying the Role of the Independent Review\\\", \\\"2.3\\\", \\\"2\\\", 89], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"based on tumor assessment\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Clarifying the Role of the Independent Review\\\", \\\"2.3\\\", \\\"2\\\", 90], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"by the IRC using RECIST v1.1, objective response\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Clarifying the Role of the Independent Review\\\", \\\"2.3\\\", \\\"2\\\", 91], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"based on\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Clarifying the Role of the Independent Review\\\", \\\"2.3\\\", \\\"2\\\", 92], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Clarifying the Role of the Independent Review\\\", \\\"2.3\\\", \\\"2\\\", 93], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"tumor assessment\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Clarifying the Role of the Independent Review\\\", \\\"2.3\\\", \\\"2\\\", 94], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"by the IRC using RECIST v1.1, and disease control\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Clarifying the Role of the Independent Review\\\", \\\"2.3\\\", \\\"2\\\", 95], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"based on tumor assessment\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"single\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Clarifying the Role of the Independent Review\\\", \\\"2.3\\\", \\\"2\\\", 96], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"by the IRC using RECIST v1.1 are secondary endpoints.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Clarifying the Role of the Independent Review\\\", \\\"2.3\\\", \\\"2\\\", 97], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Exploratory objectives include evaluating the antitumor activity of MSC2156119J according to mRECIST by IRC assessment.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Clarifying the Role of the Independent Review\\\", \\\"2.3\\\", \\\"2\\\", 98], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\" 2.4Rationale for Corrections\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Corrections\\\", \\\"2.4\\\", \\\"2\\\", 99], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The protocol has been corrected in order to address the following discrepancies and omissions:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Corrections\\\", \\\"2.4\\\", \\\"2\\\", 100], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In the Synopsis, exclusion criterion number 5 was corrected for consistency with Section 5.3.2 so that the threshold for a hematological test abnormality for hemoglobin, without transfusion or growth factor support in the preceding 14 days is \\\\u2264 8.5 g/dL.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Corrections\\\", \\\"2.4\\\", \\\"2\\\", 101], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The treatment duration figure (Figure 3) was updated to show the Molecular Prescreening period (Phase II only).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Corrections\\\", \\\"2.4\\\", \\\"2\\\", 102], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The duration of the Clinical Screening period was corrected to \\\\u201c-14 to -1 days\\\\u201d.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Corrections\\\", \\\"2.4\\\", \\\"2\\\", 103], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In Section 7.1.3.2, text was updated to clarify that the predose electrocardiogram (ECG) assessment on Cycle 1, Day 15 is a single 12-lead ECG recording, and the postdose ECG assessment at 4 hours (\\\\u00b1 12 minutes) comprises triplet 12-lead ECG recordings.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Corrections\\\", \\\"2.4\\\", \\\"2\\\", 104], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In Section 7.2, text was updated to clarify that subjects should have an Eastern Cooperative Oncology Group performance status of < 2 to participate in the trial, for consistency with the inclusion criteria.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Corrections\\\", \\\"2.4\\\", \\\"2\\\", 105], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In Section 8.3.2, the list of secondary endpoints was updated to include progression-free survival based on tumor assessment by the investigator, objective response based on tumor assessment by the investigator, and disease control based on tumor assessment by the investigator.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Corrections\\\", \\\"2.4\\\", \\\"2\\\", 106], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The newly described secondary endpoints are typical of endpoints seen in this type of study and tumor assessment by the investigator was already planned (see Section 7.3); however, until now, statistical evaluation of the new secondary endpoints was not adequately described in the protocol.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Corrections\\\", \\\"2.4\\\", \\\"2\\\", 107], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Text was added to Section 8.5.3.1 and Section 8.5.3.4 to clarify the analysis of new secondary endpoints.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Corrections\\\", \\\"2.4\\\", \\\"2\\\", 108], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\" 2.5Rationale for Other Protocol Clarifications\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Other Protocol Clarifications\\\", \\\"2.5\\\", \\\"2\\\", 109], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The amendment includes a number of clarifications that aim to eliminate ambiguity and to ensure the trial is conducted consistently at all sites:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Other Protocol Clarifications\\\", \\\"2.5\\\", \\\"2\\\", 110], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The details for the Protocol Lead and Sponsor Biostatistician were updated.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Other Protocol Clarifications\\\", \\\"2.5\\\", \\\"2\\\", 111], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The list of abbreviations was updated and the definition of V\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Other Protocol Clarifications\\\", \\\"2.5\\\", \\\"2\\\", 112], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"ss\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Unmapped\\\", \\\"Rationale for Other Protocol Clarifications\\\", \\\"2.5\\\", \\\"2\\\", 113], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"/f was updated to \\\\u2018apparent volume of distribution at steady state'.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Other Protocol Clarifications\\\", \\\"2.5\\\", \\\"2\\\", 114], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In Section 3.5, the text describing identified risks from clinical studies and potential risks from non-clinical studies was updated.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Other Protocol Clarifications\\\", \\\"2.5\\\", \\\"2\\\", 115], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In Section 5.3.1, inclusion criterion number 2 was updated to clarify that eligible subjects may have intermediate HCC of Barcelona Clinic Liver Cancer (BCLC) Stage B, if they are not eligible for surgical and/or local-regional therapies or have progressive disease after surgical and/or local-regional therapies (local-regional therapy must not contain sorafenib), or advanced HCC of BCLC Stage C.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Other Protocol Clarifications\\\", \\\"2.5\\\", \\\"2\\\", 116], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In Section 5.3.2, exclusion criterion number 3 was updated to clarify that prior local-regional radiation therapy within 4 weeks prior to Day 1 of trial treatment does not include palliative bone-directed radiotherapy and radiotherapy administered to superficial lesions.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Other Protocol Clarifications\\\", \\\"2.5\\\", \\\"2\\\", 117], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In Section 6.2.5, text was added to clarify that subjects who miss more than 21 consecutive days of trial treatments for non-medical reasons are considered non-compliant and should be withdrawn from trial treatments.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Other Protocol Clarifications\\\", \\\"2.5\\\", \\\"2\\\", 118], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Dose modification guidelines for subjects experiencing hepatitis B virus (HBV) or hepatitis C virus (HCV) reactivation are now reiterated in Section 6.2.5.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Other Protocol Clarifications\\\", \\\"2.5\\\", \\\"2\\\", 119], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A link to the United States Food and Drug Administration Drug Development and Labeling Web page (http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ DrugInteractionsLabeling/default.htm) was added to Sections 6.5.1 and 6.5.2.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Other Protocol Clarifications\\\", \\\"2.5\\\", \\\"2\\\", 120], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"This Web page includes links providing further examples of substrates and inhibitors for P-glycoprotein and breast cancer resistance protein, and examples of clinical inhibitors and inducers for CYP3A-mediated metabolism.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Other Protocol Clarifications\\\", \\\"2.5\\\", \\\"2\\\", 121], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In Section 6.5.3.1, it was clarified that instructions on sample collection and processing for HBV and HCV assessments will be provided in the laboratory manual.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Other Protocol Clarifications\\\", \\\"2.5\\\", \\\"2\\\", 122], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In Section 7.1.2, it was clarified that demographic data and disease history will be collected at Molecular Prescreening.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Other Protocol Clarifications\\\", \\\"2.5\\\", \\\"2\\\", 123], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In Sections 7.1.3.1, 7.1.3.2, and 7.1.4, text was updated to clarify that an additional signed Informed Consent Form (ICF) is required for optional tumor biopsies and pharmacogenetic blood sampling.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Other Protocol Clarifications\\\", \\\"2.5\\\", \\\"2\\\", 124], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In addition, the protocol was updated to clarify that the following Phase Ib/Phase II assessments are optional and collected only after subjects sign a separate ICF:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Other Protocol Clarifications\\\", \\\"2.5\\\", \\\"2\\\", 125], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Tumor biopsy on Cycle 1, Day 1; Cycle 1, Day 15; and end of treatment\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Other Protocol Clarifications\\\", \\\"2.5\\\", \\\"2\\\", 126], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Pharmacogenetic blood sampling on Cycle 1, Day 1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Other Protocol Clarifications\\\", \\\"2.5\\\", \\\"2\\\", 127], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In Sections 7.1.3.1 and 7.1.3.2, a \\\\u00b1 1 minute time window was added for triplet 12-lead ECG recordings with 2-minute intervals.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Other Protocol Clarifications\\\", \\\"2.5\\\", \\\"2\\\", 128], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In Section 7.1.4, text was updated to clarify that end of treatment ECG and laboratory assessments (hematology, coagulation, chemistry, urinalysis, and hepatitis markers) are not required for subjects with prior ECG and laboratory assessments, respectively, within 7 days of the end of treatment visit.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Other Protocol Clarifications\\\", \\\"2.5\\\", \\\"2\\\", 129], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In Section 7.3, text was updated to clarify that computed tomography or magnetic resonance imaging is required, rather than recommended, for tumor assessment.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Other Protocol Clarifications\\\", \\\"2.5\\\", \\\"2\\\", 130], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In Section 7.3, text was added to clarify that, in the event that unscheduled imaging does not meet progressive disease by RECIST v 1.1, the next scheduled imaging assessment should still be performed on time unless the next scheduled imaging assessment is within 14 days following the unscheduled imaging.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Other Protocol Clarifications\\\", \\\"2.5\\\", \\\"2\\\", 131], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In Section 7.4.1.1, the definition of AE/SAEs observed in association with disease progression was updated.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Other Protocol Clarifications\\\", \\\"2.5\\\", \\\"2\\\", 132], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In Section 7.5, a definition of \\\\u201cselected sites\\\\u201d for extended sparse PK sampling was added.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Other Protocol Clarifications\\\", \\\"2.5\\\", \\\"2\\\", 133], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In accordance with an Institutional Review Board request, details about the collection, preparation analysis and storage of tumor and blood samples were added to Section 7.5.1 and Section 7.6.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Other Protocol Clarifications\\\", \\\"2.5\\\", \\\"2\\\", 134], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In Appendices H and J, it was clarified that computed tomography/magnetic resonance imaging assessments should be collected predose.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Other Protocol Clarifications\\\", \\\"2.5\\\", \\\"2\\\", 135], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Imaging assessments are to be performed at the following time points:\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Other Protocol Clarifications\\\", \\\"2.5\\\", \\\"2\\\", 136], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"o\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Courier New\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Other Protocol Clarifications\\\", \\\"2.5\\\", \\\"2\\\", 137], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Screening\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Other Protocol Clarifications\\\", \\\"2.5\\\", \\\"2\\\", 138], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Within 5 days prior to Day 1 of Cycles 3, 5, 7, 9, 11, 13, and every 4 cycles thereafter\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Other Protocol Clarifications\\\", \\\"2.5\\\", \\\"2\\\", 139], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"o\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Courier New\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Other Protocol Clarifications\\\", \\\"2.5\\\", \\\"2\\\", 140], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"End of treatment\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Other Protocol Clarifications\\\", \\\"2.5\\\", \\\"2\\\", 141], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In addition, a small number of administrative updates were made to improve the clarity of the protocol text.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Rationale for Other Protocol Clarifications\\\", \\\"2.5\\\", \\\"2\\\", 142], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\" List of Changes\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading1\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"List of Changes\\\", \\\"3\\\", \\\"1\\\", 143], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Changes to the clinical trial protocol text are presented in the table below.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"List of Changes\\\", \\\"3\\\", \\\"1\\\", 144], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Additions and amended text are shown in bold.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"List of Changes\\\", \\\"3\\\", \\\"1\\\", 145], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"If the original clinical trial protocol text was already bold, changes are shown in bold and underlined, deletions are marked using strike through.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"List of Changes\\\", \\\"3\\\", \\\"1\\\", 146], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"List of Changes\\\", \\\"3\\\", \\\"1\\\", 147], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Comparison with Clinical Trial Protocol Version 3.0, 24 June 2016 (Amendment No. 4.0)\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"List of Changes\\\", \\\"3\\\", \\\"1\\\", 148], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Administrative update</td>\\\\n      <td>Title page</td>\\\\n      <td>1</td>\\\\n      <td>Trial Phase [ \\\\u2026] Coordinating Investigator Dr Shukui Qin [\\\\u2026] Medical Responsible (Regional): Junfang Xu, MD Merck Serono (Beijing), Pharmaceutical R&D Co. Ltd. 28/F, Greentech Tower, 436 Hengfeng Road Shanghai 2000070 People\\\\u2019s Republic of China Tel.: +86 21 22265587</td>\\\\n      <td><strike>Trial</strike> Phase [ \\\\u2026] Coordinating Investigator Dr Shukui Qin MD [\\\\u2026] Medical Responsible <strike>(Regional)</strike> : Charles Zhao, MD, MBA EMD Serono, Inc. 45A Middlesex Turnpike Billerica MA 01821 United States of America Tel: +1 978 294 1133 Fax: +1 978 294 1200 <strike>Junfang Xu, MD</strike> <strike>Merck Serono (Beijing), Pharmaceutical R&D Co.</strike>  <strike>Ltd.</strike> <strike>28/F, Greentech Tower, 436 Hengfeng Road</strike> <strike>Shanghai 2000070</strike> <strike>People\\\\u2019s Republic of China</strike> <strike>Tel.: +86 21 22265587</strike></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Administrative update</td>\\\\n      <td>Signature page</td>\\\\n      <td>3</td>\\\\n      <td>Name, academic degree: Junfang Xu, MD Function: Medical Responsible Institution: Merck Serono (Beijing), Pharmaceutical R&D Co. Ltd. Address: 28/F, Greentech Tower 436 Hengfeng Road Shanghai 2000070 People\\\\u2019s Republic of China Telephone number: +86 21 22265587 E-mail address: junfang.xu@merckgroup.com</td>\\\\n      <td>Name, academic degree: <strike>Junfang Xu, MD</strike> Charles Zhao, MD, MBA Function: Medical Responsible Institution: <strike>Merck Serono (Beijing),</strike>  <strike>Pharmaceutical R&D Co.</strike> <strike>Ltd.</strike> EMD Serono, Inc. Address: <strike>28/F, Greentech Tower</strike> <strike>436 Hengfeng Road</strike> <strike>Shanghai 2000070</strike> <strike>People\\\\u2019s Republic of China</strike> 45A Middlesex Turnpike Billerica MA 01821 United States of America</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"11\\\", \\\"TableIndex\\\": \\\"4\\\", \\\"TableName\\\": \\\"Comparison with Clinical Trial Protocol Version 3.0, 24 June 2016 (Amendment No. 4.0)\\\", \\\"Header\\\": [0, 1, 2]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"List of Changes\\\", \\\"3\\\", \\\"1\\\", 149], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 150], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Telephone number: <strike>+86 21 22265587</strike> +1 978 294 1133 Fax number: +1 978 294 1200 E-mail address: <strike>junfang.xu@merckgroup.com</strike> charles.zhao@emdserono.com</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Administrative update</td>\\\\n      <td>Signature page</td>\\\\n      <td>4</td>\\\\n      <td>Name, academic degree: Shukui Qin, MD [\\\\u2026]</td>\\\\n      <td>Name, academic degree: Dr Shukui Qin, MD [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Administrative update</td>\\\\n      <td>Signature page</td>\\\\n      <td>5</td>\\\\n      <td>Biostatistician Name: Wenfeng Chen, PhD Function: Global Biostatistics Institution: Merck-Serono (Beijing), Pharmaceutical R&D Co., Ltd. Telephone number: +86 10 59031541 Fax number: +86 10 59072699 E-mail address: wenfeng.chen@merckgroup.com</td>\\\\n      <td>Biostatistician Name: <strike>Wenfeng Chen, PhD</strike> Dongli Zhou, PhD Function: <strike>Global Biostatistics</strike> Senior Principal Biostatistician Institution: Merck-Serono (Beijing), Pharmaceutical R&D Co., Ltd. Telephone number: <strike>+86 10 59031541</strike> +86 10 59077400 Fax number: <strike>+86 10 59072699</strike> +86 10 59072433 E-mail address: <strike>wenfeng.chen@merckgroup.com</strike> dongli.zhou@merckgroup.com</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Administrative update</td>\\\\n      <td>List of Abbreviations</td>\\\\n      <td>12-14</td>\\\\n      <td>Not applicable</td>\\\\n      <td>c-Met Mesenchymal-epithelial transition factor [\\\\u2026] HBsAb Hepatitis B surface antibodies [\\\\u2026] mITT Modified intent-to-treat [\\\\u2026] OCT1 Organic cation transporter 1</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>Administrative update</td>\\\\n      <td>List of Abbreviations</td>\\\\n      <td>15</td>\\\\n      <td>[\\\\u2026] SBP Systolic blood pressure [\\\\u2026] V ss /f Volume of distribution at steady state [\\\\u2026]</td>\\\\n      <td>[\\\\u2026] <strike>SBP Systolic blood pressure</strike> [\\\\u2026] V ss /f Apparent volume <strike>Volume</strike> of distribution at steady state [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>Administrative update</td>\\\\n      <td>Section 1, Synopsis, Trial objectives</td>\\\\n      <td>17</td>\\\\n      <td>Exploratory objectives will be assessed in Phase Ib and Phase II for subjects with available baseline and on-treatment biopsies</td>\\\\n      <td>Exploratory objectives will be assessed in Phase Ib and Phase II for subjects with available baseline and on-treatment biopsies and/or blood</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"5\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1, 2, 3]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 151], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 152], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 153], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 154], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 155], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 156], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>and/or blood samples, and/or available patient reported outcome (PRO) data, and may include exploring the antitumor activity of MSC2156119J according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) by Independent Review Committee (IRC) assessment, and evaluating the MSC2156119J concentration-response with respect to QTc</td>\\\\n      <td>samples, and/or available patient reported outcome (PRO) data . <strike>and</strike> These objectives may include exploring the antitumor activity of MSC2156119J according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) by Independent Review Committee (IRC) assessment, and may include evaluating the MSC2156119J concentration-response with respect to QTc .</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Change relating to early discontinuation of prescreening</td>\\\\n      <td>Section 1, Synopsis, Planned number of subjects</td>\\\\n      <td>18</td>\\\\n      <td>Phase II: Approximately 140 subjects will be randomized on a 1:1 basis to receive MSC2156119J or sorafenib.</td>\\\\n      <td>Phase II: Approximately 140 subjects were planned to <strike>will</strike> be randomized on a 1:1 basis to receive MSC2156119J or sorafenib. The sponsor subsequently decided to stop prescreening/enrollment after 40 TTP events (assessed by an IRC) or on 15 August 2017, whichever occurs first.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Administrative update</td>\\\\n      <td>Section 1, Synopsis, Schedule of visits and assessments</td>\\\\n      <td>18</td>\\\\n      <td>The subject must sign a main informed consent form (ICF) before any trial procedures are performed. In Phase II, subjects must also sign the prescreening informed consent form. Subjects will undergo a Molecular Prescreening period and a Clinical Screening period. In Phase II, MET status will be confirmed during Molecular Prescreening. [\\\\u2026]</td>\\\\n      <td>The subject must sign a main informed consent form (ICF) before any trial procedures are performed. In Phase II, subjects must also sign the prescreening and clinical screening <strike>informed consent form</strike> ICF . In Phase II, subjects <strike>Subjects</strike> will undergo a Molecular Prescreening period and a Clinical Screening period. <strike>In Phase II,</strike> MET status will be confirmed during Molecular Prescreening. [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Clarification of ICF requirements for optional assessments Change relating to early discontinuation of prescreening</td>\\\\n      <td>Section 1, Synopsis, Schedule of visits and assessments</td>\\\\n      <td>19-22</td>\\\\n      <td>[\\\\u2026] Cycle 1, Day 1 On Cycle 1, Day 1 of Phase Ib, the following assessments/treatment administrations will occur: dispensing of study drug; 12-lead electrocardiogram (ECG); serial PK blood samples; pretreatment tumor biopsy (excluding fine needle aspiration and cytology samples) (optional); blood samples for exploratory markers (predose only); and pharmacogenetic (PGx) blood sample (predose only; optional, will be collected after subject\\\\u2019s signing off separate ICF).</td>\\\\n      <td>[\\\\u2026] Cycle 1, Day 1 On Cycle 1, Day 1 of Phase Ib, the following assessments/treatment administrations will occur: dispensing of study drug; 12-lead electrocardiogram (ECG); serial PK blood samples; pretreatment tumor biopsy (excluding fine needle aspiration and cytology samples ; <strike>)</strike>  <strike>(</strike> optional will be collected after subjects have signed a separate ICF ); blood samples for exploratory markers (predose only); and pharmacogenetic (PGx) blood sample (predose only; optional, will be collected after subjects</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"6\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1, 2, 3]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 157], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 158], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 159], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 160], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 161], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>[\\\\u2026] Cycle 1, Day 15 On Cycle 1, Day 15 of Phase Ib, the following assessments/treatment administrations will occur: tumor biopsy (excluding fine needle aspiration and cytology samples; optional); 12lead ECG; and serial PK blood samples. [\\\\u2026] Cycles \\\\u2265 3, Day 1 [\\\\u2026] In addition, a complete tumor assessment of all lesions by radiographic or other modality (using response evaluation criteria in solid tumors [RECIST v 1.1]) identified at the screening visit will be performed on Day 1 of Cycles 3, 5, 7, 9, 11, 13, and every 4 cycles thereafter until disease progression or trial medication discontinuation. [\\\\u2026] End of Treatment Visit At the subject\\\\u2019s discontinuation of the trial medication (due to disease progression [as assessed by the investigator], intolerable toxicity, or withdrawal), the following evaluations, which include safety/tumor assessment, will be performed: tumor biopsy (excluding fine needle aspiration and cytology samples; optional); physical examination/weight; ECOG PS; AEs; concomitant medication/procedure; vital signs; 12-lead ECG; hematology; coagulation; chemistry; urinalysis; monitoring of subjects with a known history or evidence of viral hepatitis infection at baseline; complete tumor assessment of all lesions by radiographic or other modality if previous assessment is more than 6 weeks old (using RECIST v 1.1); serum AFP; and blood samples for exploratory markers analysis.</td>\\\\n      <td>have signed a <strike>subject\\\\u2019s signing off</strike> separate ICF). [\\\\u2026] Cycle 1, Day 15 On Cycle 1, Day 15 of Phase Ib, the following assessments/treatment administrations will occur: tumor biopsy (excluding fine needle aspiration and cytology samples; optional will be collected after subjects have signed a separate ICF ); 12lead ECG; and serial PK blood samples. [\\\\u2026] Cycles \\\\u2265 3, Day 1 [\\\\u2026] In addition, a complete tumor assessment of all lesions by radiographic or other modality (using response evaluation criteria in solid tumors [RECIST v 1.1]) identified at the screening visit will be performed predose on or up to 5 days prior to, Day 1 of Cycles 3, 5, 7, 9, 11, 13, and every 4 cycles thereafter until disease progression or trial medication discontinuation. [\\\\u2026] End of Treatment Visit At the subject\\\\u2019s discontinuation of the trial medication (due to disease progression [as assessed by the <strike>i</strike> I nvestigator], intolerable toxicity, or withdrawal), the following evaluations, which include safety/tumor assessment, will be performed: tumor biopsy (excluding fine needle aspiration and cytology samples; optional will be collected after subjects sign a separate ICF ); physical examination/weight; ECOG PS; AEs; concomitant medication/procedure; vital signs; 12-lead ECG; hematology; coagulation; chemistry; urinalysis; monitoring of subjects with a known history or evidence of viral hepatitis infection at baseline; complete tumor assessment of all lesions by radiographic or other modality if previous assessment is more than 6 weeks old</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"7\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 162], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 163], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 164], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 165], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 166], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Assessments for the end of treatment visit in Phase II include all assessments in Phase Ib. In addition, FHSI-8 and PRO (FACT-HP) will be assessed. [\\\\u2026] Survival Follow-up Assessments Survival data (subject survival and anticancer therapies) in Phase Ib and Phase II will be collected every 3 months (\\\\u00b1 2 weeks) after the dose of study drug. Subjects will be contacted by telephone.</td>\\\\n      <td>(using RECIST v 1.1); and serum AFP <strike>; and blood</strike>  <strike>samples for exploratory markers analysis</strike> . Assessments for the end of treatment visit in Phase II include all assessments in Phase Ib. In addition, FHSI-8 and PRO (FACT-HP) will be assessed and blood samples for exploratory marker analysis will be performed . Note: end of treatment ECG and laboratory assessments (hematology, coagulation, chemistry, urinalysis, and hepatitis markers) are not required for subjects with previous ECG and laboratory assessments, respectively, within 7 days of the end of treatment visit. [\\\\u2026] Survival Follow-up Assessments Survival data (subject survival and anticancer therapies) in Phase Ib and Phase II will be collected every 3 months (\\\\u00b1 2 weeks) after the last dose of study drug. Subjects will be contacted by telephone. Assessments After the Enrollment Stop Date  (15 August 2017) Subjects who sign the ICF prior to 15 August 2017 and undergo prescreening/screening after the enrollment stop date may still be randomized in the trial. Subjects receiving study treatment may continue treatment after discussion with their Investigator. Subjects who decide to continue treatment will continue on their originally randomized treatment, at their most recent dose according to the protocol. Safety monitoring and data collection will continue without modification through to the end of the trial.</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"8\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 167], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 168], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 169], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 170], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 171], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Clarification of inclusion criteria</td>\\\\n      <td>Section 1, Synopsis, Diagnosis and main inclusion and exclusion criteria</td>\\\\n      <td>22</td>\\\\n      <td>Inclusion Criteria [\\\\u2026] Subjects with advanced HCC of BCLC Stage B or C, who are not eligible for surgical and/or local-regional therapies or who have progressive disease (PD) after surgical and/or local-regional therapies. (Note: the local-regional therapy must not contain sorafenib.). [\\\\u2026] MET+ status (Phase II only), as determined by the central laboratory (Phase Ib retrospectively, Phase II  for subject selection) is defined as c-Met protein overexpression (e.g., moderate (2+) or strong (3+) staining intensity for cMet using immunohistochemistry [IHC] in the majority [\\\\u2265 50%] of tumor cells) [\\\\u2026]</td>\\\\n      <td>Inclusion Criteria [\\\\u2026] Subjects with either intermediate <strike>advanced</strike> HCC of BCLC Stage B <strike>or C</strike> who are not eligible for surgical and/or local-regional therapies or who have progressive disease (PD) after surgical and/or local-regional therapies <strike>.</strike> ( <strike>N</strike> n ote: the local-regional therapy must not contain sorafenib <strike>.</strike> ) or advanced HCC of BCLC Stage C [\\\\u2026] MET+ status (Phase II only), as determined by the central laboratory (Phase Ib retrospectively, Phase II  for subject selection) is defined as mesenchymal-epithelial transition factor ( c-Met ) protein overexpression (e.g., moderate <strike>(</strike> [ 2+ ] <strike>)</strike> or strong <strike>(</strike> [ 3+ ] <strike>)</strike> staining intensity for c-Met using immunohistochemistry [IHC] in the majority [\\\\u2265 50%] of tumor cells) [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Permitted types of radiation therapy clarified</td>\\\\n      <td>Section 1, Synopsis, Diagnosis and main inclusion and exclusion criteria</td>\\\\n      <td>23</td>\\\\n      <td>Exclusion Criteria [\\\\u2026]  Prior local-regional therapy within 4 weeks prior to Day 1 of trial treatment (e.g., major surgery, radiation therapy, hepatic arterial embolization, transcatheter arterial chemoembolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection, or cryoablation) [\\\\u2026]</td>\\\\n      <td>Exclusion Criteria [\\\\u2026]  Prior local-regional therapy within 4 weeks prior to Day 1 of trial treatment (e.g., major surgery, radiation therapy [with the exception of palliative bone-directed radiotherapy and radiotherapy administered to superficial lesions] hepatic arterial embolization, transcatheter arterial chemoembolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection, or cryoablation) NOTE: palliative bone-directed radiotherapy should be within a limited field of radiation and for palliation only; it should be a short course, according to</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"9\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1, 2]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 172], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 173], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>local institutional recommendations, and should be completed at least 7 days prior to the first administration of trial treatment [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Correction Administrative update</td>\\\\n      <td>Section 1, Synopsis, Diagnosis and main inclusion and exclusion criteria</td>\\\\n      <td>23-25</td>\\\\n      <td>[\\\\u2026] Hematological test abnormalities of either hemoglobin < 8.5 g/dL (without transfusion or growth factor support in the preceding 14 days), neutrophils < 1.5 \\\\u00d7 10 <sup>9</sup> /L, or platelets < 60 \\\\u00d7 10 <sup>9</sup> /L (without transfusion or growth factor support in the preceding 7 days) Liver dysfunction defined by total bilirubin > 3 mg/dL, aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 5 \\\\u00d7 upper limit of normal (ULN) [\\\\u2026] Female subjects who are pregnant or lactating, or males and females of reproductive potential not willing or not able to employ a highly effective method of birth control/contraception to prevent pregnancy from 2 weeks before receiving study drug until 3 months after receiving the last dose of study drug. A highly effective method of contraception is defined as having a low failure rate (< 1% per year) when used consistently and correctly. [\\\\u2026] Subjects with any concurrent medical condition or disease that will potentially compromise the conduction of the study at the discretion of the investigators</td>\\\\n      <td>[\\\\u2026] Note: sub-bullets were used to clearly identify laboratory abnormalities o Hematological test abnormalities of either hemoglobin <strike><</strike> \\\\u2264 8.5 g/dL (without transfusion or growth factor support in the preceding 14 days), neutrophils < 1.5 \\\\u00d7 10 <sup>9</sup> /L, or platelets < 60 \\\\u00d7 10 <sup>9</sup> /L (without transfusion or growth factor support in the preceding 7 days) o Liver dysfunction defined by total bilirubin > 3 mg/dL, or aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 5 \\\\u00d7 upper limit of normal (ULN) [\\\\u2026] Female subjects who are pregnant or lactating, or males and females of reproductive potential not willing or not able to employ a highly effective method of birth control/contraception to prevent pregnancy from 2 weeks before receiving study drug until 3 months after receiving the last dose of study drug. A highly effective method of contraception is defined as having a low failure rate (< 1% per year) when used consistently and correctly <strike>.</strike> [\\\\u2026] Subjects with any concurrent medical condition or disease that will potentially compromise the conduct <strike>ion</strike> of the study at the discretion of the investigators</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"10\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1, 2]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 174], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 175], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 176], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 177], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 178], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 179], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Administrative update</td>\\\\n      <td>Section 1, Synopsis, Investigational Medicinal Product: dose/mode of administration/dosing schedule</td>\\\\n      <td>26</td>\\\\n      <td>[\\\\u2026] Subjects will be instructed to swallow the whole tablets and to avoid biting or breaking the tablets, or attempting to dissolve in water before taking them. [\\\\u2026]</td>\\\\n      <td>[\\\\u2026] Subjects will be instructed to swallow the <strike>whole</strike> tablets whole and to avoid biting or breaking the tablets, or attempting to dissolve the tablets in water before taking them. [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Clarification of the role of the IRC</td>\\\\n      <td>Section 1, Synopsis, Primary endpoints</td>\\\\n      <td>27</td>\\\\n      <td>Phase II:  TTP assessed by an IRC . TTP is defined as the time (in months) from randomization to date of the observation of radiological PD assessed by an IRC</td>\\\\n      <td>Phase II:  TTP <strike>assessed</strike> based on tumor assessment by an IRC . TTP is defined as the time (in months) from randomization to date of the observation of radiological PD assessed by an IRC</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Clarification of the role of the IRC List of secondary endpoints updated</td>\\\\n      <td>Section 1, Synopsis, Secondary endpoints</td>\\\\n      <td>28</td>\\\\n      <td>Phase Ib and Phase II: Progression-free survival (PFS) assessed by the IRC. PFS time is defined as the time (in months) from randomization to either first observation of disease progression or occurrence of death due to any cause within 84 days of either randomization or the last tumor assessment. [\\\\u2026] Objective response (OR) assessed by the IRC. OR is defined as complete response (CR) or partial response (PR) as the best overall response according to radiological assessments as adjudicated by the IRC from randomization to first occurrence of PD. Responses do not require confirmation according to RECIST v 1.1. Disease control assessed by the IRC. Disease control is defined as CR, PR, or stable disease (SD) as the best overall response according to radiological assessments as adjudicated by the IRC from the date of randomization to the first occurrence of PD. In the case of SD, measurements must have met the SD criteria at least once after study entry at a</td>\\\\n      <td>Phase Ib and Phase II: Progression-free survival (PFS) <strike>assessed</strike> based on tumor assessment by the IRC. PFS time is defined as the time (in months) from randomization to either first observation of disease progression or occurrence of death due to any cause within 84 days of either randomization or the last tumor assessment. PFS based on tumor assessment by the investigator. PFS time is defined as the time (in months) from randomization to either first observation of radiologically confirmed PD by the investigator or occurrence of death due to any cause within 84 days of either randomization or the last tumor assessment. [\\\\u2026] Objective response (OR) <strike>assessed</strike> based on tumor assessment by the IRC. OR is defined as complete response (CR) or partial response (PR) as the best overall response according to radiological assessments as adjudicated by the IRC from randomization to first occurrence of PD. Responses do not require confirmation according to RECIST v 1.1.</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"11\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1, 2, 3]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 180], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 181], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>minimum interval of 42 days after randomization. [\\\\u2026]</td>\\\\n      <td>OR based on tumor assessment by the investigator. OR is defined as CR or PR as the best overall response according to radiological assessments as adjudicated by the investigator from randomization to first occurrence of PD. Responses do not require confirmation according to RECIST v 1.1. Disease control <strike>assessed</strike> based on tumor assessment by the IRC. Disease control is defined as CR, PR, or stable disease (SD) as the best overall response according to radiological assessments as adjudicated by the IRC from the date of randomization to the first occurrence of PD. In the case of SD, measurements must have met the SD criteria at least once after study entry at a minimum interval of 42 days after randomization. Disease control based on tumor assessment by the investigator. Disease control is defined as CR, PR, or SD as the best overall response according to radiological assessments as adjudicated by the investigator from the date of randomization to the first occurrence of PD. In the case of SD, measurements must have met the SD criteria at least once after study entry at a minimum interval of 42 days after randomization. [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Administrative update</td>\\\\n      <td>Section 1, Synopsis, Secondary endpoints</td>\\\\n      <td>29</td>\\\\n      <td>[\\\\u2026]  Incidence and type of AEs (all grades as per the National Cancer Institute\\\\u2019s (NCI)CTCAE version 4.0): all treatment emergent adverse events (TEAEs), related TEAEs, treatment emergent serious adverse events (SAEs), related treatment emergent SAEs, TEAEs of NCI-CTCAE</td>\\\\n      <td>[\\\\u2026]  Incidence and type of AEs (all grades as per the National Cancer Institute\\\\u2019s [ <strike>(</strike> NCI ] <strike>)</strike> - Common Terminology Criteria for Adverse Events [ CTCAE ] version 4.0): all treatment emergent adverse events (TEAEs), related TEAEs, treatment emergent serious adverse events (SAEs), related treatment emergent</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"12\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1, 2]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 182], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 183], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 184], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 185], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 186], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>(version 4.0) with Grade \\\\u2265 3, related TEAEs \\\\u2265 Grade 3, and TEAEs leading to temporary/permanent treatment discontinuation. [\\\\u2026]</td>\\\\n      <td>SAEs, TEAEs of NCI-CTCAE (version 4.0) with Grade \\\\u2265 3, related TEAEs <strike>\\\\u2265</strike> Grade \\\\u2265 3, and TEAEs leading to temporary/permanent treatment discontinuation. [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Administrative update</td>\\\\n      <td>Section 1, Synopsis, Pharmacokinetics</td>\\\\n      <td>29</td>\\\\n      <td>Phase Ib: PK endpoint (for MSC2156119J only): area under the curve from time zero to time t (AUC 0-t ), area under the plasma concentration versus time curve within 1 dosing interval (AUC 0-tau ), maximum concentration (C max ), average plasma concentration within 1 dosing interval (C av ), observed minimum plasma concentration (C min ), time to maximum concentration (t max ), area under the curve from time zero to infinity following last administration (AUC 0-\\\\u221e ), apparent clearance (CL/f), apparent volume distribution associated to the terminal phase (V z /f), volume of distribution at steady state (V ss /f), area under the curve terminal phase rate constant (\\\\u03bb z ), and half-life (t 1/2 ) when appropriate</td>\\\\n      <td>Phase Ib: PK endpoint (for MSC2156119J only): area under the curve from time zero to time t (AUC 0-t ), area under the plasma concentration versus time curve within 1 dosing interval (AUC 0-tau ), maximum concentration (C max ), average plasma concentration within 1 dosing interval (C av ), observed minimum plasma concentration (C min ), time to maximum concentration (t max ), area under the curve from time zero to infinity following last administration (AUC 0-\\\\u221e ), apparent clearance (CL/f), apparent volume distribution associated to the terminal phase (V z /f), apparent volume of distribution at steady state (V ss /f), area under the curve terminal phase rate constant (\\\\u03bb z ), and half-life (t 1/2 ) when appropriate .</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Administrative update</td>\\\\n      <td>Section 1, Synopsis, Exploratory endpoints, Phase II</td>\\\\n      <td>30</td>\\\\n      <td>[\\\\u2026]  Exploratory PK-efficacy endpoints (including but not limited to, objective response, absolute tumor shrinkage from baseline, and TTP) assessed per mRECIST criteria as adjudicated by the IRC, and the MSC2156119J concentrationresponse of QTc</td>\\\\n      <td>[\\\\u2026]  Exploratory PK-efficacy endpoints (including but not limited to, <strike>objective response</strike> OR absolute tumor shrinkage from baseline, and TTP) assessed per mRECIST criteria as adjudicated by the IRC, and the MSC2156119J concentration-response of QTc</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Final analysis cut-off updated Analysis population updated to mITT</td>\\\\n      <td>Section 1, Synopsis, Statistical methods (includes sample size calculation)</td>\\\\n      <td>30-31</td>\\\\n      <td>[\\\\u2026] Statistical analyses will be performed using electronic case report form (eCRF) data obtained until a clinical cut-off date in Phase II, which is determined by the date after the required number of events for the primary endpoint has been reported in the primary analysis population, i.e., 100 TTP events for</td>\\\\n      <td>[\\\\u2026] Primary <strike>S</strike> s tatistical analyses will be performed using electronic case report form (eCRF) data obtained until a clinical cut-off date in Phase II, which is determined by the date after the required number of events for the primary endpoint has been reported in the primary analysis population, i.e., <strike>100</strike> 40 TTP events for the modified intent-to-treat <strike>Intent-To-Treat</strike> ( m ITT)</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"13\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1, 3]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 187], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 188], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 189], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 190], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 191], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>the Intent-To-Treat (ITT) Population in Phase II. [\\\\u2026] The ITT Population will be primarily used in the analysis of baseline characteristics and efficacy. Analyses on the ITT Population will consider subjects\\\\u2019 allocation to treatment groups as randomized. Selected efficacy analyses will be repeated for the Per Protocol (PP) Population and for subgroups. In case that the PP Population includes more than 90% of the ITT Population, additional efficacy analyses on the PP Population will be omitted. [\\\\u2026]</td>\\\\n      <td><strike>P</strike> p opulation in Phase II or on 15 August 2017, whichever occurs first . The final statistical analyses for the Phase II study will be performed at approximately 6 months after the last subject is first dosed. Determination of MET status is planned at Molecular Prescreening (Phase Ib retrospectively, Phase II for subject selection); rescoring will be performed as a quality control measure. The mITT population excludes subjects who were randomized but for whom, retrospectively, a c-Met status of 1+ or \\\\u2018not assessable\\\\u2019 was detected . [\\\\u2026] The m ITT <strike>P</strike> p opulation will be primarily used in the analysis of baseline characteristics and efficacy. Analyses on the m ITT <strike>P</strike> p opulation will consider subjects\\\\u2019 allocation to treatment groups as randomized. Selected efficacy analyses will be repeated for the intent-to-treat population, the Per Protocol (PP) <strike>P</strike> p opulation and for subgroups. In case that the PP <strike>P</strike> p opulation includes more than 90% of the m ITT <strike>P</strike> p opulation, additional efficacy analyses on the PP <strike>P</strike> p opulation will be omitted. [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Administrative update</td>\\\\n      <td>Section 1, Synopsis, Statistical methods (includes sample size calculation)</td>\\\\n      <td>31</td>\\\\n      <td>Phase Ib: For Phase Ib, the total number of subjects in this trial is up to 21.</td>\\\\n      <td>Phase Ib: For Phase Ib, the total number of subjects to be enrolled in this trial is up to 21.</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"14\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1, 2]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 192], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 193], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 194], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 195], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 196], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Removal of interim futility analysis Clarification of MET+ HCC population Change relating to early discontinuation of prescreening</td>\\\\n      <td>Section 1, Synopsis, Statistical methods (includes sample size calculation)</td>\\\\n      <td>32</td>\\\\n      <td>Phase II For Phase II, the sample size requires 100 TTP events (assessed by an IRC) to ensure 80% power with a two-sided significance level of 10% for rejecting the null hypothesis of equal treatment effect between treatment arms, assuming a true hazard ratio (HR) of 0.6. Assuming a median TTP in Asian subjects for the sorafenib arm of 2.8 months, an HR of 0.6 represents a 1.87 month increase, resulting in a median TTP of 4.67 months for the MSC2156119J arm. One formal interim futility analysis with O\\\\u2019Brien Flemming method as futility boundary calculation will be performed after observation of 50% of TTP events. A total number of 140 subjects will be randomized on a 1:1 basis to receive MSC2156119J or sorafenib.</td>\\\\n      <td>Phase II For Phase II, the initial sample size planning required <strike>requires</strike> 100 TTP events (assessed by an IRC) to ensure 80% power with a two-sided significance level of 10% for rejecting the null hypothesis of equal treatment effect between treatment arms, assuming a true hazard ratio (HR) of 0.6. Assuming a median TTP in Asian subjects for the sorafenib arm of 2.8 months, an HR of 0.6 represents a 1.87 month increase, resulting in a median TTP of 4.67 months for the MSC2156119J arm. <strike>One formal interim futility analysis with O\\\\u2019Brien</strike>  <strike>Flemming method as futility boundary calculation</strike>  <strike>will be performed after observation of 50% of TTP</strike>  <strike>events.</strike> A total number of 140 subjects with MET+ HCC were planned to <strike>will</strike> be randomized on a 1:1 basis to receive MSC2156119J or sorafenib. Prescreening/enrollment will be stopped following 40 TTP events (assessed by an IRC) or on 15 August 2017, whichever occurs first. It is expected that approximately 90 subjects will be randomized by 15 August 2017. The sponsor\\\\u2019s decision to stop enrollment is due to business-related considerations not related to any safety issues.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Administrative update</td>\\\\n      <td>Section 2.1, Sponsor</td>\\\\n      <td>33</td>\\\\n      <td>Merck KGaA will be the sponsor of this Asian clinical trial of c-Met inhibitor MSC2156119J (International Nonproprietary Name: tepotinib).</td>\\\\n      <td>Merck KGaA will be the sponsor of this Asian clinical trial of mesenchymal epithelial transcription factor ( c-Met ) inhibitor MSC2156119J (International Nonproprietary Name: tepotinib).</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Clarification of the role of the IRC</td>\\\\n      <td>Section 2.2.3, Independent Review Committee</td>\\\\n      <td>34</td>\\\\n      <td>An Independent Review Committee (IRC) will conduct a blinded review of the images of all subjects using the same criteria based on a separate charter outlining details of the review process. In addition, images may be evaluated by the IRC in accordance with modified</td>\\\\n      <td>An Independent Review Committee (IRC) will conduct a blinded review of the images of all subjects using the same criteria based on a separate charter outlining details of the review process. In addition, images will <strike>may</strike> be evaluated by the IRC in accordance with modified</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"15\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1, 2, 3]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 197], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 198], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Response Evaluation Criteria in Solid Tumors (mRECIST) (1).</td>\\\\n      <td>Response Evaluation Criteria in Solid Tumors (mRECIST) (1).</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Administrative update</td>\\\\n      <td>Section 3.2, c-Met</td>\\\\n      <td>35</td>\\\\n      <td>The mesenchymal-epithelial transition factor (c-Met) receptor tyrosine kinase is a cell surface receptor capable of mediating pleiotropic effects, including cell migration, survival, and proliferation. [\\\\u2026] In postnatal live, c-Met signaling has been implicated in wound healing and regeneration of damaged organs, in particular the liver (11). [\\\\u2026]</td>\\\\n      <td>The <strike>mesenchymal-epithelial transition factor</strike>  <strike>(</strike> c-Met <strike>)</strike> receptor tyrosine kinase is a cell surface receptor capable of mediating pleiotropic effects, including cell migration, survival, and proliferation. [\\\\u2026] In postnatal <strike>live</strike> life c-Met signaling has been implicated in wound healing and regeneration of damaged organs, in particular the liver (11). [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Administrative update</td>\\\\n      <td>Section 3.3.2, Clinical Experience</td>\\\\n      <td>36</td>\\\\n      <td>[\\\\u2026] The last subject-last visit in the FIM trial took place on 08 October 2015 and the Clinical Trial Report is in preparation. [\\\\u2026]</td>\\\\n      <td>[\\\\u2026] The last subject-last visit in the FIM trial took place on 08 October 2015 and the Clinical Trial Report <strike>is in preparation</strike> has been finalized . [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Administrative update</td>\\\\n      <td>Section 3.4, Rationale for the Current Trial</td>\\\\n      <td>38-39</td>\\\\n      <td>[\\\\u2026] The rationale that MSC2156119J as monotherapy is to be compared with sorafenib in the first-line treatment for advanced HCC with MET+ is as following: [\\\\u2026] While the relative improvement in median OS was similar (HR for OS of 0.68 (95% CI: 0.500.93) and 0.69 (95% CI: 0.55-0.87) in Asian and other subjects, respectively) the absolute improvement in terms of median OS was 6.5 and 10.7 months in sorafenib arm in Asian subjects and other subjects, respectively (7, 8). [\\\\u2026]</td>\\\\n      <td>[\\\\u2026] The rationale that MSC2156119J as monotherapy is to be compared with sorafenib in the first-line treatment for advanced HCC with MET+ is as follow s <strike>ing</strike> : [\\\\u2026] While the relative improvement in median OS was similar (HR for OS of 0.68 <strike>(</strike> [ 95% CI: 0.500.93 ] <strike>)</strike> and 0.69 <strike>(</strike> [ 95% CI: 0.55-0.87 ] <strike>)</strike> in Asian and other subjects, respectively)  the absolute improvement in terms of median OS was 6.5 and 10.7 months in sorafenib arm in Asian subjects and other subjects, respectively (7, 8). [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>Identified and potential risks updated</td>\\\\n      <td>Section 3.5, Risk-benefit evaluation</td>\\\\n      <td>40</td>\\\\n      <td>Overall in the ongoing FIM trial, MSC2156119J was well tolerated (refer to the latest IB). Important identified risk thus far with the application of MSC2156119J is an asymptomatic elevation of pancreatic enzymes. Potential risks associated with study</td>\\\\n      <td>Overall in the ongoing and completed <strike>FIM</strike> trial s MSC2156119J was well tolerated (refer to the <strike>latest</strike> current IB). Asymptomatic pancreatic enzyme elevations are an identified risk from clinical studies, and hepatobiliary toxicity and drug-drug interaction with P-glycoprotein (P</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"16\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 2, 3]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 199], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 200], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 201], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 202], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 203], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>drug application from preclinical studies are hepatobiliary toxicity and drug-drug interaction with P-glycoprotein (P-gp) mediated transport drugs.</td>\\\\n      <td>gp), breast cancer resistance protein (BCRP) and organic cation transporter 1 (OCT1) mediated transport drugs are potential risks from nonclinical studies. <strike>Important identified</strike>  <strike>risk thus far with the application of MSC2156119J</strike>  <strike>is an asymptomatic elevation of pancreatic</strike>  <strike>enzymes.</strike> <strike>Potential risks associated with study</strike>  <strike>drug application from preclinical studies are</strike>  <strike>hepatobiliary toxicity and drug-drug interaction</strike>  <strike>with P-glycoprotein (P-gp) mediated transport</strike>  <strike>drugs.</strike></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Administrative update</td>\\\\n      <td>Section 4.3, Exploratory Objectives</td>\\\\n      <td>41</td>\\\\n      <td>The exploratory objectives are:  Phase Ib: To assess genetic variations of genes, such as P-gp breast cancer resistance protein (BCRP), that may be involved in the PK and safety of MSC2156119J, to assess exploratory biomarkers of c-Met and network alterations in serum and tumor tissue (if available) and their potential correlation with prognosis and MSC2156119J\\\\u2019s activity</td>\\\\n      <td>The exploratory objectives are:  Phase Ib: To assess genetic variations of genes, such as P-gp <strike>breast cancer resistance</strike>  <strike>protein (</strike> BCRP <strike>)</strike> that may be involved in the PK and safety of MSC2156119J, to assess exploratory biomarkers of c-Met and network alterations in serum and tumor tissue (if available) and their potential correlation with prognosis and MSC2156119J\\\\u2019s activity</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Administrative update Clarification of MET+ HCC population Clarification of IDMC responsibilities</td>\\\\n      <td>Section 5.1, Overall Trial Design and Plan</td>\\\\n      <td>41-44</td>\\\\n      <td>[\\\\u2026] Approximately 140 subjects will be randomized on a 1:1 basis to receive MSC2156119J or sorafenib. The assessment for safety profile and interim analysis results will be performed by the IDMC in Phase II, as described in Section 8.6. [\\\\u2026]</td>\\\\n      <td>[\\\\u2026] Approximately 140 subjects with MET+ HCC were planned to <strike>wil</strike> l be randomized on a 1:1 basis to receive MSC2156119J or sorafenib. The assessment for safety profile <strike>and interim analysis</strike>  <strike>results</strike> will be performed by the IDMC in Phase II, as described in Section 8.6. [...]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Correction</td>\\\\n      <td>Figure 3: Treatment Duration</td>\\\\n      <td>45</td>\\\\n      <td></td>\\\\n      <td>See Appendix 4.1.</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"17\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 3]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 204], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 205], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 206], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 207], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 208], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 209], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Administrative update</td>\\\\n      <td>Section 5.2, Discussion of Trial Design</td>\\\\n      <td>45</td>\\\\n      <td>[\\\\u2026] In the ongoing FIM trial, MSC2156119J has a favorable safety profile. A RP2D of 500 mg once daily has been determined, based on PK/Pd modeling and supported by data on target inhibition from paired tumor biopsies, rather than as an MTD based on safety signals; there were no DLTs at the RP2D. [\\\\u2026]</td>\\\\n      <td>[\\\\u2026] In the <strike>ongoing</strike> completed FIM trial, MSC2156119J has a favorable safety profile. A RP2D of 500 mg once daily has been determined, based on PK/Pd modeling and supported by data on target inhibition from paired tumor biopsies, rather than as an MTD based on safety signals; there were no DLTs at the RP2D. [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Clarification of inclusion criteria Administrative update</td>\\\\n      <td>Section 5.3.1, Inclusion Criteria</td>\\\\n      <td>46-47</td>\\\\n      <td>[\\\\u2026] 2. Subjects with advanced HCC of BCLC Stage B or C, who are not eligible for surgical and/or local-regional therapies or who have progressive disease (PD) after surgical and/or local-regional therapies. See Appendix K NOTE: Local-regional therapy MUST NOT contain sorafenib [\\\\u2026] 5. MET+ status (Phase II only), as determined by the central laboratory (Phase Ib retrospectively, Phase II for subject selection) is defined as c-Met protein overexpression (e.g., moderate (2+) or strong (3+) staining intensity for cMet using IHC in the majority [\\\\u2265 50%] of tumor cells) (see Appendix A) [\\\\u2026]</td>\\\\n      <td>[\\\\u2026] 2. Subjects with either intermediate <strike>advanced</strike> HCC of BCLC Stage B <strike>or C</strike> who are not eligible for surgical and/or localregional therapies or who have progressive disease (PD) after surgical and/or local-regional therapies or with advanced HCC of BCLC Stage C . See Appendix K NOTE: <strike>L</strike> l ocal-regional therapy MUST NOT contain sorafenib [\\\\u2026] 5. MET+ status (Phase II only), as determined by the central laboratory (Phase Ib retrospectively, Phase II for subject selection) is defined as c-Met protein overexpression (e.g., moderate [ <strike>(</strike> 2+ <strike>)</strike> ] or strong [ <strike>(</strike> 3+ <strike>)</strike> ] staining intensity for c-Met using IHC in the majority [\\\\u2265 50%] of tumor cells) (see Appendix A) [\\\\u2026]</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"18\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1, 2]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 210], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 211], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Permitted types of radiation therapy clarified</td>\\\\n      <td>Section 5.3.2, Exclusion Criteria</td>\\\\n      <td>47-50</td>\\\\n      <td>[\\\\u2026] 3. Prior local-regional therapy within 4 weeks prior to Day 1 of trial treatment (e.g., major surgery, radiation therapy, hepatic arterial embolization, transcatheter arterial chemoembolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection, or cryoablation) [\\\\u2026] 22. Subjects with any concurrent medical condition or disease that will potentially compromise the conduction of the study at the discretion of the investigators [\\\\u2026]</td>\\\\n      <td>[\\\\u2026] 3. Prior local-regional therapy within 4 weeks prior to Day 1 of trial treatment (e.g., major surgery, radiation therapy [with the exception of palliative bone-directed radiotherapy and radiotherapy administered to superficial lesions] hepatic arterial embolization, transcatheter arterial chemoembolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection, or cryoablation) NOTE: palliative bone-directed radiotherapy should be within a limited field of radiation and for palliation only; it should be a short course, according to local institutional recommendations, and should be completed at least 7 days prior to the first administration of trial treatment [\\\\u2026] 22. Subjects with any concurrent medical condition or disease that will potentially compromise the conduct <strike>ion</strike> of the study at the discretion of the investigators [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Administrative update</td>\\\\n      <td>Section 5.5.3, Withdrawal from Trial Therapy</td>\\\\n      <td>51</td>\\\\n      <td>[\\\\u2026] o dose delay time is more than 21 days at the lowest dose, as defined in Section 6.2.5 [\\\\u2026]</td>\\\\n      <td>[\\\\u2026] o dose delay time is more than 21 consecutive days at the lowest dose, as defined in Section 6.2.5 [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Administrative update</td>\\\\n      <td>Section 5.6, Premature Discontinuation of the Trial</td>\\\\n      <td>52</td>\\\\n      <td>The whole trial may be discontinued prematurely in the event of any of the following:  New information leading to unfavorable risk-benefit judgment of MSC2156119J, e.g., due to o Evidence of inefficacy</td>\\\\n      <td>The whole trial may be discontinued prematurely in the event of any of the following:  New information leading to unfavorable riskbenefit judgment of MSC2156119J, e.g., due to o Evidence of inefficacy</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"19\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1, 2]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 212], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 213], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n      <th>6.0</th>\\\\n      <th>7.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td></td>\\\\n      <td>Previous Wording</td>\\\\n      <td></td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>o [\\\\u2026]</td>\\\\n      <td>(Note: evidence of inefficacy may arise from this trial or from other trials; unfavorable safety findings may arise from clinical or nonclinical examinations, e.g., toxicology.) Safety findings that preclude further continuation of the trial</td>\\\\n      <td>o [\\\\u2026]</td>\\\\n      <td>(Note: evidence of inefficacy may arise from this trial or from other trials <strike>;</strike>  <strike>unfavorable safety findings may arise</strike>  <strike>from clinical or nonclinical</strike>  <strike>examinations, e.g., toxicology.</strike> ) . Safety findings that preclude further continuation of the trial (Note: unfavorable safety findings may arise from clinical or nonclinical examinations, e.g., toxicology).</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Change relating to early discontinuation of prescreening</td>\\\\n      <td>Section 5.7, Definition of End of Trial</td>\\\\n      <td>52</td>\\\\n      <td>[\\\\u2026] However, under certain circumstances, subjects may be given the opportunity to participate in a rollover trial or the Sponsor may terminate the trial early.</td>\\\\n      <td>[\\\\u2026] However, under certain circumstances, subjects may be given the opportunity to participate in a rollover trial or the Sponsor may terminate the trial early.</td>\\\\n      <td>[\\\\u2026] However, under certain circumstances, subjects may be given the opportunity to participate in a rollover trial or the <strike>S</strike> s ponsor may terminate the trial early. The sponsor will stop prescreening/enrollment following 40 TTP events (assessed by an IRC) or on 15 August 2017, whichever occurs first. Subjects who sign the ICF prior to 15 August 2017 and undergo prescreening/screening after the enrollment stop date may still be randomized in the trial. Subjects who are currently receiving treatment may continue treatment after discussion with their Investigator. If the subject decides to continue treatment, they will continue on their originally randomized treatment, at their most recent dose according to the protocol. Safety monitoring and data collection will continue without modification through to the end of the trial.</td>\\\\n      <td>[\\\\u2026] However, under certain circumstances, subjects may be given the opportunity to participate in a rollover trial or the <strike>S</strike> s ponsor may terminate the trial early. The sponsor will stop prescreening/enrollment following 40 TTP events (assessed by an IRC) or on 15 August 2017, whichever occurs first. Subjects who sign the ICF prior to 15 August 2017 and undergo prescreening/screening after the enrollment stop date may still be randomized in the trial. Subjects who are currently receiving treatment may continue treatment after discussion with their Investigator. If the subject decides to continue treatment, they will continue on their originally randomized treatment, at their most recent dose according to the protocol. Safety monitoring and data collection will continue without modification through to the end of the trial.</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"20\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1, 2]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 214], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 215], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 216], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 217], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 218], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 219], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 220], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Administrative update</td>\\\\n      <td>Section 6.2, Dosage and Administration, Phase Ib</td>\\\\n      <td>53</td>\\\\n      <td>[\\\\u2026] Subjects will be instructed to swallow the whole tablets and to avoid biting or breaking the tablets, or attempting to dissolve in water before taking them. [\\\\u2026]</td>\\\\n      <td>[\\\\u2026] Subjects will be instructed to swallow the <strike>whole</strike> tablets whole and to avoid biting or breaking the tablets, or attempting to dissolve the tablets in water before taking them. [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Administrative update</td>\\\\n      <td>Section 6.2.2, Definition of DLT</td>\\\\n      <td>55</td>\\\\n      <td>[\\\\u2026] Using the National Cancer Institute\\\\u2019s (NCI)-CTCAE version 4.0, DLT is defined as any of the following toxicities at any dose level and judged to be related to the trial treatment by the investigator and/or the sponsor: [\\\\u2026]</td>\\\\n      <td>[\\\\u2026] Using the National Cancer Institute\\\\u2019s (NCI)- Common Terminology Criteria for Adverse Events ( CTCAE ) version 4.0, DLT is defined as any of the following toxicities at any dose level and judged to be related to the trial treatment by the investigator and/or the sponsor: [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Definition of noncompliance updated</td>\\\\n      <td>Section 6.2.5, Dose Adjustment and Missed Dose</td>\\\\n      <td>57-58</td>\\\\n      <td>Missed doses of trial treatment will not be made up unless the subject is seen to vomit the entire tablet immediately after administration of the study drug. An administration time delay \\\\u2264 12 hours compared to the scheduled administration time is permitted; however, if the time delay is > 12 hours, study drug should not be administered on the current day. [\\\\u2026] Subjects who miss more than ~20% of doses planned during Cycle 1 (i.e., 4 days) for reasons other than adverse drug reactions or DLTs will not be fully evaluable for the assessment of the primary endpoints of Phase Ib. The new subjects will be replaced for assessment of DLT. [\\\\u2026]</td>\\\\n      <td>Missed doses of trial treatment will not be made up unless the subject is seen to vomit the entire tablet immediately after administration of the study drug. An administration time delay \\\\u2264 12 hours compared to the scheduled administration time is permitted; however, if the time delay is > 12 hours, study drug should not be administered on the current day. In Phase Ib and Phase II, subjects who miss more than 21 consecutive days of trial treatments for non-medical reasons are considered non-compliant and should be withdrawn from trial treatments (see Section 5.5.3). [\\\\u2026] Subjects who miss more than ~20% of doses planned during Cycle 1 (i.e., 4 days) for reasons other than adverse drug reactions or DLTs will not be fully evaluable for the assessment of the primary endpoints of Phase Ib ; these <strike>.</strike> <strike>The new</strike> subjects will be replaced for assessment of DLT. [\\\\u2026]</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"21\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1, 2, 3]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 221], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 222], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>HBV/HCV reactivation guidelines reiterated</td>\\\\n      <td>Section 6.2.5, Dose Adjustment and Missed Dose</td>\\\\n      <td>58</td>\\\\n      <td>[\\\\u2026]  Asymptomatic lipase and/or amylase elevation, i.e., without confirmation of pancreatitis [\\\\u2026]</td>\\\\n      <td>[\\\\u2026] Asymptomatic lipase and/or amylase elevation, i.e., without confirmation of pancreatitis In the event of a subject experiencing Hepatitis B virus (HBV) or Hepatitis C virus (HCV) reactivation (see Section 6.5.3.1), the following dose modification guidelines should be followed: HBV reactivation: Provide antiviral treatment and/or adjust current antiviral treatment Interrupt MSC2156119J until HBV DNA resolves to \\\\u2264 baseline levels If resolution takes longer than 21 days, discontinue MSC2156119J If resolution is within 21 days, MSC2156119J can be resumed at a minus 1 dose level HCV reactivation: Discontinue MSC2156119J [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Administrative update</td>\\\\n      <td>Section 6.3, Assignment to Treatment Groups</td>\\\\n      <td>59</td>\\\\n      <td>The last 4 numbers will be the sequential order in which subjects are enrolled into the trial by signing the main informed consent form (ICF) (beginning with 0001)</td>\\\\n      <td>The last 4 numbers will be the sequential order in which subjects are enrolled into the trial by signing the main <strike>informed consent form (</strike> ICF <strike>)</strike> (beginning with 0001)</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Administrative update FDA Drug Interactions and Labeling Web page added</td>\\\\n      <td>Section 6.5.1, Permitted Medicines</td>\\\\n      <td>60</td>\\\\n      <td>[\\\\u2026]  Oral antivirals for chronic hepatitis are permitted before and during the study . The prescription of these agents for subjects with chronic hepatitis during the study is recommended based on the clinical guidelines. [\\\\u2026]</td>\\\\n      <td>[\\\\u2026]  Oral antivirals for chronic hepatitis are permitted before and during the study . The prescription of these agents for subjects with chronic hepatitis during the study is recommended based on the clinical guidelines <strike>.</strike> [\\\\u2026]</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"22\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 223], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 224], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Concomitant medications that have a narrow therapeutic window and are known to be transported by P-gp (e.g., rivaroxaban, apixaban, ranolazine, talinolol, digoxin), breast cancer resistance protein (BCRP) (e.g., rosuvastatin), or organic cation transporter 1 (OCT1) are permitted, but should be used with caution Concomitant medications that are known to inhibit P-gp (e.g., itraconazole, telaprevir, clarithromycin, ketoconazole, and conivaptan) are permitted but should be used with caution [\\\\u2026]</td>\\\\n      <td>Concomitant medications that have a narrow therapeutic window and are known to be transported by P-gp (e.g., rivaroxaban, apixaban, ranolazine, talinolol, digoxin), <strike>breast cancer resistance protein (</strike> BCRP <strike>)</strike> (e.g., rosuvastatin), or <strike>organic cation transporter 1</strike>  <strike>(</strike> OCT1 <strike>)</strike> are permitted, but should be used with caution (refer to http://www.fda.gov/Drugs/Development ApprovalProcess/Development Resources/DrugInteractionsLabeling/ default.htm for examples of in vitro, in vivo, and clinical substrates for P-gp and BCRP) Concomitant medications that are known to inhibit P-gp (e.g., itraconazole, telaprevir, clarithromycin, ketoconazole, and conivaptan) are permitted but should be used with caution (refer to http://www.fda.gov/Drugs/Development ApprovalProcess/Development Resources/DrugInteractionsLabeling/ default.htm for examples of clinical inhibitors for P-gp and BCRP) [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>FDA Drug Interactions and Labeling Web page added</td>\\\\n      <td>Section 6.5.2, Non-Permitted Medicines</td>\\\\n      <td>61</td>\\\\n      <td>[\\\\u2026] Drug(s) for which the package insert/Summary of Product Characteristics includes a contraindication for P-gp (e.g., dabigatran, aliskiren, colchicine), BCRP, and/or OCT1 inhibiting drugs must not be combined with MSC2156119J Drug(s) that are known to induce P-gp and thereby may decrease the efficacy of MSC2156119J (e.g., avasimibe, carbamazepine, phenytoin, rifampin, St John\\\\u2019s Wort) [\\\\u2026]</td>\\\\n      <td>[\\\\u2026] Drug(s) for which the package insert/Summary of Product Characteristics includes a contraindication for P-gp (e.g., dabigatran, aliskiren, colchicine), BCRP, and/or OCT1 inhibiting drugs must not be combined with MSC2156119J (refer to http://www.fda.gov/Drugs/Development ApprovalProcess/Development Resources/DrugInteractionsLabeling/ default.htm for examples of clinical inhibitors for CYP3A-mediated metabolisms) Drug(s) that are known to induce P-gp and thereby may decrease the efficacy of</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"23\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1, 2]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 225], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 226], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 227], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 228], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 229], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>MSC2156119J (e.g., avasimibe, carbamazepine, phenytoin, rifampin, St John\\\\u2019s Wort) (refer to http://www.fda.gov/Drugs/Development ApprovalProcess/Development Resources/DrugInteractionsLabeling/ default.htm for examples of clinical inducers for CYP3A-mediated metabolisms) [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Administrative update Reference to laboratory manual added</td>\\\\n      <td>Section 6.5.3.1, Guidelines for Subjects with Hepatitis B or Hepatitis C</td>\\\\n      <td>62</td>\\\\n      <td>Hepatitis B virus serology (2 mL serum sample) i.e., hepatitis B surface antigen (HBsAg), hepatitis B core antibodies (HBcAb), hepatitis B surface antibodies (HBsAb), hepatitis B e antigen (HBeAg) and hepatitis B e antibodies (HBeAb) [\\\\u2026] Instructions on sample collection and processing will be provided. [\\\\u2026]</td>\\\\n      <td>Hepatitis B virus serology (2 mL serum sample) i.e., hepatitis B surface antigen (HBsAg), hepatitis B core antibodies <strike>(HBcAb)</strike> hepatitis B surface antibodies (HBsAb), hepatitis B e antigen (HBeAg) and hepatitis B e antibodies <strike>(HBeAb)</strike> [\\\\u2026] Instructions on sample collection and processing will be provided in the laboratory manual . [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Administrative update to table footnote</td>\\\\n      <td>Table 1: Monitoring of Subjects According to Baseline Virology Status</td>\\\\n      <td>62</td>\\\\n      <td>a. Except for positive HBsAb after vaccination.</td>\\\\n      <td>a. Except for positive <strike>HBsAb</strike> hepatitis B surface antibodies after vaccination.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Administrative update</td>\\\\n      <td>Section 6.5.3.1, Guidelines for Subjects with Hepatitis B or Hepatitis C</td>\\\\n      <td>62</td>\\\\n      <td>[\\\\u2026] If necessary, appropriate antiviral treatment should be provided to subjects prior to the first dose of trial treatment and/or during trial treatment (refer to local guidelines and to: American Association for the Study of Liver Diseases [AASLD] Guidelines for Treatment of Hepatitis B, 2015 and Hepatitis C Guidance: AASLD-Infectious Diseases Society of America [IDSA] Recommendations for Testing, Managing, and Treating Adults Infected With Hepatitis C Virus, 2015). [\\\\u2026]</td>\\\\n      <td>[\\\\u2026] If necessary, appropriate antiviral treatment should be provided to subjects prior to the first dose of trial treatment and/or during trial treatment (refer to local guidelines and to: American Association for the Study of Liver Diseases [AASLD] Guidelines for Treatment of Hepatitis B, 2015 and Hepatitis C Guidance: AASLD-Infectious Diseases Society of America <strike>[IDSA]</strike> Recommendations for Testing, Managing, and Treating Adults Infected With Hepatitis C Virus, 2015). [\\\\u2026]</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"24\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1, 2, 3]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 230], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 231], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 232], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 233], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 234], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 235], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Clarification of Molecular Prescreening assessments Administrative updates</td>\\\\n      <td>Section 7.1.2, Screening Period</td>\\\\n      <td>66-67</td>\\\\n      <td>[\\\\u2026] In Phase II, subjects will have a Molecular Prescreening period prior to Clinical Screening during which (subject to the provision of informed consent) their MET status will be determined in order to confirm their suitability for the trial, and demographic data and disease history may also be collected. [\\\\u2026] Chemistry (blood nitrogen urea [BUN], creatinine, AST, ALT, gamma-glutamyl transpeptidase (GGT), total bilirubin [including direct fraction if total bilirubin is abnormal], lipase, amylase, total protein, albumin, alkaline phosphatase, sodium, potassium, calcium, magnesium, and glucose) [\\\\u2026] Hepatitis B virus serology: hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis B surface antibody (HBsAb), hepatitis B e antigen (HBeAg) and hepatitis B e antibodies (HBeAb) Hepatitis B virus DNA (viral load) Hepatitis C virus RNA by polymerase chain reaction (PCR) (HCV RNA) [\\\\u2026] Complete tumor assessment of all lesions by radiographic or other modality (using RECIST v 1.1). Computed tomography or magnetic resonance imaging (MRI) of the chest, abdomen, and pelvis to evaluate disease in these locations. CT/MRI of the head for subjects who are suspected to have CNS metastases [\\\\u2026]</td>\\\\n      <td>[\\\\u2026] In Phase II, subjects will have a Molecular Prescreening period prior to Clinical Screening during which (subject to the provision of informed consent) their MET status will be determined in order to confirm their suitability for the trial, and demographic data and disease history will <strike>may</strike> also be collected. [\\\\u2026] Chemistry (blood nitrogen urea [BUN], creatinine, AST, ALT, gamma-glutamyl transpeptidase <strike>(</strike> [ GGT ] <strike>)</strike> total bilirubin [including direct fraction if total bilirubin is abnormal], lipase, amylase, total protein, albumin, alkaline phosphatase, sodium, potassium, calcium, magnesium, and glucose) [\\\\u2026] Hepatitis B virus serology: <strike>hepatitis B surface</strike>  <strike>antigen (</strike> HBsAg <strike>)</strike> hepatitis B core antibody <strike>(HBcAb)</strike>  <strike>hepatitis B surface antibody</strike>  <strike>(</strike> HBsAb <strike>)</strike>  <strike>hepatitis B e antigen (</strike> HBeAg <strike>)</strike> and hepatitis B e antibodies <strike>(HBeAb)</strike> Hepatitis B virus DNA (viral load) <strike>Hepatitis C virus RNA by polymerase chain</strike>  <strike>reaction (PCR) (</strike> HCV RNA -PCR <strike>)</strike> [\\\\u2026] Complete tumor assessment of all lesions by radiographic or other modality (using RECIST v 1.1). Computed tomography or <strike>magnetic</strike>  <strike>resonance imaging (</strike> MRI <strike>)</strike> of the chest, abdomen, and pelvis to evaluate disease in these locations. CT/MRI of the head for subjects who are suspected to have CNS metastases [\\\\u2026]</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"25\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 236], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 237], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Clarification of ICF requirements for optional assessments Time window added for triplet 12-lead ECG recordings</td>\\\\n      <td>Section 7.1.3.1, Cycle 1, Day 1</td>\\\\n      <td>68</td>\\\\n      <td>[\\\\u2026] Tumor biopsy (excluding fine needle aspiration and cytology samples) (undergoing paired tumor biopsy is not mandatory, but highly recommended for subjects with accessible tumors: the paired tumor biopsy will be performed before the first treatment (i.e., during screening or on Cycle 1, Day 1 prior to the first dose of trial treatment), and anytime between Cycle 1, Day 15 and the beginning of Cycle 3 [optional] Triplet 12-lead ECG recordings with 2-minute intervals after at least 5 minutes rest in supine position at predose (within 60 minutes prior to dose) and 4 hours (\\\\u00b1 12 minutes) postdose. ECGs should be performed within 10 minutes prior to PK sampling at time points where both assessments are performed [\\\\u2026] PGx blood sample (predose only; optional, will be collected after subject\\\\u2019s signing off separate ICF)</td>\\\\n      <td>[\\\\u2026] Tumor biopsy (excluding fine needle aspiration and cytology samples) . <strike>(u</strike> U ndergoing paired tumor biopsy is not mandatory, but highly recommended for subjects with accessible tumors: the paired tumor biopsy will be performed before the first treatment (i.e., during screening or on Cycle 1, Day 1 prior to the first dose of trial treatment), and anytime between Cycle 1, Day 15 and the beginning of Cycle 3 <strike>[</strike> ( optional will be collected after subjects have signed a separate ICF) <strike>]</strike> Triplet 12-lead ECG recordings with 2-minute intervals (\\\\u00b1 1 minute) after at least 5 minutes rest in supine position at predose (within 60 minutes prior to dose) and 4 hours (\\\\u00b1 12 minutes) postdose. ECGs should be performed within 10 minutes prior to PK sampling at time points where both assessments are performed [\\\\u2026] PGx blood sample (predose only; optional, will be collected after subjects have signed a <strike>subject\\\\u2019s signing off</strike> separate ICF)</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Clarification of ICF requirements for optional assessments Correction (single 12-lead ECG on Cycle 1, Day 15 predose) Time window added for triplet 12-lead ECG recordings</td>\\\\n      <td>Section 7.1.3.2, Cycle 1, Day 15</td>\\\\n      <td>69</td>\\\\n      <td>[\\\\u2026] Tumor biopsy (excluding fine needle aspiration and cytology samples). Undergoing paired tumor biopsy is not mandated, but highly recommended for subjects with accessible tumors: the paired tumor biopsy will be performed before treatment at screening or on Cycle 1, Day 1 and anytime between Cycle 1, Day 15 and beginning of Cycle 3. A predose PK is recommended to be taken on the day of the second biopsy. Triplet 12-lead ECG recordings with 2minute intervals after at least 5 minutes rest in supine position at predose (within</td>\\\\n      <td>[\\\\u2026]  Tumor biopsy (excluding fine needle aspiration and cytology samples) . Undergoing paired tumor biopsy is not <strike>mandated</strike> mandatory but highly recommended for subjects with accessible tumors: the paired tumor biopsy will be performed before treatment at screening or on Cycle 1, Day 1 and anytime between Cycle 1, Day 15 and beginning of Cycle 3 (optional, will be collected after subjects have signed a separate ICF) . A predose PK is recommended to be taken on the day of the second biopsy.</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"26\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1, 2]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 238], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 239], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>40 minutes prior to dose) and 4 hours (\\\\u00b1 12 minutes) postdose. ECGs should be performed within 10 minutes prior to PK sampling at time points where both assessments are performed  PK blood samples . Samples will be taken predose (trough value, within 30 minutes prior to dose) and at 0.25, 0.5, 1, 2, 4, 8, 10, and 24 hours postdose; Note: the 24-hour postdose sample from Day 1 and Day 15 are the predose samples from Day 2 and Day 16, respectively. Postdose PK samples should be taken within \\\\u00b1 5% of the scheduled assessment time, e.g., the 4-hour postdose sample should be obtained at 4 hours \\\\u00b1 12 minutes [\\\\u2026]</td>\\\\n      <td><strike>Triplet 12-lead ECG recordings with 2-minute</strike>  <strike>intervals</strike> A single 12-lead ECG recording after at least 5 minutes rest in supine position at predose (within 40 minutes prior to dose) and triplet 12-lead ECG recordings with 2-minute intervals (\\\\u00b1 1 minute) at 4 hours (\\\\u00b1 12 minutes) postdose. ECGs should be performed within 10 minutes prior to PK sampling at time points where both assessments are performed PK blood samples <strike>.</strike> <strike>S</strike> (s amples will be taken predose <strike>(</strike> [ trough value, within 30 minutes prior to dose ] <strike>)</strike> and at 0.25, 0.5, 1, 2, 4, 8, 10, and 24 hours postdose ). <strike>;</strike> Note: the 24-hour postdose sample from Day 1 and Day 15 are the predose samples from Day 2 and Day 16, respectively. Postdose PK samples should be taken within \\\\u00b1 5% of the scheduled assessment time, e.g., the 4-hour postdose sample should be obtained at 4 hours \\\\u00b1 12 minutes [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Time window added for triplet 12-lead ECG recordings</td>\\\\n      <td>Section 7.1.3.3, Cycle 2, Day 1</td>\\\\n      <td>70</td>\\\\n      <td>[\\\\u2026]  Triplet 12-lead ECG recordings with 2-minute intervals after at least 5 minutes rest in supine position at predose (within 40 minutes prior to dose) and 4 hours (\\\\u00b1 12 minutes) postdose . ECGs should be performed within 10 minutes prior to PK sampling at time points where both assessments are performed [\\\\u2026]</td>\\\\n      <td>[\\\\u2026]  Triplet 12-lead ECG recordings with 2-minute intervals (\\\\u00b1 1 minute) after at least 5 minutes rest in supine position at predose (within 40 minutes prior to dose) and 4 hours (\\\\u00b1 12 minutes) postdose . ECGs should be performed within 10 minutes prior to PK sampling at time points where both assessments are performed [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Clarification of the timing of tumor imaging assessments</td>\\\\n      <td>Section 7.1.3.5, Cycle \\\\u2265 3, Day 1</td>\\\\n      <td>71</td>\\\\n      <td>[\\\\u2026] In addition, a complete tumor assessment of all lesions by radiographic or other modality (using RECIST v 1.1) identified at the screening visit will be performed on Day 1 of Cycles 3, 5, 7, 9, 11, 13, and every 4 cycles thereafter until disease progression or trial medication discontinuation.</td>\\\\n      <td>[\\\\u2026] In addition, a complete tumor assessment of all lesions by radiographic or other modality (using RECIST v 1.1) identified at the screening visit will be performed predose on or up to 5 days prior to, Day 1 of Cycles 3, 5, 7, 9, 11, 13, and every 4 cycles thereafter until disease progression</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"27\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1, 2, 3]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 240], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 241], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 242], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 243], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 244], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>[\\\\u2026]</td>\\\\n      <td>starting a new anti-tumor therapy, or death <strike>or</strike>  <strike>trial medication discontinuation</strike> . [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Clarification of ICF requirements for optional assessments Administrative update Clarification of EoT assessments</td>\\\\n      <td>Section 7.1.4, End of Treatment Visit</td>\\\\n      <td>71-72</td>\\\\n      <td>[\\\\u2026]  Tumor biopsy to be taken at the time of progression on the last day of drug application (excluding fine needle aspiration and cytology samples; optional) . Whenever possible, the biopsy taken at progression for determination of the MET status should be taken from the progressing lesion, provided that the lesion is accessible and there are no medical or safety reasons precluding a biopsy of the progressing lesion. [\\\\u2026] Assessments for the end of treatment visit in Phase II include all assessments in Phase Ib. In addition, FHSI-8 and PRO (FACT-HP) will be assessed.</td>\\\\n      <td>[\\\\u2026]  Tumor biopsy to be taken at the time of progression on the last day of drug application (excluding fine needle aspiration and cytology samples; optional will be collected after subjects sign a separate ICF ) . Whenever possible, the biopsy taken at progression for determination of the MET status should be taken from the progressing lesion, provided that the lesion is accessible and there are no medical or safety reasons precluding a biopsy of the progressing lesion. [\\\\u2026] Assessments for the end of treatment visit in Phase II include all assessments in Phase Ib. In addition, FHSI-8 and PRO (FACT-HP) will be assessed. Note: end of treatment ECG and laboratory assessments (hematology, coagulation, chemistry, urinalysis, and hepatitis markers) are not required for subjects with previous ECG and laboratory assessments, respectively, within 7 days of the end of treatment visit.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Correction Administrative update</td>\\\\n      <td>Section 7.2, Demographic and Other Baseline Characteristics</td>\\\\n      <td>74-75</td>\\\\n      <td>[\\\\u2026] Subjects should have a score of \\\\u2264 2 to participate in this trial. Details are described in Appendix D. [\\\\u2026]  Concomitant Medication/Procedures [\\\\u2026]</td>\\\\n      <td>2 to participate in this trial. Details are described in Appendix D. [\\\\u2026]  Concomitant <strike>M</strike> m edication/ <strike>P</strike> p rocedures [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Administrative update Clarification of imaging assessments</td>\\\\n      <td>Section 7.3, Assessment of Efficacy</td>\\\\n      <td>75</td>\\\\n      <td>Tumor assessment will be performed according to RECIST v 1.1 (see Appendix C) locally by the investigators and centrally by an independent radiologist. The baseline tumor</td>\\\\n      <td>Tumor assessment will be performed according to RECIST v 1.1 (see Appendix C) locally by the <strike>i</strike> I nvestigators and centrally by an independent radiologist. The baseline tumor assessment is</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"28\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 2, 3]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 245], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 246], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 247], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 248], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 249], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>assessment is scheduled to be performed during Clinical Screening (see Section 7.1.2). CT or MRI with contrast enhancement is recommended for tumor assessment. [\\\\u2026]</td>\\\\n      <td>scheduled to be performed during <strike>Clinical</strike>  <strike>Screening</strike> the Screening period of Phase Ib (see Section 7.1.2) and during the Clinical Screening period of Phase II . CT or MRI with contrast enhancement is <strike>recommended</strike> required for tumor assessment. [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Clarification of the timing of imaging assessments</td>\\\\n      <td>Section 7.3, Assessment of Efficacy</td>\\\\n      <td>76</td>\\\\n      <td>[\\\\u2026] Clinical progression, at any time, requires a physical examination and prompt radiological confirmation rather than waiting for the next scheduled imaging assessment.</td>\\\\n      <td>[\\\\u2026] Clinical progression, at any time, requires a physical examination and prompt radiological confirmation rather than waiting for the next scheduled imaging assessment. If unscheduled imaging does not meet progressive disease by RECIST v 1.1, the next scheduled imaging assessment should still be performed on time unless the next scheduled imaging assessment is within 14 days following the unscheduled imaging.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Definition of AE/SAEs observed in association with disease progression updated</td>\\\\n      <td>Section 7.4.1.1, Adverse Event Definitions</td>\\\\n      <td>79</td>\\\\n      <td>AE/SAEs Observed in Association with Disease Progression Disease progression recorded in the course of efficacy assessments only, but without any adverse signs or symptoms should not be reported as AEs. However, if adverse signs or symptoms occur in association with disease progression then these should be recorded as AEs and reported as SAEs if they meet the criteria for seriousness.</td>\\\\n      <td>AE/SAEs Observed in Association with  Disease Progression Progression of the disease/disorder being studied assessed by measurement of lesions on radiographs or other methods as well as associated clinical signs or symptoms (including laboratory abnormalities) should not be reported as an (S)AE, unless the subject\\\\u2019s general condition is more severe than expected for the participant\\\\u2019s condition and/or unless the outcome is fatal within the AE reporting period (as defined in Section 7.4.1.3). <strike>Disease progression recorded</strike>  <strike>in the course of efficacy assessments only, but</strike>  <strike>without any adverse signs or symptoms should</strike>  <strike>not be reported as AEs.</strike> <strike>However, if adverse signs or symptoms occur in</strike>  <strike>association with disease progression then these</strike>  <strike>should be recorded as AEs and reported as SAEs</strike>  <strike>if they meet the criteria for seriousness.</strike></td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"29\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1, 2, 3]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 250], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 251], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 252], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 253], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 254], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Administrative update</td>\\\\n      <td>Section 7.4.1.2, Methods of Recording and Assessing Adverse Events</td>\\\\n      <td>80</td>\\\\n      <td>[\\\\u2026] It is important that each AE report include a description of the event, its duration (onset and resolution dates (and times when it is important to assess the time of AE onset relative to the recorded treatment administration time), its severity, its causal relationship with the trial treatment, any other potential causal factors, any treatment given or other action taken (including dose modification or discontinuation of MSC2156119J/sorafenib) and its outcome. [\\\\u2026]</td>\\\\n      <td>[\\\\u2026] It is important that each AE report include s a description of the event, its duration (onset and resolution dates <strike>(</strike> and times when it is important to assess the time of AE onset relative to the recorded treatment administration time), its severity, its causal relationship with the trial treatment, any other potential causal factors, any treatment given or other action taken (including dose modification or discontinuation of MSC2156119J/sorafenib) and its outcome. [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Administrative update</td>\\\\n      <td>Section 7.4.1.3, Definition of the Adverse Event Reporting Period</td>\\\\n      <td>80</td>\\\\n      <td>[\\\\u2026] If post-treatment follow-up visit was not performed (e.g., the subject could not come back to the site for a visit), a telephone contact should be completed and documented for AE assessment. [\\\\u2026]</td>\\\\n      <td>[\\\\u2026] If the post-treatment follow-up visit was not performed (e.g., the subject could not come back to the site for a visit), a telephone contact should be completed and documented for AE assessment. [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Administrative update</td>\\\\n      <td>Section 7.4.3.4, Urinalysis</td>\\\\n      <td>84</td>\\\\n      <td>Urinalysis assessments (dispstick) for Phase Ib and Phase II are presented in Table 6. The dipstick urinalysis will be followed by microscopic examination if abnormal results. [\\\\u2026]</td>\\\\n      <td>Urinalysis assessments (di <strike>s</strike> pstick) for Phase Ib and Phase II are presented in Table 6. The dipstick urinalysis will be followed by microscopic examination if abnormal results. [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Table footnote added</td>\\\\n      <td>Table 7: Hepatitis B Virus Serology Panel</td>\\\\n      <td>85</td>\\\\n      <td>Not applicable</td>\\\\n      <td>Abbreviations: HBc, Hepatitis B core; HBe, Hepatitis B e; HBs, Hepatitis B surface.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>Administrative update</td>\\\\n      <td>Section 7.4.4.2, Vital Signs</td>\\\\n      <td>85</td>\\\\n      <td>Systolic blood pressure (SBP), diastolic blood pressure, respiratory rate, and pulse rate (beats per minute) will be measured in seated position after 5 minutes resting (for individual subjects, measurements at different visits should be taken in the same position). Body temperature will be recorded. [\\\\u2026]</td>\\\\n      <td>Systolic blood pressure <strike>(SBP)</strike> diastolic blood pressure, respiratory rate, and pulse rate (beats per minute) will be measured in seated position after 5 minutes resting (for individual subjects, measurements at different visits should be taken in the same position). Body temperature will be recorded. [\\\\u2026]</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"30\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1, 2]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 255], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 256], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Administrative update Time window added for triplet 12-lead ECG recordings</td>\\\\n      <td>Section 7.4.4.3, Electrocardiogram</td>\\\\n      <td>86</td>\\\\n      <td>A single standard 12-lead ECG will be recorded after the subject has rested at least for 5 minutes in a supine position. At least 5 to 7 beats for each lead run. For time points where both ECGs and PK samples are obtained, 12-lead ECGs should be taken in triplicate at 2-minute intervals, and should be performed within a maximum of 10 minutes prior to PK sampling. [\\\\u2026]</td>\\\\n      <td>A single standard 12-lead ECG will be recorded after the subject has rested at least for 5 minutes in a supine position. At least 5 to 7 beats are required for each lead run. For time points where both ECGs and PK samples are obtained, 12-lead ECGs should be taken in triplicate at 2-minute intervals (\\\\u00b1 1 minute) and should be performed within a maximum of 10 minutes prior to PK sampling. [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Definition of selected sites for extended sparse PK sampling added</td>\\\\n      <td>Section 7.5, Pharmacokinetics</td>\\\\n      <td>86</td>\\\\n      <td>[\\\\u2026] For Phase II, sparse PK sampling will be performed at predose and at 4 hours postdose on Cycle 1, Day 1 and Cycle 2, Day 1 in the MSC2156119J arm (total of 4 samples in Phase II). However, at selected sites, sparse PK sampling will be performed at predose and at 1.5, 3.5, and 6.5-8 hours postdose on Cycle 1, Day 1, and at predose and at 2 and 6-8 hours postdose on Cycle 2, Day 1. [\\\\u2026]</td>\\\\n      <td>[\\\\u2026] For Phase II, sparse PK sampling will be performed at predose and at 4 hours postdose on Cycle 1, Day 1 and Cycle 2, Day 1 in the MSC2156119J arm (total of 4 samples in Phase II). However, <strike>at selected sites</strike> for subjects who consent  extended sparse PK sampling will instead be performed at predose and at 1.5, 3.5, and 6.5-8 hours postdose on Cycle 1, Day 1, and at predose and at 2 and 6-8 hours postdose on Cycle 2, Day 1. [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Administrative change Text updated in accordance with IRB request</td>\\\\n      <td>Section 7.5.1, Body Fluids</td>\\\\n      <td>87</td>\\\\n      <td>Blood sampling will be taken as specified in the schedule of assessments (see Section 7.1, Appendix H, and Appendix I). Preparation of blood samples are described in the MOP. [\\\\u2026] The plasma samples must be divided into 2 equal aliquots (A and B). Plasma aliquots A will be assigned for analysis of MSC2156119J for calculation of PK parameters. Plasma aliquots B may be used for exploratory quantification of metabolites of MSC2156119J. The plasma samples for analysis of exploratory biomarkers must be divided into 2 equal aliquots (A and B) and stored at -20\\\\u00b0C: Quantifications may be performed on behalf of the sponsor and results may be reported separately.</td>\\\\n      <td>Blood sampling will be taken as specified in the schedule of assessments (see Section 7.1, Appendix H, and Appendix I). Preparation of blood samples <strike>are</strike> is described in the MOP. [\\\\u2026] The plasma samples for PK must be divided into 2 equal aliquots (A and B). Plasma aliquots A will be assigned for analysis of MSC2156119J for calculation of PK parameters. Plasma aliquots B <strike>may</strike> will be used <strike>for exploratory</strike> as back-up samples. Exploratory quantification of metabolites of MSC2156119J may be performed using the same blood sample . <strike>The plasma</strike>  <strike>samples for analysis of exploratory biomarkers</strike>  <strike>must be divided into 2 equal aliquots (A and B)</strike>  <strike>and stored at -20\\\\u00b0C: Quantifications may be</strike></td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"31\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1, 2, 3]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 257], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 258], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Details about the tumor and blood sampling and processing procedures, storage, and transportation will be provided in a separate laboratory manual. Values and changes over time in Pd and screening markers will be assessed during the trial. Sampling time points of blood samples are detailed in Appendix H (Phase Ib) and Appendix I (Phase II). The storage period of tumor tissue and blood will be up to 12 years after the end of the trial and then destroyed by the sponsor. [\\\\u2026]</td>\\\\n      <td><strike>performed on behalf of the sponsor and results</strike>  <strike>may be reported separately.</strike> During this research trial, blood, urine, and tumor tissue samples will be collected for laboratory testing. These samples will be collected, prepared and shipped at the site according to the laboratory instruction manual for this study. The samples will be shipped via courier to the relevant central laboratory \\\\u201cQ2 Solutions\\\\u201d located in Singapore (for samples from outside of China) and Beijing (for samples from China), where they will either be analyzed or stored until shipment to third party vendors for analysis. <strike>Details about the tumor and blood sampling and</strike>  <strike>processing procedures, storage, and</strike>  <strike>transportation will be provided in a separate</strike>  <strike>laboratory manual.</strike> <strike>Values and changes over time</strike>  <strike>in Pd and screening markers will be assessed during the trial.</strike> <strike>Sampling time points of blood</strike>  <strike>samples are detailed in Appendix H (Phase Ib)</strike>  <strike>and Appendix I (Phase II).</strike> <strike>The storage period of</strike>  <strike>tumor tissue and blood will be up to 12 years after</strike>  <strike>the end of the trial and then destroyed by the</strike>  <strike>sponsor.</strike> [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Updated the definition of V ss /f</td>\\\\n      <td>Section 7.5.2, Pharmacokinetic Calculations</td>\\\\n      <td>88</td>\\\\n      <td>[\\\\u2026] V ss /f: volume of distribution at steady state, CL\\\\u2219MRT [\\\\u2026]</td>\\\\n      <td>[\\\\u2026] V ss /f: apparent volume of distribution at steady state, CL\\\\u2219MRT [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Text updated in accordance with IRB request</td>\\\\n      <td>Section 7.6, Biomarkers/ Pharmacogenetics</td>\\\\n      <td>89</td>\\\\n      <td>Not applicable</td>\\\\n      <td>Details about the tumor and blood sampling and processing procedures, storage, and transportation will be provided in a separate laboratory manual. Quantifications may be performed on behalf of the sponsor and results may be reported separately. Values and changes over time in predictive and screening markers will be assessed during the trial. Sampling time points of blood samples are detailed in Appendix H (Phase Ib)</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"32\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1, 2, 3]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 259], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 260], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 261], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 262], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 263], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>and Appendix I (Phase II). The storage period of tumor tissue and blood will be up to 12 years after the end of the trial and then samples will be destroyed by the sponsor.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Administrative update</td>\\\\n      <td>Section 7.6.1, Tumor Biopsies</td>\\\\n      <td>89</td>\\\\n      <td>[\\\\u2026] An associated pathology report must also be sent to the central laboratory prior to enrolment/randomization. Undergoing paired tumor biopsy is not mandated, but highly recommended for subjects with accessible tumors (Phase Ib and Phase II). [\\\\u2026]</td>\\\\n      <td>[\\\\u2026] An associated pathology report must also be sent to the central laboratory prior to enro l lment/randomization. Undergoing paired tumor biopsy is not mandat ory <strike>ed</strike> but highly recommended for subjects with accessible tumors (Phase Ib and Phase II). [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Clarification of MET+ HCC population Change relating to early discontinuation of prescreening</td>\\\\n      <td>Section 8.1, Sample Size</td>\\\\n      <td>90-91</td>\\\\n      <td>For Phase Ib, the total number of subjects in this trial is up to 21. [\\\\u2026] For Phase II, the sample size requires 100 TTP events (assessed by an IRC) to ensure 80% power with a two-sided significance level of 10% for rejecting the null hypothesis of equal treatment effect between treatment arms, assuming a true hazard ratio (HR) of 0.6. Assuming a median TTP in Asian subjects for the sorafenib arm of 2.8 months, a HR of 0.6 represents a 1.87 month increase, resulting in a median TTP of 4.67 months for the MSC2156119J arm. With other assumptions: Accrual period of 12 months and follow-up period of 6 months, Overall drop-out rate of 17.4%, One formal interim futility analysis with O\\\\u2019Brien-Flemming method as futility boundary calculation will be performed after observation of 50% of TTP events. A total number of 140 subjects will be randomized on a 1:1 basis to receive MSC2156119J or sorafenib. The detailed</td>\\\\n      <td>For Phase Ib, the total number of subjects to be enrolled in this trial is up to 21. [\\\\u2026] For Phase II, the initial sample size planning required <strike>requires</strike> 100 TTP events (assessed by an IRC) to ensure 80% power with a two-sided significance level of 10% for rejecting the null hypothesis of equal treatment effect between treatment arms, assuming a true hazard ratio (HR) of 0.6. Assuming a median TTP in Asian subjects for the sorafenib arm of 2.8 months, a HR of 0.6 represents a 1.87 month increase, resulting in a median TTP of 4.67 months for the MSC2156119J arm. With other assumptions: Accrual period of 12 months and follow-up period of 6 months, Overall drop-out rate of 17.4% <strike></strike> . <strike>One formal interim futility analysis with</strike>  <strike>O\\\\u2019Brien-Flemming method as futility boundary</strike>  <strike>calculation will be performed after observation</strike>  <strike>of 50% of TTP events.</strike> A total number of 140 subjects with MET+ HCC were planned to <strike>will</strike> be randomized on a 1:1 basis to receive MSC2156119J or sorafenib. <strike>The</strike>  <strike>detailed information regarding futility boundary</strike></td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"33\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1, 2, 3]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 264], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 265], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 266], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 267], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 268], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 269], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>information regarding futility boundary will be provided in the section of interim analysis in the SAP.</td>\\\\n      <td><strike>will be provided in the section of interim analysis</strike>  <strike>in the SAP.</strike> However, due to business-related considerations not related to any safety issues, the sponsor will stop prescreening/enrollment when 40 TTP events are observed (assessed by an IRC) or 15 August 2017, whichever occurs first. It is expected that approximately 90 subjects will be randomized by 15 August 2017.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Administrative update</td>\\\\n      <td>Section 8.2, Randomization</td>\\\\n      <td>91</td>\\\\n      <td>[\\\\u2026]  BCLC Stage: Stage B vs Stage C [\\\\u2026]</td>\\\\n      <td>[\\\\u2026]  BCLC Stage: Stage B versus <strike>vs</strike> Stage C [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Clarification of the role of the IRC</td>\\\\n      <td>Section 8.3.1, Primary Endpoints</td>\\\\n      <td>91</td>\\\\n      <td>[\\\\u2026]  Phase II: TTP assessed by an IRC . TTP is defined as the time (in months) from randomization to date of the observation of radiological PD assessed by an IRC [\\\\u2026]</td>\\\\n      <td>[\\\\u2026]  Phase II: TTP <strike>assessed</strike> based on tumor assessment by an IRC . TTP is defined as the time (in months) from randomization to date of the observation of radiological PD assessed by an IRC [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Clarification of the role of the IRC List of secondary endpoints updated</td>\\\\n      <td>Section 8.3.2, Secondary Endpoints</td>\\\\n      <td>92</td>\\\\n      <td>[\\\\u2026] PFS assessed by the IRC. PFS time is defined as the time (in months) from randomization to either first observation of disease progression or occurrence of death due to any cause within 84 days of either randomization or the last tumor assessment. [\\\\u2026] Objective response (OR) assessed by the IRC. OR is defined as complete response (CR) or partial response (PR) as the best overall response according to radiological assessments as adjudicated by the IRC from randomization to first occurrence of PD. Response do not require confirmation</td>\\\\n      <td>[\\\\u2026] PFS <strike>assessed</strike> based on tumor assessment by the IRC. PFS time is defined as the time (in months) from randomization to either first observation of disease progression or occurrence of death due to any cause within 84 days of either randomization or the last tumor assessment. PFS based on tumor assessment by the investigator. PFS time is defined as the time (in months) from randomization to either first observation of radiologically confirmed PD by the investigator or occurrence of death due to any cause within 84 days of either randomization or the last tumor assessment. [\\\\u2026]</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"34\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1, 2, 3]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 270], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 271], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 272], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 273], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 274], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>6.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>according to RECIST v 1.1 (see Appendix C).  Disease control assessed by the IRC . Disease control is defined as CR, PR, or stable disease (SD) as the best overall response according to radiological assessments as adjudicated by the IRC from the date of randomization to the first occurrence of PD . In the case of SD, measurements must have met the SD criteria at least once after study entry at a minimum interval of 42 days after randomization. [\\\\u2026]</td>\\\\n      <td>Objective response (OR) <strike>assessed</strike> based on tumor assessment by the IRC. OR is defined as complete response (CR) or partial response (PR) as the best overall response according to radiological assessments as adjudicated by the IRC from randomization to first occurrence of PD. Response s do not require confirmation according to RECIST v 1.1 (see Appendix C). OR based on tumor assessment by the investigator. OR is defined as CR or PR as the best overall response according to radiological assessments as adjudicated by the investigator from randomization to first occurrence of PD. Responses do not require confirmation according to RECIST v 1.1 (see Appendix C).</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Disease control <strike>assessed</strike> based on tumor assessment by the IRC. Disease control is defined as CR, PR, or stable disease (SD) as the best overall response according to radiological assessments as adjudicated by the IRC from the date of randomization to the first occurrence of PD. In the case of SD, measurements must have met the SD criteria at least once after study entry at a minimum interval of 42 days after randomization.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Disease control based on tumor assessment by the investigator. Disease control is defined as CR, PR, or SD as the best overall response according to radiological assessments as adjudicated by the investigator from the date of randomization to the first occurrence of PD. In the case of SD, measurements must have met the SD criteria at least once after study entry at a minimum interval of 42 days after randomization.</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"35\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1, 2, 3]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 275], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 276], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 277], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 278], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 279], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 280], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 281], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 282], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 283], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 284], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 285], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 286], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 287], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 288], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 289], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 290], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 291], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 292], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Administrative update</td>\\\\n      <td>Section 8.3.3, Safety Endpoints</td>\\\\n      <td>92</td>\\\\n      <td>The safety endpoints apart of the DLT objective are: Drug exposure Incidence and type of AEs (all grades as per NCI-CTCAE version 4.0): all treatment emergent adverse events (TEAEs), related TEAEs, treatment emergent SAEs, related treatment emergent SAEs, TEAEs of NCI-CTCAE (version 4.0) with Grade \\\\u2265 3, related TEAEs \\\\u2265 Grade 3, and TEAEs leading to temporary/permanent treatment discontinuation [\\\\u2026]</td>\\\\n      <td>The safety endpoints not including <strike>apart of</strike> the DLT primary objective (see Section 8.3.1), are: Drug exposure Incidence and type of AEs (all grades as per NCI-CTCAE version 4.0): all treatment emergent adverse events (TEAEs), related TEAEs, treatment emergent SAEs, related treatment emergent SAEs, TEAEs of NCI-CTCAE (version 4.0) <strike>with</strike> Grade \\\\u2265 3, related TEAEs <strike>\\\\u2265</strike> Grade \\\\u2265 3, and TEAEs leading to temporary/permanent treatment discontinuation [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Administrative update Analysis population updated to mITT New subgroup of interest added</td>\\\\n      <td>Section 8.4, Analysis Sets</td>\\\\n      <td>93-94</td>\\\\n      <td>[\\\\u2026] Subjects who have been replaced during the Cycle 1 or whom belong to the Chinese (Mainland) subject cohort will be excluded from the DLT Analysis set (for replacement criteria, see Section 5.5.2). [\\\\u2026] ITT Analysis Set: The ITT Analysis Set in Phase II part of this trial consists of all subjects who were randomized to study treatment. Subjects will be allocated as randomized. The ITT Analysis Set will be used to assess the tumor activity and the efficacy of the compound. PP Analysis Set: The PP Analysis Set is defined as all ITT subjects who meet the following criteria: [\\\\u2026] o Age: < 65 years vs. \\\\u2265 65 years o Gender: male vs. female o Geographic region: Greater China vs. outside of Greater China</td>\\\\n      <td>[\\\\u2026] Subjects who have been replaced during the Cycle 1 or whom belong to the Chinese (Mainland) subject cohort will be excluded from the DLT Analysis <strike>s</strike> S et (for replacement criteria, see Section 5.5.2). [\\\\u2026] Intent-to-treat ( ITT ) Analysis Set: The ITT Analysis Set in the Phase II part of this trial consists of all subjects who were randomized to study treatment. Subjects will be allocated as randomized. <strike>The ITT Analysis Set will be used to assess</strike>  <strike>the tumor activity and the efficacy of the</strike>  <strike>compound.</strike> Modified intent-to-treat (mITT) Analysis Set: The mITT Analysis Set in the Phase II part of this trial consists of all subjects with MET+ HCC who were randomized to study treatment. Subjects will be allocated as randomized. Determination of MET status is planned at Molecular Prescreening (Phase Ib retrospectively, Phase II for subject selection); rescoring will be</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"36\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1, 2]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 293], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 294], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n      <th>6.0</th>\\\\n      <th>7.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td></td>\\\\n      <td>Previous Wording</td>\\\\n      <td></td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>BCLC Stage: Stage B vs Stage C o Type of MET+: overexpression vs. amplification (including subjects with co-existing amplification and overexpression) Vascular invasion and/or extrahepatic spread: presence vs. absence The underlying disease or medical condition related to etiology: HBV vs. Other AFP elevation at the baseline: Yes vs. No Prior local-regional therapy: Yes vs. No [\\\\u2026] Pharmacodynamic Analysis Set:  All subjects who have received at least 1 dose of MSC2156119J and have the baseline and at least 1 post-baseline Pd/Biomarkers assessment.</td>\\\\n      <td>BCLC Stage: Stage B vs Stage C o Type of MET+: overexpression vs. amplification (including subjects with co-existing amplification and overexpression) Vascular invasion and/or extrahepatic spread: presence vs. absence The underlying disease or medical condition related to etiology: HBV vs. Other AFP elevation at the baseline: Yes vs. No Prior local-regional therapy: Yes vs. No [\\\\u2026] Pharmacodynamic Analysis Set:  All subjects who have received at least 1 dose of MSC2156119J and have the baseline and at least 1 post-baseline Pd/Biomarkers assessment.</td>\\\\n      <td>[\\\\u2026]</td>\\\\n      <td>performed as a quality control measure Subjects with IHC c-Met status 1+ or \\\\u2018not assessable\\\\u2019 on re-scoring will be excluded from the primary analysis. The mITT Analysis Set will be used for the primary analysis of tumor activity and efficacy of the compound. PP Analysis Set: The PP Analysis Set is defined as all m ITT subjects who meet the following criteria: Age: < 65 years versus <strike>vs.</strike> \\\\u2265 65 years o Gender: male versus <strike>vs.</strike> female Geographic region: Greater China versus <strike>vs.</strike> outside of Greater China BCLC <strike>S</strike> s tage: Stage B versus <strike>vs</strike> Stage C o Type of MET+: overexpression versus <strike>vs.</strike> amplification (including subjects with co-existing amplification and overexpression) Vascular invasion and/or extrahepatic spread: presence versus <strike>vs.</strike> absence The underlying disease or medical condition related to etiology: HBV versus <strike>vs.</strike> Other AFP elevation at the baseline: Yes versus <strike>vs.</strike> No Prior local-regional therapy: Yes versus <strike>vs.</strike> No Subjects with a change in IHC c-Met status from 2+ or 3+ to either 1+ or \\\\u2018not assessable\\\\u2019, based on a re-assessment planned for quality</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"37\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 295], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 296], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 297], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 298], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 299], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 300], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 301], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>assurance purposes (subgroup of the ITT Analysis Set) [\\\\u2026] <strike>Pharmacodynamic</strike> Biomarker Analysis Set:  All subjects who have received at least 1 dose of MSC2156119J and have the baseline and at least 1 post-baseline <strike>Pd/</strike> Biomarkers assessment.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Final analysis cut-off updated Analysis population updated to mITT</td>\\\\n      <td>Section 8.5.1, General Considerations</td>\\\\n      <td>95</td>\\\\n      <td>[\\\\u2026] Data of Phase Ib will be analyzed after a follow-up of at least 21 days for the last subject. Statistical analyses will be performed using eCRF data in general. The ITT analysis of efficacy endpoints in Phase II will require a clinical cut-off date, which is determined by the date after the required number of events for the primary endpoint has been reported in the primary analysis population, i.e., 100 TTP events for the ITT Population in Phase II. [\\\\u2026] The ITT Population will be primarily used in the analysis of baseline characteristics and efficacy. Analyses on the ITT Population will consider subjects\\\\u2019 allocation to treatment groups as randomized. Selected efficacy analyses will be repeated for the PP Population and for subgroups (see Section 8.4. In case that PP Population includes more than 90% of the ITT Population, additional efficacy analyses on the PP Population will be omitted. [\\\\u2026]</td>\\\\n      <td>[\\\\u2026] Data of Phase Ib will be analyzed after a follow-up of at least 21 days for the last subject. Statistical analyses will be performed using eCRF data in general. <strike>The ITT analysis of efficacy</strike>  <strike>endpoints in Phase II will require a clinical cut-off</strike>  <strike>date, which is determined by the date after the</strike>  <strike>required number of events for the primary</strike>  <strike>endpoint has been reported in the primary</strike>  <strike>analysis population, i.e., 100 TTP events for the</strike>  <strike>ITT population in Phase II.</strike> Primary statistical analysis of endpoints will be performed using eCRF data obtained until a clinical cut-off date in Phase II. The Phase II clinical cut-off date is determined by the date after the required number of events for the primary endpoint has been reported in the primary analysis population, i.e., 40 TTP events for the mITT population (assessed by an IRC) in Phase II, or on 15 August 2017, whichever occurs first. The final statistical analyses for the Phase II study will be performed at approximately 6 months after the last subject is first dosed. [\\\\u2026] The m ITT <strike>P</strike> p opulation will be primarily used in the analysis of baseline characteristics and efficacy. Analyses on the m ITT <strike>P</strike> p opulation will consider subjects\\\\u2019 allocation to treatment groups as randomized. Selected efficacy analyses will be repeated for the ITT population, the PP <strike>P</strike> p opulation and for subgroups (see Section 8.4 ) . In case that PP</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"38\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1, 2]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 302], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 303], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 304], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 305], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 306], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 307], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td><strike>P</strike> p opulation includes more than 90% of the m ITT <strike>P</strike> p opulation, additional efficacy analyses on the PP <strike>P</strike> p opulation will be omitted. [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Administrative update</td>\\\\n      <td>Section 8.5.1.2, Missing Data</td>\\\\n      <td>96</td>\\\\n      <td>[\\\\u2026] Incomplete stop dates will be replaced by the last day of the month (if day is missing only), if not resulting in a date later than the date of subject's death. In the later case the date of death will be used to impute the incomplete stop date. [\\\\u2026]</td>\\\\n      <td>[\\\\u2026] Incomplete stop dates will be replaced by the last day of the month (if day is missing only), if not resulting in a date later than the date of subject's death. In the lat t er case  the date of death will be used to impute the incomplete stop date. [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Clarification of the role of the IRC Analysis population updated to mITT TTP subgroup analysis added</td>\\\\n      <td>Section 8.5.2.2, Statistical Analysis of Primary Endpoint of Phase II</td>\\\\n      <td>97-98</td>\\\\n      <td>The primary endpoint of Phase II in this trial is TTP assessed by an IRC. [\\\\u2026] The primary analysis will test the equality of TTP between treatment groups, based on the ITT Population, applying two-sided unstratified log-rank test at a significance level of 10%. [\\\\u2026] Comparisons of survival rates will be performed from a Z-test using estimates and standard errors derived from the Kaplan-Meier method and Greenwood\\\\u2019s formula.</td>\\\\n      <td>The primary endpoint of Phase II in this trial is TTP <strike>assessed</strike> based on tumor assessment by an IRC. [\\\\u2026] The primary analysis will test the equality of TTP between treatment groups, based on the m ITT <strike>P</strike> p opulation, applying two-sided unstratified log-rank test at a significance level of 10%. [\\\\u2026] Comparisons of survival rates will be performed from a Z-test using estimates and standard errors derived from the Kaplan-Meier method and Greenwood\\\\u2019s formula. TTP will be further explored considering the ITT population, the PP population and pre-defined subgroups (see Section 8.4).</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Analysis population updated to mITT Analysis of new secondary endpoints clarified</td>\\\\n      <td>Section 8.5.3.1, Progression-free survival</td>\\\\n      <td>98</td>\\\\n      <td>Progression-free survival (assessed by the IRC) time is defined as the time (in months) from randomization to either first observation of progression disease or occurrence of death due to any cause within 84 days of either randomization or the last tumor assessment. If no progression or death is observed, or if death without previously documented PD is observed after more than 84 days of last tumor assessment without progression, the PFS time</td>\\\\n      <td>Progression-free survival (assessed by the IRC) time is defined as the time (in months) from randomization to either first observation of progression disease or occurrence of death due to any cause within 84 days of either randomization or the last tumor assessment. If no progression or death is observed at the time of analysis or if death without previously documented PD is observed after more than 84 days of last tumor assessment without</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"39\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1, 2, 3]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 308], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 309], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 310], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 311], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 312], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 313], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>will be censored on the date of last tumor assessment or date of randomization, whatever occurs later. The 84-day time window represents the time between 2 scheduled tumor assessments. Treatment groups will be compared based on ITT population, applying two-sided unstratified log-rank test at a significance level of 10%. The same survival analysis methods will be employed as for the primary endpoint, PFS will be further explored considering the PP Population and pre-defined subgroups (see Section 8.4).</td>\\\\n      <td>progression, the PFS time will be censored on the date of last tumor assessment or date of randomization, whatever occurs later. The 84-day time window represents the time between 2 scheduled tumor assessments. Treatment groups will be compared based on m ITT population, applying two-sided unstratified log-rank test at a significance level of 10%. The same survival analysis methods will be employed as for the primary endpoint, PFS will be further explored considering the ITT population, the PP <strike>P</strike> p opulation and pre-defined subgroups (see Section 8.4). Progression-free survival based on tumor assessment by the investigator will also be analyzed in the same way as described above.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Analysis population updated to mITT</td>\\\\n      <td>Section 8.5.3.2, Overall Survival</td>\\\\n      <td>98-99</td>\\\\n      <td>A preliminary analysis on overall survival will be performed at the time when TTP is statistically analyzed. Final OS analysis will be carried out when at least 80% of the subjects have either died or dropped out of the trial. [\\\\u2026] Treatment groups will be compared based on the ITT Population, applying two-sided unstratified log-rank test (\\\\u03b1 = 10%). OS data will be further explored considering the PP Population and predefined subgroups (see Section 8.4).</td>\\\\n      <td><strike>A preliminary analysis on overall survival will be</strike>  <strike>performed at the time when TTP is statistically</strike>  <strike>analyzed.</strike> <strike>Final OS analysis will be carried out</strike>  <strike>when at least 80% of the subjects have either</strike>  <strike>died or dropped out of the trial.</strike> [\\\\u2026] Treatment groups will be compared based on the m ITT <strike>P</strike> p opulation, applying two-sided unstratified log-rank test (\\\\u03b1 = 10%). OS data will be further explored considering the ITT population, the PP <strike>P</strike> p opulation and predefined subgroups (see Section 8.4).</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Administrative update TTSP subgroup analysis removed</td>\\\\n      <td>Section 8.5.3.3, Time-to-symptomatic Progression</td>\\\\n      <td>99</td>\\\\n      <td>[\\\\u2026] Treatment groups will be compared based on the ITT Population, applying two-sided unstratified log-rank test (\\\\u03b1 = 10%). TTSP data will be further explored considering the PP Population and predefined subgroups (see Section 8.4).</td>\\\\n      <td>[\\\\u2026] Treatment groups will be compared based on the m ITT Population, applying two-sided unstratified log-rank test (\\\\u03b1 = 10%). <strike>TTSP data will be further explored considering</strike>  <strike>the PP Population and predefined subgroups</strike>  <strike>(see Section 8.4).</strike></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Analysis population updated to mITT Administrative update</td>\\\\n      <td>Section 8.5.3.4, Antitumor Activity</td>\\\\n      <td>99-100</td>\\\\n      <td>Objective response and disease control will be evaluated based on the ITT Population. [\\\\u2026]</td>\\\\n      <td>Objective response and disease control will be evaluated based on the m ITT <strike>P</strike> p opulation. [\\\\u2026]</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"40\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1, 2, 3]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 314], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 315], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 316], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 317], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 318], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Tumor response subgroup analysis removed Analysis of new secondary endpoints clarified</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>The Fisher\\\\u2019s exact test will be performed for analysis and will test the following two-sided hypothesis: [\\\\u2026] Further exploratory analyses will be performed using the PP population. Tumor response will be explored in predefined subgroups (see Section 8.4).</td>\\\\n      <td><strike>The</strike> Fisher\\\\u2019s exact test will be performed for analysis and will test the following two-sided hypothesis: [\\\\u2026] <strike>Further exploratory analyses will be performed</strike>  <strike>using the PP population.</strike> <strike>Tumor response will be</strike>  <strike>explored in predefined subgroups (see Section</strike>  <strike>8.4).</strike> Objective response rate and disease control rate based on tumor assessment by the investigator will also be analyzed in the same way as described above.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>PK data cut-off clarified</td>\\\\n      <td>Section 8.5.3.6, Pharmacokinetics</td>\\\\n      <td>101</td>\\\\n      <td>All PK parameters will be determined for each subject as described in Section 7.5.2. The following analyses will be performed for each dose group of Phase Ib. [\\\\u2026]</td>\\\\n      <td>All PK parameters will be determined for each subject as described in Section 7.5.2. PK data of subjects enrolled up to 15 August 2017 will be considered for the analysis. The following analyses will be performed for each dose group of Phase Ib. [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Section heading updated</td>\\\\n      <td>Section 8.5.3.7, Biomarkers</td>\\\\n      <td>102</td>\\\\n      <td>Pharmacodynamic Biomarkers</td>\\\\n      <td><strike>Pharmacodynamic</strike> Biomarkers</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Role of IDMC clarified Final analysis cut-off updated</td>\\\\n      <td>Section 8.6, Interim Analysis</td>\\\\n      <td>103</td>\\\\n      <td>[\\\\u2026] The IDMC will be responsible for periodic (as defined by the IDMC charter) evaluations of the clinical trial to ensure continued subject safety as well as the validity and scientific merit of the study. In addition to periodic evaluations and a final analysis, 1 formal interim analysis for futility is planned in this study, occurring after observation of 50% of the planned maximal number of events in the primary analysis population (i.e., after 50 TTP events). Details of the formal stopping rule are provided in the IDMC SAP. Final analysis of data is event driven and is expected to be approximately 18 months after the start of Phase II. The designated independent statistician will provide the IDMC with the safety summaries</td>\\\\n      <td>[\\\\u2026] The IDMC will be responsible for periodic (as defined by the IDMC charter) evaluations of the clinical trial to ensure continued subject safety as well as the validity and scientific merit of the study. <strike>In addition to periodic evaluations and a</strike>  <strike>final analysis, 1 formal interim analysis for futility</strike>  <strike>is planned in this study, occurring after</strike>  <strike>observation of 50% of the planned maximal</strike>  <strike>number of events in the primary analysis</strike>  <strike>population (i.e., after 50 TTP events).</strike> <strike>Details of</strike>  <strike>the formal stopping rule are provided in the IDMC</strike>  <strike>SAP.</strike> <strike>Final analysis of data is event driven and is</strike>  <strike>expected to be approximately 18 months after the</strike>  <strike>start of Phase II.</strike> The designated independent statistician will provide the IDMC with the safety summaries periodically for review. <strike>At the time of the interim</strike></td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"41\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1, 2, 3]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 319], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 320], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 321], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 322], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>periodically for review. At the time of the interim analysis, the independent statistician will have access to the subject treatment assignments. No individuals involved with the direct monitoring of this study will have access to the treatment identities. [\\\\u2026]</td>\\\\n      <td><strike>analysis, the independent statistician will have</strike>  <strike>access to the subject treatment assignments.</strike> No individuals involved with the direct monitoring of this study will have access to the treatment identities. In addition to periodic evaluations and a final analysis, a formal primary analysis based on key statistical endpoints will occur after observation of 40 TTP events (assessed by an IRC) in the primary analysis population or 15 August 2017, whichever occurs first. [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Correction</td>\\\\n      <td>Section 11. References</td>\\\\n      <td>110-111</td>\\\\n      <td>4. Parkin D, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108. [\\\\u2026] Gherardi E, Birchmeier W, Birchmeier C, et al. Nat Rev Cancer 2012;12(2):89-103. Liu X, YaoW, Newton RC, et al. Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Investig Drugs 2008;17:997-1011. Benvenuti S, Comoglio PM. The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol 2007;213:316. Gentile A, Trusolino L, Comoglio PM. The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev 2008;27:85. [\\\\u2026] 16. Kim DW, Soo RA, Yang JCH, Park K, Stammberger U, Xiong H, Ihling C, Wu YL. Antitumor activity of tepotinib plus gefitinib in Asian patients with Met-positive NSCLC. 16th World Congress on Lung Cancer. 2015 September, Abstract No. 763. [\\\\u2026]</td>\\\\n      <td>4. Parkin D, Bray F, Ferlay J, <strike>Pisani P</strike> et al . Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108. [\\\\u2026] Gherardi E, Birchmeier W, Birchmeier C, et al. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012;12(2):89-103. Liu X, Yao W, Newton RC, et al. Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Investig Drugs 2008;17:997-1011. Benvenuti S, Comoglio PM. The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol 2007;213:316 -325 . Gentile A, Trusolino L, Comoglio PM. The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev 2008;27:85 -94 . [\\\\u2026] 16. Kim DW, Soo RA, Yang JCH, et al <strike>Park K,</strike>  <strike>Stammberger U, Xiong H, Ihling C, Wu YL</strike> . Antitumor activity of tepotinib plus gefitinib in Asian patients with Met-positive NSCLC. 16th World Congress on Lung Cancer. 2015 September, Abstract No. 763. [\\\\u2026]</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Heading added</td>\\\\n      <td>Section 12. Appendices</td>\\\\n      <td>112</td>\\\\n      <td>Not applicable</td>\\\\n      <td>12 Appendices</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"3\\\", \\\"TableIndex\\\": \\\"42\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0, 1, 2, 3]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 323], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 324], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 325], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 326], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 327], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Change</td>\\\\n      <td>Section</td>\\\\n      <td>Page</td>\\\\n      <td>Previous Wording</td>\\\\n      <td>New Wording</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>Timing of tumor assessments clarified</td>\\\\n      <td>Appendix H: Phase Ib Schedule of Dosing and Assessments</td>\\\\n      <td>132-134</td>\\\\n      <td></td>\\\\n      <td>See Appendix 4.2.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Timing of tumor assessments clarified</td>\\\\n      <td>Appendix I: Phase II Schedule of Dosing and Assessments</td>\\\\n      <td>135-138</td>\\\\n      <td></td>\\\\n      <td>See Appendix 4.3.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Clarification of ICF requirements</td>\\\\n      <td>Appendix J: Blood Sampling Schedule and Blood Volumes for PK, Pd/Biomarkers, and PGx</td>\\\\n      <td>139-140</td>\\\\n      <td></td>\\\\n      <td>See Appendix 4.4.</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"52\\\", \\\"TableIndex\\\": \\\"43\\\", \\\"TableName\\\": \\\"\\\", \\\"Header\\\": [0]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Arial\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 328], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 329], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 330], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 331], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 332], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"MSC2156119J (tepotinib)       Efficacy, Safety, and PK of MSC2156119J in Asian Subjects with\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 333], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"EMR200095-004\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 334], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 335], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"HCC\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Signature page\\\", \\\"\\\", \\\"1\\\", 336], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\" Appendices\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading1\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Appendices\\\", \\\"4\\\", \\\"1\\\", 337], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\" 4.1Updated Treatment Duration Figure (Figure 3)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 338], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"In Figure 3, the duration of the Screening period was corrected to \\\\u201c-14 to -1 days\\\\u201d (previously \\\\u201c-28 to -1 days\\\\u201d) and a Molecular Prescreening period was added.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 339], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 340], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Abbreviations: DLT, dose-limiting toxicity; IMP, investigational medicinal product.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 341], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"NOTE: IMP (i.e., MSC2156119J) is administered once daily (Phase Ib and Phase II); sorafenib is administered twice daily (Phase II).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 342], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Document No. 0900babe80c5f21bv1.0\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 343], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 344], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 345], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"C O N F I D E N T I A L\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 346], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 347], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"53/62\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 28, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 28, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"subscript\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 348], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Object No. 0900babe80cf65da\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 349], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 350], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 351], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"I N F O R M A T I O N\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 352], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 353], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\" Updated Phase Ib Schedule of Dosing and Assessments (Appendix H)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 354], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"4.2The Phase Ib Schedule of Dosing and Assessments was updated and assessment of exploratory markers in plasma at Cycle 2, Day 1; Cycle 3, Day 1; and end of treatment were removed.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 355], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Footnote e was updated to highlight that paired tumor biopsy is optional.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 356], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Footnote i was updated to include a \\\\u00b1 1 minute time window for triplicate ECGs obtained at 2-minute intervals.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 357], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Footnote l was added to clarify the end of treatment laboratory assessment requirements.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 358], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Footnote u (previously t) was updated with additional information about scheduled imaging assessments following unscheduled imaging.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 359], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Footnote v (previously u) was updated to clarify the timing of tumor imaging assessments.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 360], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 361], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n      <th>6.0</th>\\\\n      <th>7.0</th>\\\\n      <th>8.0</th>\\\\n      <th>9.0</th>\\\\n      <th>10.0</th>\\\\n      <th>11.0</th>\\\\n      <th>12.0</th>\\\\n      <th>13.0</th>\\\\n      <th>14.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td></td>\\\\n      <td>Screening</td>\\\\n      <td></td>\\\\n      <td>Cycle 1 Day</td>\\\\n      <td>Cycle 1 Day</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Cycle 2 Day <sup>a</sup></td>\\\\n      <td>Cycle 2 Day <sup>a</sup></td>\\\\n      <td></td>\\\\n      <td>Cycle \\\\u2265 3 Day</td>\\\\n      <td>EoT Visit <sup>b</sup></td>\\\\n      <td>Post- Treatment F/U Visit <sup>c</sup></td>\\\\n      <td>Survival F/U <sup>d</sup></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>DAY</td>\\\\n      <td>-14 to 0</td>\\\\n      <td>1</td>\\\\n      <td>2</td>\\\\n      <td>8</td>\\\\n      <td>15</td>\\\\n      <td>1</td>\\\\n      <td>8</td>\\\\n      <td></td>\\\\n      <td>15</td>\\\\n      <td>1</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>MSC2156119J</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>QD</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Written informed consent</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Dispensing of study drug</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>Demography, height</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>Medical history</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td>Smoking status and alcohol use</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>8</th>\\\\n      <td>Tumor biopsy</td>\\\\n      <td></td>\\\\n      <td>X<sup> e</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> e</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> f</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>9</th>\\\\n      <td>Physical examination/weight</td>\\\\n      <td>X</td>\\\\n      <td>X<sup> g</sup></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>10</th>\\\\n      <td>ECOG PS</td>\\\\n      <td>X</td>\\\\n      <td>X<sup> g</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>11</th>\\\\n      <td>Vital signs <sup>h</sup></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>12</th>\\\\n      <td>ECG <sup>i</sup></td>\\\\n      <td>X</td>\\\\n      <td>X<sup> j</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> j</sup></td>\\\\n      <td>X<sup> k</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> k</sup></td>\\\\n      <td>X<sup> l</sup></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>13</th>\\\\n      <td>Hematology and coagulation <strike><sup>l</sup></strike> <sup>m</sup></td>\\\\n      <td>X</td>\\\\n      <td>X<sup> g</sup></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X<sup> l</sup></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>14</th>\\\\n      <td>Chemistry <strike><sup>m</sup></strike> <sup>n</sup></td>\\\\n      <td>X</td>\\\\n      <td>X<sup> g</sup></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X<sup> l</sup></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>15</th>\\\\n      <td>Urinalysis <strike><sup>n</sup></strike> <sup>o</sup></td>\\\\n      <td>X</td>\\\\n      <td>X<sup> g</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X<sup> l</sup></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>16</th>\\\\n      <td>HBV viral serology panel <strike><sup>o</sup></strike> <sup>p</sup></td>\\\\n      <td>X<sup> <strike>p</strike> q</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>q</strike> r</sup></td>\\\\n      <td>X<sup> <strike>q</strike> l,r</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>17</th>\\\\n      <td>HBV DNA (viral load) <strike><sup>q</sup></strike> <sup>r</sup></td>\\\\n      <td>X<sup> <strike>p</strike> q</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>q</strike> r</sup></td>\\\\n      <td>X<sup> <strike>q</strike> l,r</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>18</th>\\\\n      <td>HCV RNA-PCR (viral load) <strike><sup>r</sup></strike> <sup>s</sup></td>\\\\n      <td>X<sup> <strike>p</strike> q</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>r</strike> s</sup></td>\\\\n      <td>X<sup> <strike>r</strike> l,s</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>19</th>\\\\n      <td>Serum pregnancy test (if applicable) <strike><sup>s</sup></strike> <sup>t</sup></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>20</th>\\\\n      <td>Tumor assessment (RECIST v 1.1) <strike><sup>t</sup></strike> <sup>u</sup></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>u</strike> v</sup></td>\\\\n      <td>X<sup> <strike>v</strike> w</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>21</th>\\\\n      <td>Serum AFP</td>\\\\n      <td>X</td>\\\\n      <td>X<sup> g</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>22</th>\\\\n      <td>PK blood samples</td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>w</strike> x</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>w</strike> x</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>23</th>\\\\n      <td>Exploratory markers in plasma</td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>x</strike> y</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>y</strike> z</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>y</strike> z</sup></td>\\\\n      <td>X<sup> <strike>x</strike> y</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>24</th>\\\\n      <td>PGx blood sample <strike><sup>z</sup></strike> <sup>aa</sup></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>25</th>\\\\n      <td>Subject survival and anticancer therapies</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>26</th>\\\\n      <td>Adverse events assessment</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>27</th>\\\\n      <td>Concomitant medication/procedure</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"52\\\", \\\"TableIndex\\\": \\\"44\\\", \\\"TableName\\\": \\\"Footnote v (previously u) was updated to clarify the timing of tumor imaging assessments.(Schedule of Assessment)\\\", \\\"FootnoteText_0\\\": \\\"Principal Investigator SignatureCenter NumberPrincipal InvestigatorI, the undersigned, am responsible for the conduct of the trial at this site and affirm that:I understand and will conduct the trial according to the clinical trial protocol, any approved protocol amendments, International Council for Harmonisation (ICH) Good Clinical Practice (GCP) (ICH Topic E6 GCP) and all applicable Regulatory Health Authority requirements and national laws.I will not deviate from the clinical protocol without prior written permission from the Sponsor and prior review and written approval from the Institutional Review Board or Independent Ethics Committee, except where necessary to prevent immediate danger to the subject.I understand that some regulatory Health Authorities require the Sponsors of clinical trials to obtain and supply, when required, details about the Investigators' ownership interests in the Sponsor or Investigational Product and information regarding any financial ties with the Sponsor.nanSignatureName, academic qualificationsPosition (job title)Address of InstitutionTelephone numberFax numberEmail addressAbbreviations: AFP, alpha-fetoprotein; ALT, alanine aminotransferase; aPTT, activated partial thromboplastin time; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CNS, central nervous system; CT, computed tomography; ECG, electrocardiogram; ECOG PS, Eastern Cooperative Oncology Group performance status; EoT, end of treatment; F/U, follow-up; GGT, gamma-glutamyl transpeptidase; HBc, hepatitis B core antigen; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCC; hepatocellular carcinoma; HCV, hepatitis C virus; INR, international normalized ratio; RECIST, response evaluation criteria in solid tumors; MRI, magnetic resonance imaging; PGx, pharmacogenetic; PK, pharmacokinetic; PT, prothrombin time; RNA, ribonucleic acid.\\\", \\\"FootnoteText_1\\\": \\\"nanPost-treatment follow-up visit, performed within 30 \\\\u00b1 3 days after the last treatment for all subjects who discontinue trial treatment permanently, including subjects who have completed an end of treatment visit.Survival data will be collected every 3 months after end of treatment until death or the end of the trial.Undergoing paired tumor biopsy is not mandatory but highly recommended for subjects with accessible tumors: the paired tumor biopsy will be performed before the first trial treatment (i.e., during Screening or on Cycle 1, Day 1, prior to the first dose of trial treatment) and anytime between Cycle 1, Day 15, and the beginning of Cycle 3(optional, will be collected after subjects have signed a separate Informed Consent Form).Optional tumor biopsy, to be taken at the time of progression on the day of the last treatment.\\\", \\\"Header\\\": [0, 1]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 362], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 363], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 364], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 365], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 366], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 367], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 368], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 369], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 370], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 371], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 372], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 373], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 374], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 375], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 376], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 377], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 378], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 379], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 380], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 381], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 382], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 383], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 384], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 385], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 386], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 387], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 388], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 389], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 390], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 391], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 392], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 393], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 394], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 395], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 396], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 397], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 398], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 399], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 400], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 401], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 402], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 403], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 404], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 405], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 406], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 407], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 408], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 409], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 410], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 411], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 412], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 413], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 414], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 415], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 416], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 417], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 418], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 419], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 420], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 421], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 422], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 423], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 424], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 425], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 426], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 427], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 428], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 429], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 430], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 431], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 432], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 433], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 434], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 435], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 436], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 437], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 438], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 439], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 440], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 441], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 442], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 443], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 444], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 445], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 446], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 447], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 448], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 449], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 450], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 451], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 452], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 453], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 454], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 455], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 456], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 457], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 458], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 459], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 460], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 461], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 462], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 463], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 464], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 465], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 466], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 467], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 468], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 469], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 470], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 471], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 472], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 473], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 474], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 475], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 476], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 477], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 478], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 479], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 480], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 481], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 482], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 483], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 484], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 485], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 486], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 487], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 488], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 489], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 490], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 491], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 492], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 493], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 494], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 495], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 496], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 497], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 498], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 499], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 500], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 501], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 502], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 503], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 504], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 505], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 506], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 507], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 508], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 509], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 510], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 511], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 512], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 513], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 514], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 515], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 516], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 517], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 518], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 519], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 520], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 521], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 522], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 523], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 524], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 525], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 526], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 527], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 528], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 529], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 530], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 531], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 532], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 533], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 534], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 535], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 536], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 537], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 538], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 539], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 540], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 541], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 542], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 543], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 544], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 545], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 546], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 547], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 548], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 549], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 550], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 551], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 552], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 553], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 554], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 555], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 556], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 557], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 558], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 559], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 560], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 561], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 562], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 563], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 564], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 565], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 566], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 567], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 568], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 569], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 570], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 571], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 572], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 573], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 574], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 575], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 576], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 577], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 578], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 579], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 580], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 581], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 582], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 583], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 584], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 585], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 586], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 587], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 588], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 589], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 590], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 591], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 592], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 593], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 594], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 595], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>i</td>\\\\n      <td>All ECGs to be taken as single 12-lead resting ECGs, except at time points where PK samples are also obtained, in which case triplicate ECGs should be obtained at 2-minute intervals (\\\\u00b1 1 minute) . Vital signs (heart rate, systolic, and diastolic blood pressure, in a seated position) should be taken within 30 minutes prior to each ECG recording after sitting for 5 minutes.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>j</td>\\\\n      <td>ECGs are recorded after at least 5 minutes rest in supine position at predose (within 60 minutes prior to dosing on Cycle 1 Day 1 and within 40 minutes prior to dosing on Cycle 1 Day 15) and at 4 hours (\\\\u00b1 12 minutes) postdose. ECG recordings should be performed within 10 minutes before PK sampling time-points on days where both assessments are performed.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>k</td>\\\\n      <td>Predose only.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>l</td>\\\\n      <td>Not required for subjects with a previous assessment within 7 days of the EoT visit.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td><strike>l</strike> m</td>\\\\n      <td>Hemoglobin, hematocrit, red blood cell count, white blood cell count, differential, platelet count, and coagulation (PT, aPTT, and INR). For the subject eligibility check at screening, these samples must be reported by a local laboratory.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td><strike>m</strike> n</td>\\\\n      <td>BUN, creatinine, AST, ALT, GGT, total bilirubin (including direct fraction if total bilirubin is abnormal), lipase, amylase, total protein, albumin, alkaline phosphatase, sodium, potassium, calcium, magnesium, and glucose. For the subject eligibility check at screening, these samples must be reported by a local laboratory.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td><strike>n</strike> o</td>\\\\n      <td>Urinalysis: dipstick followed by microscopic examination if abnormal results.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td><strike>o</strike> p</td>\\\\n      <td>HBV serology panel: HBc antibodies, HBs antibodies, HBs antigen, HBe antigen, HBe antibodies.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>8</th>\\\\n      <td><strike>p</strike> q</td>\\\\n      <td>The purpose of these samples is to establish baseline values. Alternatively, samples may be taken predosing on Day 1 of Cycle 1.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>9</th>\\\\n      <td><strike>q</strike> r</td>\\\\n      <td>HBV DNA will be evaluated in all subjects at baseline. Thereafter, HBV DNA and serology will be monitored every 3 cycles and at EoT for all subjects with known HBV history, or who were positive for HBV DNA at baseline, or are positive for HBV serology. See Section 6.5.3.1.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>10</th>\\\\n      <td><strike>r</strike> s</td>\\\\n      <td>HCV RNA-PCR will be evaluated in all subjects at baseline. Thereafter, HCV RNA-PCR will be monitored every 3 cycles and at EoT for all subjects with known HCV history or who were positive for HCV RNA-PCR at baseline. See Section 6.5.3.1.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>11</th>\\\\n      <td><strike>s</strike> t</td>\\\\n      <td>Only for women of childbearing potential, including those who have had a tubal ligation.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>12</th>\\\\n      <td><strike>t</strike> u</td>\\\\n      <td>Complete tumor assessment of all lesions by radiographic or other modality (using RECIST v 1.1). CT or MRI of the chest, abdomen, and pelvis to evaluate disease in these locations. CT/MRI of the head at baseline for subjects who are suspected to have CNS metastases. Tumor assessments to be performed at baseline and after every 2 cycles (6 weeks) (i.e., before start of next odd-numbered cycle) until Cycle 13 and after every 4 cycles (12 weeks) after Cycle 13. The scheduled 6-week (or 12-week) interval between tumor response evaluations should be maintained through the trial regardless of any delay or interruption to trial treatment. Subjects who are discontinued from the trial due to unacceptable toxicity should perform the tumor assessment at 6 week intervals until Cycle 13 and 12 week interval (4 cycles) after Cycle 13 until disease progression, starting a new therapy, or death. Clinical progression, at any time, requires a physical examination and prompt radiological confirmation rather than waiting for the next scheduled imaging assessment. If unscheduled imaging does not meet progressive disease by RECIST v1.1, the next scheduled imaging assessment should still be performed on time unless the next scheduled imaging assessment is within 14 days following the unscheduled imaging. See Section 7.3.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>13</th>\\\\n      <td><strike>u</strike> v</td>\\\\n      <td>To be performed predose on or within 5 days prior to, Day 1 of Cycles 3, 5, 7, 9, 11, 13, i.e., at 6-week intervals, and every 4 cycles thereafter, i.e., at 12-week intervals, until disease progression starting a new anti-tumor therapy, or death <strike>or study drug discontinuation</strike> . The scheduled 6-week (or 12-week) interval between tumor response assessments should be maintained through the trial regardless of any delay or interruption to trial treatment.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>14</th>\\\\n      <td><strike>v</strike> w</td>\\\\n      <td>If a subject discontinues trial treatment for a reason other than disease progression or death, tumor assessment will be performed at EoT if it has not been done within the past 6 weeks, and will be repeated every 6 weeks (\\\\u00b1 1 week) until radiological progression per RECIST v 1.1, death or start of new anticancer therapy, whichever occurs first.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>15</th>\\\\n      <td><strike>w</strike> x</td>\\\\n      <td>Samples will be taken predose, and at 0.25, 0.5, 1, 2, 4, 8, 10, and 24 hours postdose. Note: The 24-hour postdose samples from Day 1 and Day 15 are the predose samples from Day 2 and Day 16, respectively. The predose sample on Cycle 1 Day 1 should be taken within 60 minutes prior to dose. The predose sample on Cycle 1 Day 15 (trough value) should be taken within 30 minutes predose. Postdose PK samples should be taken within \\\\u00b1 5% of the scheduled assessment time, e.g., the 4-hour postdose sample should be obtained at 4 hours \\\\u00b1 12 minutes.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>16</th>\\\\n      <td><strike>x</strike> y</td>\\\\n      <td>Mandatory blood sample, predose only.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>17</th>\\\\n      <td><strike>y</strike> z</td>\\\\n      <td>Mandatory blood sample, predose only. The first on-treatment blood samples should be taken anytime between Cycle 1, Day 15 and Cycle 2, Day 15. The second ontreatment blood sample should be drawn between Cycle 2, Day 15 and Cycle 4, Day 1.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>18</th>\\\\n      <td><strike>z</strike> aa</td>\\\\n      <td>Optional; predose only. Will be collected after subjects have signed <strike>subject\\\\u2019s signing off</strike> a separate Informed Consent Form.</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"56\\\", \\\"TableIndex\\\": \\\"45\\\", \\\"TableName\\\": \\\"Where ECGs are performed in triplicate, vital signs only need to be recorded once prior to the first ECG.\\\", \\\"Header\\\": [0, 3]}, {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 596], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Treatment Duration Figure (Figure 3)\\\", \\\"4.1\\\", \\\"2\\\", 597], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\" 4.3Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 598], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Details of the MET status rescoring process were added to footnote e.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 599], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Footnote f was updated to highlight that paired tumor biopsy is optional.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 600], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Footnote k was updated to include a \\\\u00b1 1 minute time window for triplicate ECGs obtained at 2-minute intervals.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 601], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Footnote n was added to clarify the end of treatment laboratory assessment requirements.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 602], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Footnote w (previously v) was updated with additional information about scheduled imaging assessments following unscheduled imaging.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 603], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Footnote x (previously w) was updated to clarify the timing of tumor imaging assessments.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 604], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Footnote z updated to clarify that sparse PK sampling will be performed only for subjects who consent.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 605], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 606], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n      <th>6.0</th>\\\\n      <th>7.0</th>\\\\n      <th>8.0</th>\\\\n      <th>9.0</th>\\\\n      <th>10.0</th>\\\\n      <th>11.0</th>\\\\n      <th>12.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td></td>\\\\n      <td>Screening</td>\\\\n      <td>Screening</td>\\\\n      <td></td>\\\\n      <td>Cycle 1 Day</td>\\\\n      <td></td>\\\\n      <td>Cycle 2 Day <sup>a</sup></td>\\\\n      <td>Cycle 2 Day <sup>a</sup></td>\\\\n      <td>Cycle \\\\u2265 3 Day</td>\\\\n      <td>EoT Visit <sup>b</sup></td>\\\\n      <td>Post- Treatment F/U Visit <sup>c</sup></td>\\\\n      <td>Survival F/U <sup>d</sup></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td>Molecular Prescreening</td>\\\\n      <td>Clinical Screening</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>DAY</td>\\\\n      <td></td>\\\\n      <td>\\\\u2264 -14 to 0</td>\\\\n      <td>1</td>\\\\n      <td>8</td>\\\\n      <td>15</td>\\\\n      <td>1</td>\\\\n      <td>8</td>\\\\n      <td>1</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>MSC2156119J</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>QD</td>\\\\n      <td>QD</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Sorafenib</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>BID</td>\\\\n      <td>BID</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>Written informed consent (Prescreening) <sup>e</sup></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>Written informed consent (main study) <sup>e</sup></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td>Eligibility</td>\\\\n      <td></td>\\\\n      <td>X<sup> e</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>8</th>\\\\n      <td>Randomization by IVRS</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>9</th>\\\\n      <td>Dispensing of study drug</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>10</th>\\\\n      <td>Demography, height <sup>e</sup></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>11</th>\\\\n      <td>Medical history <sup>e</sup></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>12</th>\\\\n      <td>Smoking status and alcohol use</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>13</th>\\\\n      <td>Tumor biopsy</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> f</sup></td>\\\\n      <td></td>\\\\n      <td>X<sup> f</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> g</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>14</th>\\\\n      <td>MET status determination <sup>e</sup></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>15</th>\\\\n      <td>Physical examination/weight <sup>h</sup></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X<sup> i</sup></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>16</th>\\\\n      <td>ECOG PS <sup>h</sup></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X<sup> i</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>17</th>\\\\n      <td>Vital signs <sup>h,j</sup></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>18</th>\\\\n      <td>ECG h,k</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X<sup> l</sup></td>\\\\n      <td></td>\\\\n      <td>X<sup> m</sup></td>\\\\n      <td>X<sup> l</sup></td>\\\\n      <td></td>\\\\n      <td>X<sup> m</sup></td>\\\\n      <td>X<sup> n</sup></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>19</th>\\\\n      <td>Hematology and coagulation <sup>h,</sup> <strike><sup>n</sup></strike> <sup>o</sup></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X<sup> i</sup></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X<sup> n</sup></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>20</th>\\\\n      <td>Chemistry <sup>h,</sup> <strike><sup>o</sup></strike> <sup>p</sup></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X<sup> i</sup></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X<sup> n</sup></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>21</th>\\\\n      <td>Urinalysis <sup>h,</sup> <strike><sup>p</sup></strike> <sup>q</sup></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X<sup> i</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X<sup> n</sup></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>22</th>\\\\n      <td>HBV viral serology panel <sup>h,</sup> <strike><sup>q</sup></strike> <sup>r</sup></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>r</strike> s</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>s</strike> t</sup></td>\\\\n      <td>X<sup> <strike>s</strike> n,t</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>23</th>\\\\n      <td>HBV DNA (viral load) <sup>h,</sup> <strike><sup>s</sup></strike> <sup>t</sup></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>r</strike> s</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>s</strike> t</sup></td>\\\\n      <td>X<sup> <strike>s</strike> n,t</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>24</th>\\\\n      <td>HCV RNA-PCR (viral load) <sup>h,</sup> <strike><sup>t</sup></strike> <sup>u</sup></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>r</strike> s</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>t</strike> u</sup></td>\\\\n      <td>X<sup> <strike>t</strike> n,u</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>25</th>\\\\n      <td>Serum pregnancy test (if applicable) <sup>h,</sup> <strike><sup>u</sup></strike> <sup>v</sup></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>26</th>\\\\n      <td>Tumor assessment (RECIST v 1.1) <strike><sup>v</sup></strike> <sup>w</sup></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>w</strike> x</sup></td>\\\\n      <td>X<sup> <strike>x</strike> y</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>27</th>\\\\n      <td>Serum AFP</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X<sup> i</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>28</th>\\\\n      <td>PK blood samples <sup>h</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>y</strike> z</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>y</strike> z</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>29</th>\\\\n      <td>Exploratory markers in plasma <sup>h</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>z</strike> aa</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>aa</strike> bb</sup></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>aa</strike> bb</sup></td>\\\\n      <td>X<sup> <strike>z</strike> aa</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>30</th>\\\\n      <td>PGx blood sample <strike><sup>bb</sup></strike> <sup>cc</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>31</th>\\\\n      <td>Subject survival and anticancer therapies</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>32</th>\\\\n      <td>Adverse events assessment</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>33</th>\\\\n      <td>Concomitant medication/procedure</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>34</th>\\\\n      <td>FHSI-8</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>35</th>\\\\n      <td>PRO (FACT-HP)</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>cc</strike> dd</sup></td>\\\\n      <td>X<sup> <strike>cc</strike> dd</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"56\\\", \\\"TableIndex\\\": \\\"46\\\", \\\"TableName\\\": \\\"Footnote z updated to clarify that sparse PK sampling will be performed only for subjects who consent.(Schedule of Assessment)\\\", \\\"Header\\\": [0, 1, 2]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 20, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 20, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 607], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 608], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 609], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 610], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 611], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 612], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 613], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 614], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 615], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 616], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 617], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 618], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 619], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 620], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 621], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 622], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 623], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 624], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 625], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 626], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 627], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 628], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 629], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 630], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 631], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 632], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 633], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 634], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 635], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 636], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 637], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 638], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 639], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 640], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 641], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 642], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 643], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 644], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 645], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 646], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 647], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 648], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 649], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 650], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 651], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 652], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 653], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 654], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 655], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 656], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 657], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 658], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 659], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 660], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 661], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 662], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 663], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 664], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 665], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 666], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 667], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 668], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 669], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 670], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 671], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 672], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 673], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 674], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 675], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 676], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 677], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 678], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 679], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 680], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 681], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 682], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 683], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 684], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 685], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 686], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 687], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 688], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 689], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 690], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 691], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 692], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 693], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 694], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 695], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 696], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 697], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 698], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 699], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 700], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 701], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 702], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 703], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 704], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 705], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 706], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 707], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 708], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 709], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 710], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 711], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 712], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 713], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 714], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 715], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 716], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 717], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 718], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 719], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 720], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 721], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 722], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 723], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 724], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 725], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 726], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 727], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 728], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 729], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 730], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 731], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 732], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 733], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 734], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 735], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 736], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 737], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 738], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 739], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 740], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 741], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 742], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 743], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 744], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 745], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 746], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 747], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 748], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 749], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 750], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 751], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 752], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 753], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 754], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 755], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 756], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 757], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 758], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 759], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 760], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 761], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 762], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 763], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 764], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 765], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 766], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 767], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 768], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 769], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 770], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 771], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 772], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 773], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 774], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 775], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 776], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 777], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 778], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 779], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 780], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 781], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 782], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 783], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 784], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 785], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 786], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 787], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 788], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 789], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 790], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 791], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 792], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 793], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 794], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 795], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 796], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 797], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 798], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 799], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 800], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 801], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 802], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 803], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 804], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 805], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 806], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 807], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 808], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 809], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 810], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 811], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 812], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 813], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 814], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 815], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 816], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 817], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 818], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 819], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 820], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 821], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 822], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 823], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 824], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 825], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 826], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 827], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 828], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 829], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 830], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 831], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 832], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 833], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 834], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 835], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 836], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 837], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 838], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 839], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 840], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 841], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 842], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 843], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 844], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 845], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 846], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 847], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 848], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 849], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 850], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 851], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 852], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 853], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 854], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 855], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 856], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 857], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 858], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 859], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 860], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 861], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 862], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 863], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 864], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 865], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 866], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 867], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 868], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 869], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 870], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 871], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 872], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 873], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 874], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 875], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Post-treatment follow-up visit, performed within 30 \\\\u00b1 3 days after the last treatment for all subjects who discontinue trial treatment permanently, including subjects who have completed an end of treatment visit.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 876], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Survival data will be collected every 3 months after end of treatment until death or the end of the trial.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 877], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"MET status will be confirmed during Molecular Prescreening after the subject has signed the prescreening ICF.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 878], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Demographic data and disease history\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 879], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"will\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 880], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"may\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": true, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 881], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"also be collected during Molecular Prescreening once the subject has signed the main ICF.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 882], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Clinical Screening will include laboratory parameters, medical history and all other assessments needed to confirm subject eligibility, plus demographic data and disease history if not already collected.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 883], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Clinical Screening assessments must be completed within 14 days prior to the initiation of study treatment.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 884], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"MET status rescoring will be performed as a quality control measure; subjects with a MET status of 1+ or \\\\u2018not assessable' on rescoring will be excluded from the modified intent-to-treat population.\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 885], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Undergoing paired tumor biopsy is not mandatory, but highly recommended for subjects with accessible tumors: the paired tumor biopsy will be performed before the first treatment (i.e., during screening or on Cycle 1, Day 1, prior to the first dose of trial treatment) and anytime between Cycle 1, Day 15 and the beginning of Cycle 3\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 886], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"(optional, will be collected after subjects have signed a separate ICF)\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 887], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\".\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 888], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Optional tumor biopsy, to be taken at the time of progression on the day of the last treatment.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 889], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Assessment can be repeated at the investigator's discretion at unscheduled visits to assess the safety and tolerability of the IMP i.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 890], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 891], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Only if screening/last assessments were performed\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 892], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Segoe UI Symbol\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 893], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"7 days prior to Cycle 1, Day 1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 894], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Heart rate, diastolic and systolic blood pressure in a seated position of 5 minutes.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 895], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"On days when ECGs are taken, vital signs should be taken within 30 minutes prior to the ECG recording.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 896], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Where ECGs are performed in triplicate, vital signs only need to be recorded once prior to the first ECG.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 897], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"All ECGs to be taken as single 12-lead resting ECGs, except at time points where PK samples are also obtained, in which case triplicate ECGs should be obtained at 2-minute intervals\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 898], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"(\\\\u00b1 1 minute)\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 899], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\".\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 900], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Vital signs (heart rate, systolic, and diastolic blood pressure, in a seated position) should be taken within 30 minutes prior to each ECG recording after sitting for 5 minutes.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 901], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"ECGs are recorded after at least 5 minutes rest in supine position at predose (within 60 minutes prior to dosing on Cycle 1 Day 1 and within 40 minutes prior to dosing on Cycle 2 Day 1) (MSC2156119J and sorafenib arms) and at 4 hours (\\\\u00b1 12 minutes) postdose (MSC2156119J arm only).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 902], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"ECG recordings should be performed within 10 minutes before PK sampling time-points on days where both assessments are performed.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 903], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"m\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 904], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 905], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Predose only.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 906], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"n\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 907], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 908], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Not required for subjects with a previous assessment within 7 days of the EoT visit.\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 909], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"n\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": true, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 910], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"o\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 911], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 912], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Hemoglobin, hematocrit, red blood cell count, white blood cell count, differential, platelet count, and coagulation (PT, aPTT, and INR).\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 913], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"For the subject eligibility check at Clinical Screening, these samples must be reported by a local laboratory.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 914], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"t\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": true, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 915], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"u\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 916], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 917], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"HCV RNA-PCR will be evaluated in all subjects at baseline.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 918], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Thereafter, HCV RNA-PCR will be monitored every 3 cycles and at EoT for all subjects with known HCV history or who were positive for HCV RNA-PCR at baseline.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 919], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"See Section 6.5.3.1.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 920], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"u\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": true, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 921], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"v\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 922], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 923], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Only for women of childbearing potential, including those who have had a tubal ligation.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 924], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 925], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td><strike>v</strike> w</td>\\\\n      <td>Complete tumor assessment of all lesions by radiographic or other modality (using RECIST v 1.1). CT or MRI of the chest, abdomen, and pelvis to evaluate disease in these locations. CT/MRI of the head at baseline for subjects who is suspected to have CNS metastases. Tumor assessments to be performed at baseline and after every 2 cycles (6 weeks) (i.e., before start of next odd-numbered cycle) until Cycle 13 and after every 4 cycles (12 weeks) after Cycle 13. The scheduled 6-week (or 12-week) interval between tumor response evaluations should be maintained through the trial regardless of any delay or interruption to trial treatment. Subjects who are discontinued from the trial due to unacceptable toxicity should perform the tumor assessment at 6-week intervals until Cycle 13 and 12-week interval (4 cycles) after Cycle 13 until disease progression, starting a new therapy, or death. Clinical progression, at any time, requires a physical examination and prompt radiological confirmation rather than waiting for the next scheduled imaging assessment. If unscheduled imaging does not meet progressive disease by RECIST v1.1, the next scheduled imaging assessment should still be performed on time unless the next scheduled imaging assessment is within 14 days following the unscheduled imaging. See Section 7.3.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td><strike>w</strike> x</td>\\\\n      <td>To be performed predose on or within 5 days prior to, Day 1 of Cycles 3, 5, 7, 9, 11, 13, i.e., at 6-week intervals, and every 4 cycles thereafter, i.e., at 12-week intervals, until disease progression, starting a new anti-tumor therapy, or death <strike>or study drug discontinuation</strike> . The scheduled 6-week (or 12 week) interval between tumor response assessments should be maintained through the trial regardless of any delay or interruption to trial treatment.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td><strike>x</strike> y</td>\\\\n      <td>If a subject discontinues trial treatment for a reason other than disease progression or death, tumor assessment will be performed at EoT if it has not been done within the past 6 weeks, and will be repeated every 6 weeks (\\\\u00b1 1 week) until radiological progression per RECIST v 1.1, death or start of new anticancer therapy, whichever occurs first.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td><strike>y</strike> z</td>\\\\n      <td>Sparse PK sampling will be performed predose and at 4 hours postdose on Cycle 1, Day 1 and on Cycle 2, Day 1 in the MSC2156119J arm (total of 4 samples in Phase II). <strike>At selected sites only</strike> For subjects who consent sparse PK sampling will be performed predose and at 1.5, 3.5 and 6.5-8 hours postdose on Cycle 1, Day 1, and at predose and at 2 and 6-8 hours postdose on Cycle 2, Day 1. The predose sample on Cycle 1 Day 1 should be taken within 60 minutes prior to dose. The predose sample on Cycle 2 Day 1 (trough value) should be taken within 30 minutes predose. Postdose PK samples should be collected within \\\\u00b1 5% of the scheduled assessment time, e.g., the 4-hour postdose sample should be obtained at 4 hours \\\\u00b1 12 minutes. The actual time of the PK sample (relative to dosing) should also be recorded. At sites performing extended PK sampling, the postdose ECG will be performed at 3.5 hours postdose on Cycle 1, Day 1 and at 2 hours postdose on Cycle 2, Day 1.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td><strike>z</strike> aa</td>\\\\n      <td>Mandatory blood sample, predose only.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td><strike>aa</strike> bb</td>\\\\n      <td>Mandatory blood sample, predose only. . The first on-treatment blood samples should be taken anytime between Cycle 1, Day 15 and Cycle 2, Day 15. The second on-treatment blood sample should be drawn between Cycle 2, Day 15 and Cycle 4, Day 1.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td><strike>bb</strike> cc</td>\\\\n      <td>Optional; will be collected after <strike>subject\\\\u2019s signing off</strike> subjects have signed a separate Informed Consent Form.</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td><strike>cc</strike> dd</td>\\\\n      <td>On Cycle 5, Day 1 and the <strike>E</strike> e nd of <strike>T</strike> t reatment <strike>V</strike> v isit (only if the subject discontinued before Cycle 5, Day 1).</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"60\\\", \\\"TableIndex\\\": \\\"47\\\", \\\"TableName\\\": \\\"Only for women of childbearing potential, including those who have had a tubal ligation.\\\", \\\"Header\\\": [0, 1, 2, 3]}, {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": true, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 926], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 927], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Efficacy, Safety, and PK of MSC2156119J in Asian Subjects with\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 928], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"HCC\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 929], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", \\\"4.3\\\", \\\"2\\\", 930], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\" Updated Blood Sampling Schedule and Blood Volumes for\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading2\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 931], [\\\"\\\", \\\"Unmapped\\\", \\\"header\\\", \\\" PK, Pd/Biomarkers, and PGx (Appendix J)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"Heading3\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 932], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"A new footnote a was added to clarify that PGx sampling is optional and will only be collected after subjects have signed a separate Informed Consent Form.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 933], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Phase Ib\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 934], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n      <th>6.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Cycle</td>\\\\n      <td>Day</td>\\\\n      <td>Time points H = hours after dosing</td>\\\\n      <td>PK</td>\\\\n      <td>Pd/Biomarkers</td>\\\\n      <td>PGx <sup>a</sup></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>2 mL</td>\\\\n      <td>20 mL</td>\\\\n      <td>6 mL</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Cycle 1</td>\\\\n      <td>Day 1</td>\\\\n      <td>Predosing</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 0.25</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 0.5</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 1</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 2</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 4</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>8</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 8</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>9</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 10</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>10</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 24 <strike>a</strike> b</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>11</th>\\\\n      <td></td>\\\\n      <td>Day 15</td>\\\\n      <td>Predosing</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>12</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 0.5</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>13</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 1</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>14</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 2</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>15</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 4</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>16</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 8</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>17</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 10</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>18</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 24 <strike>b</strike> c</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>19</th>\\\\n      <td></td>\\\\n      <td>EoT</td>\\\\n      <td></td>\\\\n      <td>-</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>20</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 4</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>21</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 4</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>22</th>\\\\n      <td></td>\\\\n      <td>EoT</td>\\\\n      <td>Predosing</td>\\\\n      <td>-</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>23</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 3.5</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>24</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 6.5-8</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>25</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 2</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>26</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 6-8</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>27</th>\\\\n      <td></td>\\\\n      <td>EoT</td>\\\\n      <td>Predosing</td>\\\\n      <td>-</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"60\\\", \\\"TableIndex\\\": \\\"48\\\", \\\"TableName\\\": \\\"(Schedule of Assessment)\\\", \\\"Header\\\": [0, 1, 0]}, {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 935], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 936], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 937], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 938], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 939], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 940], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 941], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 942], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 943], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 944], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 945], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 946], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 947], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 948], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 949], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 950], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 951], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 952], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 953], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 954], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 955], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 956], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 957], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 958], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 959], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 960], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 961], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 962], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 963], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 964], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 965], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 966], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 967], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 968], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 969], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 970], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 971], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 972], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 973], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Abbreviation: EoT, end of treatment; H, hour\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 974], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"; Pd, pharmacodynamic; PGx, pharmacogenetic; PK, pharmacokinetic\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 975], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\".\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 976], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"a\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"superscript\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 977], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Optional.\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 978], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Will be collected after subjects have signed a separate Informed Consent Form.\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 979], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"a\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": true, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"superscript\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 980], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"b\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"superscript\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 981], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The 24-hour postdose sample is the predose samples from Day 2.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 982], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"b\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": true, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"superscript\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 983], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"c\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"superscript\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 984], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The 24-hour postdose sample is the predose samples from Day 16.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 985], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The predose PK sample on Cycle 1 Day 1 should be taken within 60 minutes prior to dose.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 986], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The predose PK sample on Cycle 1 Day 15 (trough value) should be taken within 30 minutes prior to dose.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 987], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Postdose PK samples should be taken within \\\\u00b1 5% of the scheduled assessment time, e.g., the 4-hour postdose sample should be obtained at 4 hours \\\\u00b1 12 minutes.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 988], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"All other predosing samples should be taken within 60 minutes before each treatment administration.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 989], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"An anticipated total blood sample volume of approximately 122 mL will be taken in Phase Ib.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 990], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 991], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"C O N F I D E N T I A L\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 992], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"61/62 Document No. 0900babe80c5f21bv1.0\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 993], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 994], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 995], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"I N F O R M A T I O N\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 996], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Object No. 0900babe80cf65da\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 997], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 998], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Efficacy, Safety, and PK of MSC2156119J in Asian Subjects with\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 999], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"HCC\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1000], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1001], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Phase II\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1002], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1003], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1004], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1005], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1006], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1007], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1008], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1009], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1010], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1011], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Abbreviation: EoT, end of treatment; H, hour\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1012], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"; Pd, pharmacodynamic; PGx, pharmacogenetic; PK, pharmacokinetic\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1013], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\".\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1014], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"a\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"superscript\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1015], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Optional.\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1016], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Will be collected after subjects have signed a separate Informed Consent Form.\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1017], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The predose PK sample on Cycle 1 Day 1 should be taken within 60 minutes prior to dose.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1018], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"The predose PK sample on Cycle 2 Day 1 (trough value) should be taken within 30 minutes prior to dose.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1019], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Postdose PK samples should be collected within \\\\u00b1 5% of the scheduled assessment time, e.g., the 4-hour postdose sample should be obtained at 4 hours \\\\u00b1 12 minutes.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1020], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"All other predosing samples should be taken within 60 minutes before each treatment administration.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1021], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"An anticipated total blood sample volume of approximately 94 mL will be taken in Phase II.\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1022], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"At Selected Sites in Phase II\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1023], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\":\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 24, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 24, \\\"SmallCaps\\\": false, \\\"Strike\\\": true, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1024], [\\\"\\\", \\\"Unmapped\\\", \\\"table\\\", \\\"\\\", {\\\"IsBold\\\": true, \\\"font_size\\\": 18, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": true, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"Times New Roman\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": 18, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1025], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1026], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1027], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1028], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1029], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1030], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1031], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1032], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1033], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1034], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1035], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1036], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1037], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1038], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1039], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1040], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Table of Contents\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1041], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1042], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1043], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1044], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1045], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"8\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1046], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1047], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"1 Introduction\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1048], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1049], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1050], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1051], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1052], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1053], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1054], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2 Rationale for Changes\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1055], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1056], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1057], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1058], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1059], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1060], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1061], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2.1 Rationale for Changes Relating to the Early Discontinuation of\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1062], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1063], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1064], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1065], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1066], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Prescreening\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1067], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1068], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1069], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1070], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1071], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"9\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1072], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1073], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2.2 Rationale for the Changes Relating to Re-scoring MET Status\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1074], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1075], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1076], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1077], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1078], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1079], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1080], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2.3 Rationale for Clarifying the Role of the Independent Review\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1081], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1082], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1083], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1084], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1085], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Committee\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1086], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1087], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1088], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1089], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1090], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1091], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1092], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2.4 Rationale for Corrections\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1093], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1094], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1095], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1096], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1097], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"10\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1098], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1099], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"2.5 Rationale for Other Protocol Clarifications\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1100], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1101], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1102], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1103], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1104], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"11\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1105], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1106], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"3 List of Changes\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1107], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1108], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1109], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1110], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1111], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"12\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1112], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1113], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"4 Appendices\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1114], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1115], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1116], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1117], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1118], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"53\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1119], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1120], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"4.1 Updated Treatment Duration Figure (Figure 3)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1121], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1122], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1123], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1124], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1125], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"53\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1126], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1127], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"4.2 Updated Phase Ib Schedule of Dosing and Assessments (Appendix H)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1128], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1129], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1130], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1131], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1132], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"54\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1133], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1134], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"4.3 Updated Phase II Schedule of Dosing and Assessments (Appendix I)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1135], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1136], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1137], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1138], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1139], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"57\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1140], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1141], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"4.4 Updated Blood Sampling Schedule and Blood Volumes for PK,\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1142], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1143], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1144], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1145], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1146], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"Pd/Biomarkers, and PGx (Appendix J)\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1147], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1148], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1149], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1150], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1151], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1152], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"61\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1153], [\\\"\\\", \\\"Unmapped\\\", \\\"text\\\", \\\"\\\", {\\\"IsBold\\\": false, \\\"font_size\\\": -1, \\\"font_style\\\": \\\"\\\", \\\"Bold\\\": false, \\\"Caps\\\": false, \\\"ColorRGB\\\": 0, \\\"DStrike\\\": false, \\\"Emboss\\\": false, \\\"Highlight\\\": \\\"\\\", \\\"Imprint\\\": false, \\\"Italics\\\": false, \\\"Outline\\\": false, \\\"rFonts\\\": \\\"\\\", \\\"rStyle\\\": \\\"\\\", \\\"Shadow\\\": false, \\\"Size\\\": -1, \\\"SmallCaps\\\": false, \\\"Strike\\\": false, \\\"Underline\\\": \\\"\\\", \\\"Vanish\\\": false, \\\"VertAlign\\\": \\\"\\\"}, \\\"Unmapped\\\", \\\"Updated Blood Sampling Schedule and Blood Volumes for\\\", \\\"4.4\\\", \\\"2\\\", 1154]], \\\"metadata\\\": {\\\"protocol_title\\\": \\\"MSC2156119J (tepotinib)  Efficacy, Safety, and PK of MSC2156119J in Asian Subjects with HCC A Multicenter, Randomized, Phase Ib/II Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of MSC2156119J as Monotherapy Versus Sorafenib in Asian Subjects with MET+ Advanced Hepatocellular Carcinoma and Child-Pugh Class A Liver Function\\\", \\\"protocol_title_short\\\": \\\"\\\", \\\"amendment_number\\\": \\\"\\\", \\\"is_amendment\\\": \\\"am1\\\", \\\"trial_phase\\\": \\\"Ib/II\\\", \\\"sponsor\\\": \\\"s1\\\", \\\"sponsor_address\\\": \\\"\\\", \\\"drug\\\": \\\"\\\", \\\"approval_date\\\": \\\"2017\\\", \\\"version_number\\\": \\\"4\\\", \\\"version_date\\\": \\\"\\\", \\\"blinded\\\": \\\"\\\", \\\"compound_number\\\": \\\"\\\", \\\"control\\\": \\\"\\\", \\\"investigator\\\": \\\"Dr Shukui Qin, MD\\\", \\\"study_id\\\": \\\"\\\", \\\"number_of_subjects\\\": \\\"90\\\", \\\"participant_age\\\": \\\"\\\", \\\"participant_sex\\\": \\\"FEMALE\\\", \\\"exclusion_criteria\\\": \\\"\\\", \\\"inclusion_criteria\\\": \\\"\\\", \\\"indication\\\": \\\"ind\\\", \\\"objectives_section\\\": \\\"\\\", \\\"study_population\\\": \\\"patient, subject, ad.. ( ), treated with diagnosis of entity: basic, word .. Diseases and Symptom.. and Diseases and Sym.. showing symptoms of ..\\\", \\\"entities_in_assessments\\\": \\\"\\\", \\\"soa_epochs\\\": \\\"\\\", \\\"assessment_footnote\\\": \\\"a  All visits and assessments from Cycle 2 onwards may be performed +/- 5 days to accommodate unforeseen delays, holidays, or vacations. b  End of treatment visit, performed on the last day of treatment, whether at the end of a cycle or not. The last day of treatment is defined as the day on which it is determined that the subject will no longer receive the study drug.\\\", \\\"upload_date\\\": \\\"20210607030123\\\", \\\"protocol_number\\\": \\\"emr2.ba9cbd08-dfd6-4a8c-8f04-9666c0313f33\\\", \\\"study_status\\\": \\\"stat\\\", \\\"molecule_device\\\": \\\"mol\\\", \\\"accuracy\\\": \\\"\\\"}}\"",
  "iqvdataSoa": "\"[{\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n      <th>6.0</th>\\\\n      <th>7.0</th>\\\\n      <th>8.0</th>\\\\n      <th>9.0</th>\\\\n      <th>10.0</th>\\\\n      <th>11.0</th>\\\\n      <th>12.0</th>\\\\n      <th>13.0</th>\\\\n      <th>14.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td></td>\\\\n      <td>Screening</td>\\\\n      <td></td>\\\\n      <td>Cycle 1 Day</td>\\\\n      <td>Cycle 1 Day</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>Cycle 2 Day <sup>a</sup></td>\\\\n      <td>Cycle 2 Day <sup>a</sup></td>\\\\n      <td></td>\\\\n      <td>Cycle \\\\u2265 3 Day</td>\\\\n      <td>EoT Visit <sup>b</sup></td>\\\\n      <td>Post- Treatment F/U Visit <sup>c</sup></td>\\\\n      <td>Survival F/U <sup>d</sup></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td>DAY</td>\\\\n      <td>-14 to 0</td>\\\\n      <td>1</td>\\\\n      <td>2</td>\\\\n      <td>8</td>\\\\n      <td>15</td>\\\\n      <td>1</td>\\\\n      <td>8</td>\\\\n      <td></td>\\\\n      <td>15</td>\\\\n      <td>1</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>MSC2156119J</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>QD</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>Written informed consent</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Dispensing of study drug</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>Demography, height</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>Medical history</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td>Smoking status and alcohol use</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>8</th>\\\\n      <td>Tumor biopsy</td>\\\\n      <td></td>\\\\n      <td>X<sup> e</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> e</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> f</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>9</th>\\\\n      <td>Physical examination/weight</td>\\\\n      <td>X</td>\\\\n      <td>X<sup> g</sup></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>10</th>\\\\n      <td>ECOG PS</td>\\\\n      <td>X</td>\\\\n      <td>X<sup> g</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>11</th>\\\\n      <td>Vital signs <sup>h</sup></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>12</th>\\\\n      <td>ECG <sup>i</sup></td>\\\\n      <td>X</td>\\\\n      <td>X<sup> j</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> j</sup></td>\\\\n      <td>X<sup> k</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> k</sup></td>\\\\n      <td>X<sup> l</sup></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>13</th>\\\\n      <td>Hematology and coagulation <strike><sup>l</sup></strike> <sup>m</sup></td>\\\\n      <td>X</td>\\\\n      <td>X<sup> g</sup></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X<sup> l</sup></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>14</th>\\\\n      <td>Chemistry <strike><sup>m</sup></strike> <sup>n</sup></td>\\\\n      <td>X</td>\\\\n      <td>X<sup> g</sup></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X<sup> l</sup></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>15</th>\\\\n      <td>Urinalysis <strike><sup>n</sup></strike> <sup>o</sup></td>\\\\n      <td>X</td>\\\\n      <td>X<sup> g</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X<sup> l</sup></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>16</th>\\\\n      <td>HBV viral serology panel <strike><sup>o</sup></strike> <sup>p</sup></td>\\\\n      <td>X<sup> <strike>p</strike> q</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>q</strike> r</sup></td>\\\\n      <td>X<sup> <strike>q</strike> l,r</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>17</th>\\\\n      <td>HBV DNA (viral load) <strike><sup>q</sup></strike> <sup>r</sup></td>\\\\n      <td>X<sup> <strike>p</strike> q</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>q</strike> r</sup></td>\\\\n      <td>X<sup> <strike>q</strike> l,r</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>18</th>\\\\n      <td>HCV RNA-PCR (viral load) <strike><sup>r</sup></strike> <sup>s</sup></td>\\\\n      <td>X<sup> <strike>p</strike> q</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>r</strike> s</sup></td>\\\\n      <td>X<sup> <strike>r</strike> l,s</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>19</th>\\\\n      <td>Serum pregnancy test (if applicable) <strike><sup>s</sup></strike> <sup>t</sup></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>20</th>\\\\n      <td>Tumor assessment (RECIST v 1.1) <strike><sup>t</sup></strike> <sup>u</sup></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>u</strike> v</sup></td>\\\\n      <td>X<sup> <strike>v</strike> w</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>21</th>\\\\n      <td>Serum AFP</td>\\\\n      <td>X</td>\\\\n      <td>X<sup> g</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>22</th>\\\\n      <td>PK blood samples</td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>w</strike> x</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>w</strike> x</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>23</th>\\\\n      <td>Exploratory markers in plasma</td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>x</strike> y</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>y</strike> z</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>y</strike> z</sup></td>\\\\n      <td>X<sup> <strike>x</strike> y</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>24</th>\\\\n      <td>PGx blood sample <strike><sup>z</sup></strike> <sup>aa</sup></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>25</th>\\\\n      <td>Subject survival and anticancer therapies</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>26</th>\\\\n      <td>Adverse events assessment</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>27</th>\\\\n      <td>Concomitant medication/procedure</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"52\\\", \\\"TableIndex\\\": \\\"44\\\", \\\"TableName\\\": \\\"Footnote v (previously u) was updated to clarify the timing of tumor imaging assessments.(Schedule of Assessment)\\\", \\\"FootnoteText_0\\\": \\\"Principal Investigator SignatureCenter NumberPrincipal InvestigatorI, the undersigned, am responsible for the conduct of the trial at this site and affirm that:I understand and will conduct the trial according to the clinical trial protocol, any approved protocol amendments, International Council for Harmonisation (ICH) Good Clinical Practice (GCP) (ICH Topic E6 GCP) and all applicable Regulatory Health Authority requirements and national laws.I will not deviate from the clinical protocol without prior written permission from the Sponsor and prior review and written approval from the Institutional Review Board or Independent Ethics Committee, except where necessary to prevent immediate danger to the subject.I understand that some regulatory Health Authorities require the Sponsors of clinical trials to obtain and supply, when required, details about the Investigators' ownership interests in the Sponsor or Investigational Product and information regarding any financial ties with the Sponsor.nanSignatureName, academic qualificationsPosition (job title)Address of InstitutionTelephone numberFax numberEmail addressAbbreviations: AFP, alpha-fetoprotein; ALT, alanine aminotransferase; aPTT, activated partial thromboplastin time; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CNS, central nervous system; CT, computed tomography; ECG, electrocardiogram; ECOG PS, Eastern Cooperative Oncology Group performance status; EoT, end of treatment; F/U, follow-up; GGT, gamma-glutamyl transpeptidase; HBc, hepatitis B core antigen; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCC; hepatocellular carcinoma; HCV, hepatitis C virus; INR, international normalized ratio; RECIST, response evaluation criteria in solid tumors; MRI, magnetic resonance imaging; PGx, pharmacogenetic; PK, pharmacokinetic; PT, prothrombin time; RNA, ribonucleic acid.\\\", \\\"FootnoteText_1\\\": \\\"nanPost-treatment follow-up visit, performed within 30 \\\\u00b1 3 days after the last treatment for all subjects who discontinue trial treatment permanently, including subjects who have completed an end of treatment visit.Survival data will be collected every 3 months after end of treatment until death or the end of the trial.Undergoing paired tumor biopsy is not mandatory but highly recommended for subjects with accessible tumors: the paired tumor biopsy will be performed before the first trial treatment (i.e., during Screening or on Cycle 1, Day 1, prior to the first dose of trial treatment) and anytime between Cycle 1, Day 15, and the beginning of Cycle 3(optional, will be collected after subjects have signed a separate Informed Consent Form).Optional tumor biopsy, to be taken at the time of progression on the day of the last treatment.\\\", \\\"Header\\\": [0, 1]}, {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n      <th>6.0</th>\\\\n      <th>7.0</th>\\\\n      <th>8.0</th>\\\\n      <th>9.0</th>\\\\n      <th>10.0</th>\\\\n      <th>11.0</th>\\\\n      <th>12.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td></td>\\\\n      <td>Screening</td>\\\\n      <td>Screening</td>\\\\n      <td></td>\\\\n      <td>Cycle 1 Day</td>\\\\n      <td></td>\\\\n      <td>Cycle 2 Day <sup>a</sup></td>\\\\n      <td>Cycle 2 Day <sup>a</sup></td>\\\\n      <td>Cycle \\\\u2265 3 Day</td>\\\\n      <td>EoT Visit <sup>b</sup></td>\\\\n      <td>Post- Treatment F/U Visit <sup>c</sup></td>\\\\n      <td>Survival F/U <sup>d</sup></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td>Molecular Prescreening</td>\\\\n      <td>Clinical Screening</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>DAY</td>\\\\n      <td></td>\\\\n      <td>\\\\u2264 -14 to 0</td>\\\\n      <td>1</td>\\\\n      <td>8</td>\\\\n      <td>15</td>\\\\n      <td>1</td>\\\\n      <td>8</td>\\\\n      <td>1</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td>MSC2156119J</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>QD</td>\\\\n      <td>QD</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td>Sorafenib</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>BID</td>\\\\n      <td>BID</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td>Written informed consent (Prescreening) <sup>e</sup></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td>Written informed consent (main study) <sup>e</sup></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td>Eligibility</td>\\\\n      <td></td>\\\\n      <td>X<sup> e</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>8</th>\\\\n      <td>Randomization by IVRS</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>9</th>\\\\n      <td>Dispensing of study drug</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>10</th>\\\\n      <td>Demography, height <sup>e</sup></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>11</th>\\\\n      <td>Medical history <sup>e</sup></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>12</th>\\\\n      <td>Smoking status and alcohol use</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>13</th>\\\\n      <td>Tumor biopsy</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> f</sup></td>\\\\n      <td></td>\\\\n      <td>X<sup> f</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> g</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>14</th>\\\\n      <td>MET status determination <sup>e</sup></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>15</th>\\\\n      <td>Physical examination/weight <sup>h</sup></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X<sup> i</sup></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>16</th>\\\\n      <td>ECOG PS <sup>h</sup></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X<sup> i</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>17</th>\\\\n      <td>Vital signs <sup>h,j</sup></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>18</th>\\\\n      <td>ECG h,k</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X<sup> l</sup></td>\\\\n      <td></td>\\\\n      <td>X<sup> m</sup></td>\\\\n      <td>X<sup> l</sup></td>\\\\n      <td></td>\\\\n      <td>X<sup> m</sup></td>\\\\n      <td>X<sup> n</sup></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>19</th>\\\\n      <td>Hematology and coagulation <sup>h,</sup> <strike><sup>n</sup></strike> <sup>o</sup></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X<sup> i</sup></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X<sup> n</sup></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>20</th>\\\\n      <td>Chemistry <sup>h,</sup> <strike><sup>o</sup></strike> <sup>p</sup></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X<sup> i</sup></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X<sup> n</sup></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>21</th>\\\\n      <td>Urinalysis <sup>h,</sup> <strike><sup>p</sup></strike> <sup>q</sup></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X<sup> i</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X<sup> n</sup></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>22</th>\\\\n      <td>HBV viral serology panel <sup>h,</sup> <strike><sup>q</sup></strike> <sup>r</sup></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>r</strike> s</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>s</strike> t</sup></td>\\\\n      <td>X<sup> <strike>s</strike> n,t</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>23</th>\\\\n      <td>HBV DNA (viral load) <sup>h,</sup> <strike><sup>s</sup></strike> <sup>t</sup></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>r</strike> s</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>s</strike> t</sup></td>\\\\n      <td>X<sup> <strike>s</strike> n,t</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>24</th>\\\\n      <td>HCV RNA-PCR (viral load) <sup>h,</sup> <strike><sup>t</sup></strike> <sup>u</sup></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>r</strike> s</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>t</strike> u</sup></td>\\\\n      <td>X<sup> <strike>t</strike> n,u</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>25</th>\\\\n      <td>Serum pregnancy test (if applicable) <sup>h,</sup> <strike><sup>u</sup></strike> <sup>v</sup></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>26</th>\\\\n      <td>Tumor assessment (RECIST v 1.1) <strike><sup>v</sup></strike> <sup>w</sup></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>w</strike> x</sup></td>\\\\n      <td>X<sup> <strike>x</strike> y</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>27</th>\\\\n      <td>Serum AFP</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X<sup> i</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>28</th>\\\\n      <td>PK blood samples <sup>h</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>y</strike> z</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>y</strike> z</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>29</th>\\\\n      <td>Exploratory markers in plasma <sup>h</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>z</strike> aa</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>aa</strike> bb</sup></td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>aa</strike> bb</sup></td>\\\\n      <td>X<sup> <strike>z</strike> aa</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>30</th>\\\\n      <td>PGx blood sample <strike><sup>bb</sup></strike> <sup>cc</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>31</th>\\\\n      <td>Subject survival and anticancer therapies</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>32</th>\\\\n      <td>Adverse events assessment</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>33</th>\\\\n      <td>Concomitant medication/procedure</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>34</th>\\\\n      <td>FHSI-8</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>35</th>\\\\n      <td>PRO (FACT-HP)</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>X</td>\\\\n      <td></td>\\\\n      <td>X<sup> <strike>cc</strike> dd</sup></td>\\\\n      <td>X<sup> <strike>cc</strike> dd</sup></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"56\\\", \\\"TableIndex\\\": \\\"46\\\", \\\"TableName\\\": \\\"Footnote z updated to clarify that sparse PK sampling will be performed only for subjects who consent.(Schedule of Assessment)\\\", \\\"Header\\\": [0, 1, 2]}, {\\\"Table\\\": \\\"<table border=\\\\\\\"1\\\\\\\" class=\\\\\\\"dataframe\\\\\\\">\\\\n  <thead>\\\\n    <tr style=\\\\\\\"text-align: right;\\\\\\\">\\\\n      <th>ColIndex</th>\\\\n      <th>1.0</th>\\\\n      <th>2.0</th>\\\\n      <th>3.0</th>\\\\n      <th>4.0</th>\\\\n      <th>5.0</th>\\\\n      <th>6.0</th>\\\\n    </tr>\\\\n  </thead>\\\\n  <tbody>\\\\n    <tr>\\\\n      <th>0</th>\\\\n      <td>Cycle</td>\\\\n      <td>Day</td>\\\\n      <td>Time points H = hours after dosing</td>\\\\n      <td>PK</td>\\\\n      <td>Pd/Biomarkers</td>\\\\n      <td>PGx <sup>a</sup></td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>1</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>2 mL</td>\\\\n      <td>20 mL</td>\\\\n      <td>6 mL</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>2</th>\\\\n      <td>Cycle 1</td>\\\\n      <td>Day 1</td>\\\\n      <td>Predosing</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n      <td>X</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>3</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 0.25</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>4</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 0.5</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>5</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 1</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>6</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 2</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>7</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 4</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>8</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 8</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>9</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 10</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>10</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 24 <strike>a</strike> b</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>11</th>\\\\n      <td></td>\\\\n      <td>Day 15</td>\\\\n      <td>Predosing</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>12</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 0.5</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>13</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 1</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>14</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 2</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>15</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 4</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>16</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 8</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>17</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 10</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>18</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 24 <strike>b</strike> c</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>19</th>\\\\n      <td></td>\\\\n      <td>EoT</td>\\\\n      <td></td>\\\\n      <td>-</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>20</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 4</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>21</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 4</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>22</th>\\\\n      <td></td>\\\\n      <td>EoT</td>\\\\n      <td>Predosing</td>\\\\n      <td>-</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>23</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 3.5</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>24</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 6.5-8</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>25</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 2</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>26</th>\\\\n      <td></td>\\\\n      <td></td>\\\\n      <td>H 6-8</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n    <tr>\\\\n      <th>27</th>\\\\n      <td></td>\\\\n      <td>EoT</td>\\\\n      <td>Predosing</td>\\\\n      <td>-</td>\\\\n      <td>X</td>\\\\n      <td>-</td>\\\\n    </tr>\\\\n  </tbody>\\\\n</table>\\\", \\\"SectionHeaderPrintPage\\\": \\\"60\\\", \\\"TableIndex\\\": \\\"48\\\", \\\"TableName\\\": \\\"(Schedule of Assessment)\\\", \\\"Header\\\": [0, 1, 0]}]\"",
  "iqvdataSoaStd": null,
  "iqvdataSummary": "\"{\\\"index\\\": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30], \\\"columns\\\": [\\\"field_name\\\", \\\"field_value\\\", \\\"field_header\\\"], \\\"data\\\": [[\\\"protocol_name\\\", \\\"\\\", \\\"Protocol Name\\\"], [\\\"protocol_number\\\", \\\"emr2.ba9cbd08-dfd6-4a8c-8f04-9666c0313f33\\\", \\\"Protocol Number\\\"], [\\\"protocol_title\\\", \\\"MSC2156119J (tepotinib)  Efficacy, Safety, and PK of MSC2156119J in Asian Subjects with HCC A Multicenter, Randomized, Phase Ib/II Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of MSC2156119J as Monotherapy Versus Sorafenib in Asian Subjects with MET+ Advanced Hepatocellular Carcinoma and Child-Pugh Class A Liver Function\\\", \\\"Protocol Title\\\"], [\\\"protocol_title_short\\\", \\\"\\\", \\\"Protocol Title Short\\\"], [\\\"is_amendment\\\", \\\"am1\\\", \\\"Is Amendment\\\"], [\\\"amendment_number\\\", \\\"\\\", \\\"Amendment Number\\\"], [\\\"trial_phase\\\", \\\"Ib/II\\\", \\\"Trial Phase\\\"], [\\\"sponsor\\\", \\\"s1\\\", \\\"Sponsor\\\"], [\\\"sponsor_address\\\", \\\"\\\", \\\"Sponsor Address\\\"], [\\\"drug\\\", \\\"\\\", \\\"Drug\\\"], [\\\"approval_date\\\", \\\"2017\\\", \\\"Approval Date\\\"], [\\\"version_number\\\", \\\"4\\\", \\\"Version Number\\\"], [\\\"version_date\\\", \\\"\\\", \\\"Version Date\\\"], [\\\"blinded\\\", \\\"\\\", \\\"Blinded\\\"], [\\\"compound_number\\\", \\\"\\\", \\\"Compound Number\\\"], [\\\"control\\\", \\\"\\\", \\\"Control\\\"], [\\\"investigator\\\", \\\"Dr Shukui Qin, MD\\\", \\\"Investigator\\\"], [\\\"study_id\\\", \\\"\\\", \\\"Study Id\\\"], [\\\"number_of_subjects\\\", \\\"90\\\", \\\"Number Of Subjects\\\"], [\\\"participant_age\\\", \\\"\\\", \\\"Participant Age\\\"], [\\\"participant_sex\\\", \\\"FEMALE\\\", \\\"Participant Sex\\\"], [\\\"exclusion_criteria\\\", \\\"\\\", \\\"Exclusion Criteria\\\"], [\\\"inclusion_criteria\\\", \\\"\\\", \\\"Inclusion Criteria\\\"], [\\\"indication\\\", \\\"ind\\\", \\\"Indication\\\"], [\\\"primary_objectives\\\", \\\"\\\", \\\"Primary Objectives\\\"], [\\\"secondary_objectives\\\", \\\"\\\", \\\"Secondary Objectives\\\"], [\\\"study_status\\\", \\\"stat\\\", \\\"Study Status\\\"], [\\\"study_population\\\", \\\"patient, subject, ad.. ( ), treated with diagnosis of entity: basic, word .. Diseases and Symptom.. and Diseases and Sym.. showing symptoms of ..\\\", \\\"Study Population\\\"], [\\\"endpoints\\\", \\\"\\\", \\\"Endpoints\\\"], [\\\"trial_type_randomized\\\", \\\"\\\", \\\"Trial Type Randomized\\\"], [\\\"molecule_device\\\", \\\"mol\\\", \\\"Molecule Device\\\"]], \\\"metadata\\\": {\\\"accuracy\\\": \\\"\\\"}}\"",
  "iqvdata": null,
  "isActive": false
}
